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Abstract 
Background: Antibody-mediated rejection is one of the major causes of acute and 
chronic rejection. This is mediated by endothelium microvascular inflammation and 
leukocyte migration to the graft. However, the role of donor specific HLA class I 
antibodies in inducing allograft rejection in the absence of complement is not fully 
understood. In this project, the mechanisms by which HLA class I antibodies induce 
endothelial cell-leukocyte interactions were examined.       
 
Methods: Human microvascular endothelial cells (HMEC-1) were stimulated with 
HLA class I antibody either mouse monoclonal (W6/32) or from sensitized kidney 
patients. The activation of cell signaling pathways was examined using Western 
blotting. The expression of adhesion molecules and chemokines were determined 
using flow cytometry and q-PCR, respectively. Monocyte adhesion and migration was 
examined using chemotaxis and flow based adhesion assays.  
   
Results: HMEC-1 cells stimulated with W6/32 antibody showed phosphorylation of a 
transcription factor CREB by a mechanism dependent on the protein kinase A 
pathway. W6/32 also induced significant expression of the adhesion molecules 
VCAM-1 and ICAM-1 (P<0.001) in a mechanism dependent on the PI3K/Akt 
pathway. Additionally, stimulated cells showed significant up-regulation in IL-6, 
CXCL8, CXCL1, CCL5 and CXCL10. The expression of CXCL8 was significantly 
reduced by knocking down CREB (p<0.001). Conditioned media from W6/32-treated 
cells was able to induce significant THP-1 monocyte migration compared to control 
(p<0.001). Furthermore, monocytes flowing at 0.5 dyne/cm
2
 significantly adhered to 
HMEC-1 cells-treated with F(ab)2-fragments of W6/32 (p<0.001). HLA class I 
alloantibodies from patients induced phosphorylation of CREB and a significant 
upregulation of VCAM-1, ICAM-1 and CXCL8. Monoclonal human HLA-B58 
antibody was also able to induce CREB phosphorylation. 
  
Conclusion: Exposure of microvascular endothelial cells to HLA class I antibodies 
induce an activation of endothelial cell signaling that are responsible for upregulation 
of adhesion molecules and chemokines. These mediators enhance the interaction 
between donor endothelium and recipient leukocytes during cellular rejection. 
Strategies that block endothelium-leukocyte interaction might reduce the incidence of 
allograft rejection and improve allograft survival. 
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1. Chapter One-General Introduction 
1.1 Historical background  
The significance of the human leukocyte antigen (HLA) system in organ 
transplantation was initially reported in skin allograft transplantation in 1946. In this 
year, Peter Medawar performed a set of transplantation experiments where skin 
transplantation was performed between rabbits. He showed that the transplanted skin 
graft was rejected by the recipient's immune system in around 10 days. However, 
transplantation of a second graft from the same donor to the same recipient resulted in 
graft rejection within 5 days. This observation led to the conclusion that the exposure 
to the skin graft for the first time immunized the recipient against specific antigens 
expressed on the transplanted graft. This effect was specific to the donor since skin 
graft from a third party induced rejection similar to the first skin transplantation. In a 
further experiment, Medawar injected a buffy coat preparation from the donor's blood 
to the intradermal region of a recipient followed by skin transplantation from the same 
donor and subsequently observed rejection within 5 days similar to the immunization 
with the skin graft. This result suggested that the leukocytes have antigens similar to 
the antigens expressed on skin graft, enhancing graft recognition and rejection 
(Medawar, 1946a; Medawar, 1946b). Several groups later identified these antigens as 
transplant antigens. Therefore, the main concept in transplantation has been identified, 
in which matching for these antigens might improve graft survival (Rapaport et al., 
1962). In a parallel manner, it was demonstrated that transplantation of the graft 
between identical siblings survived longer than that between non-identical which may 
differ in their HLA expression (Amos et al., 1969). These observations were 
confirmed by in vitro examination where leukocytes from HLA identical sibling failed 
to react in mixed lymphocyte reaction (Bach and Amos, 1967).  
In terms of alloantibody formation, early studies by Peter Gorer showed that skin 
allograft into mice induced the formation of alloantibody that agglutinated donor red 
blood cells (Gorer, 1936). However, the contribution of HLA antibodies in inducing 
skin allograft rejection was excluded when the passive transfer of alloantibodies to 
mice allo-transplanted with skin graft did not induce rejection (Makela and Mitchison, 
1965). This was accompanied by the observation that T-cell deficient mice do not 
reject an allograft and the transfer of sensitized lymphocytes caused rejection. 
However, the concept of allograft rejection by humoral response was renewed by 
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Winn et al. in 1973 when a passive transfer of mouse anti-rat sera to rats transplanted 
with a skin allograft for 2 weeks induced complete graft failure within 2 days (Winn et 
al., 1973). The failure to induce rejection in the previous model was due to delay in 
the blood supply to the transplanted skin for the first few days following 
transplantation; reducing the interaction between the donor endothelium and the 
antibody (Jeannet et al., 1970). From animal model to humans, it was shown that the 
presence of circulating donor-specific antibody in sensitized patients induced 
hyperacute rejection of transplanted kidneys and cross matching of patients serum 
with donor cells reduced the incidence of the rejection (Kissmeyer-Nielsen et al., 
1966). The involvement of de novo synthesized antibody in inducing chronic renal 
rejection was then investigated in cross match negative transplant (Jeannet et al., 
1970). Terasaki et al. and other groups showed later that circulating HLA antibodies is 
associated with increased frequency of graft rejection (Terasaki et al., 2007).      
1.2 Forms of antibody-mediated rejection 
Antibody-mediated rejection can occur in all types of solid organ transplantation 
including lung, heart, kidney, pancreas and liver. The incidence of organ rejection is 
accelerated by but not restricted to pre-sensitization. There are four different forms of 
antibody-mediated rejection which might occur separately or sequentially. They are 
classified according to histological findings and time frame rather than mechanisms 
into; hyperacute, acute, chronic and subclinical rejection (Cai and Terasaki, 2005).  
1.2.1 Hyperacute antibody-mediated rejection 
Before the introduction of cross-matching techniques, hyperacute rejection was the 
most common and first described form of antibody-mediated rejection post-
transplantation. This type of rejection occurs as a result of the presence of preformed 
circulating donor-specific antibody either against ABO blood group antigens or HLA 
antigens. Aggressive immune response occurs following antibody binding and 
complement system activation. As a consequence, histological and morphological 
damage to the transplanted allograft occurs within a few hours after transplantation. In 
kidney transplantation, hyperacute rejection is manifested by a rapid swelling of the 
kidney with hemorrhagic cortical necrosis and vascular thrombosis. Neutrophil and 
platelet margination along the endothelial cells of the peritubular capillaries and the 
glomeruli is also seen. With increasing sensitivity of cross-matching techniques and 
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improvement in blood grouping, the incidence of hyperacute rejection post 
transplantation is minimal (Puttarajappa et al., 2012).   
1.2.2 Acute/accelerated antibody-mediated rejection 
Accelerated rejection occurs as a result of the presence of memory cells before 
transplantation while acute antibody-mediated rejection occurs as a result of the 
development of antibodies specific to donor antigens following transplantation. These 
antibodies are mostly formed in pre-sensitized patients who received a preconditioning 
treatment before transplantation or in patients with a low antibody titer that cannot be 
detected by screening methods (Sellares et al., 2012). The development of these 
antibodies induces a microvascular endothelium inflammation associated with 
leukocyte infiltration resulting in disturbance of organ function. Aggregation of 
different subsets of leukocytes can be seen in peritubular capillaries of transplanted 
kidneys associated with fibrinoid necrosis of arteries (Sis et al., 2012), myocardial 
capillaries in transplanted hearts (Loupy et al., 2011), interacinar capillaries in 
transplanted pancreas (Drachenberg et al., 2011) and alveolar capillaries in 
transplanted lungs (Girnita et al., 2006). The common diagnostic criteria in all solid 
organ transplants include; circulating donor specific antibody, C4d deposition, 
evidence of histological tissue damage associated with graft dysfunction. Positive 
staining for C4d may occur in 95% of patients with donor specific HLA class I 
antibodies as a finger print of complement activation on the endothelium (Cornell et 
al., 2008). C4d is an inactive fragment of the C4b which forms by C4 breakdown, an 
essential component of the classical pathway. It has a hidden sulfhydryl group which 
can form thioester bonds with tissue proteins, forming a long lasting complex which 
can be detected by immunohistochemistry (Feucht et al., 1991; Nickeleit and 
Mihatsch, 2003). This type of rejection might occur within months to a year after 
transplantation (Halloran et al., 2010). It was estimated that around 25% of all acute 
rejection cases are due to antibodies specific to HLA molecules (Cornell et al., 2008). 
1.2.3 Chronic antibody-mediated rejection 
This late form of rejection occurs sometimes concurrent with the formation of de novo 
antibodies specific for mismatched donor HLA antigens. Although the term "chronic" 
is more related to morphological changes rather than time, it has been estimated that 
circulating HLA antibodies can be followed by chronic rejection within 6 months to 8 
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years (Lee et al., 2002). Chronic rejection is characterized by serious irreversible 
morphological and structural changes to transplanted allografts leading to dysfunction 
and failure (Sellares et al., 2012). In kidney transplantation, chronic rejection is 
diagnosed by histological evidence of arterial intimal and interstitial fibrosis, 
duplication of glomerular basement membrane, thickening of peritubular capillaries, 
loss of endothelial fenestrations with cytoplasmic swelling and C4d deposition with 
the evidence of circulating donor specific HLA antibodies (Solez et al., 2007). C4d 
deposition can be used either as a diagnostic marker or as a predictive factor for 
subsequent chronic-antibody mediated rejection. Deposition of C4d in peritubular 
capillaries was detected in 61% of biopsies with transplant glomerulopathy of which 
88% had donor specific HLA antibodies (Mauiyyedi et al., 2001). In another study, 
34% of kidney patients diagnosed with transplant glomerulopathy stained positive for 
C4d in which the deposition of this factor preceded chronic rejection in around 80% of 
the studied cases (Regele et al., 2002). However, emerging data show that transplant 
glomerulopathy can occur without any evidence of C4d deposition in the presence of 
donor specific HLA antibody. The C4d-negative antibody-mediated rejection 
phenotype shows also irreversible histological changes such as endothelial swelling 
and duplication of basement membrane. Therefore, different studies reported the 
insensitivity of C4d as an antibody-mediated rejection marker (Sis et al., 2007; 
Einecke et al., 2009).  
1.2.4 Subclinical antibody-mediated rejection 
The concept of subclinical antibody-mediated rejection has been reported by Haas and 
Gloor to define a group of patients with histological graft injury accompanied with 
normal allograft function (Gloor et al., 2006; Haas et al., 2007). This has been 
observed in renal transplant patients with a positive cross-match who have been 
transplanted after de-sensitisation process, or patients with low level donor specific 
antibodies. Histological examination of biopsies shows positive C4d staining and 
leukocyte infiltration in peritubular capillaries associated with glomerulitis. This type 
of silent rejection can be a predictive factor and a risk factor for the development of 
subsequent allograft dysfunction. In a study of 54 kidney transplanted patients with 
donor specific HLA antibodies, 3 month screening demonstrated that around 31% of 
patients showed histological evidence of subclinical antibody-mediated rejection with 
~49% of these having negative C4d staining. This led to a high rate of allograft 
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dysfunction associated with the development of transplant glomerulopathy within 1 
year after transplantation (Loupy et al., 2009).  
1.3 Clinical relevant antibody in solid organ transplantation 
Different types of antigens can elicit humoral immune responses following 
transplantation leading to allograft dysfunction mediated by antibody formation. ABO 
blood group antigens, HLA, non-HLA antigens and autoantigens can induce the 
formation of corresponding antibodies following transplantation affecting long term 
allograft survival.  
1.3.1 Blood group antibodies 
Shortage in donor organs for transplantation renders the transplantation across the 
ABO barrier an attractive option in particular for urgent transplantation (Takahashi 
and Saito, 2013). ABO antigens are carbohydrate antigens expressed on almost all 
cells including endothelial cells and erythrocytes (Cai and Terasaki, 2005). In ABO-
incompatible transplantation, the presence of a high titer of donor specific anti-ABO 
antibodies at the time of transplantation can cause an immediate hyperacute rejection 
within hours following reperfusion of the graft. The new immunosuppressive 
treatments and immunoadsorption permits ABO-incompatible transplantation with a 
minimum risk of hyperacute rejection. However, the reformation of anti-A or anti-B 
antibodies following transplantation can induce acute-antibody rejection; inducing 
allograft dysfunction (Westphal et al., 2013).  
1.3.2 HLA antibodies 
Donor specific HLA antibodies are a major cause of chronic allograft rejection (Cai et 
al., 2013). Around 15 to 23% of kidney transplanted patients develop donor specific 
HLA antibody within 8 months to 4 years following transplantation, with similar 
frequency in other solid organ transplantation (Kaneku, 2012). The presence of both 
donor specific HLA class I and HLA class II antibody is associated with poor allograft 
outcome (Otten et al., 2012). The development of antibodies specific to donor HLA 
class I antigens can induce acute and chronic allograft rejection in kidney 
transplantation (Varnavidou-Nicolaidou et al., 2004). Recent study showed that renal 
transplanted patients who developed HLA class I but not HLA class II donor specific 
antibodies experienced episodes of rejection within one year following transplantation 
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(Thiyagarajan et al., 2012). However, other studies showed the negative impact of 
donor specific HLA class II antibody on allograft function. In kidney transplantation, 
de novo synthesized donor specific HLA class II antibody is associated with a high 
incidence of acute rejection and a reduction in 5-year allograft survival (Freitas et al., 
2013). The development of donor specific HLA class II antibody has also a negative 
impact on allograft function in lung (Lobo et al., 2013), heart (Ticehurst et al., 2011) 
and liver transplantation (O'Leary and Klintmalm, 2013).  
1.3.3 Polymorphic non-HLA antibodies 
Transplantation from a fully HLA matched donor does not guarantee the absence of 
antibody-mediated rejection episodes following transplantation. Donor specific 
antibodies against polymorphic non-HLA molecules have been reported to induce 
allograft rejection. Major Histocompatibility Complex (MHC) class I related chain A 
or B (MICA-MICB) are polymorphic cell surface glycoproteins expressed on 
endothelial, epithelial cells, keratinocytes and monocytes but not on peripheral blood 
lymphocytes. They do not present antigens to T-cells but they bind specific NK 
receptors. In contrast to HLA class I molecules, the polymorphism in MIC antigens is 
distributed along the molecules in addition to the polymorphism in the transmembrane 
region (Zou and Stastny, 2011; Liu et al., 2012). Transplantation across MICA 
sensitization has been associated with poor allograft outcome as observed in lung 
transplantation (Lyu et al., 2012). In addition, the development of these antibodies 
post-transplantation is associated with acute rejection in heart and kidney 
transplantation (Cox et al., 2011; Zhang et al., 2011a). Antibodies against minor 
histocompatibility antigens can also induce allograft rejection and reduce graft 
survival. Minor histocombatibility antigens are polymorphic self-peptides encoded by 
autosomal gene or Y-chromosome related gene. They are presented by cell surface 
HLA molecules in HLA allele-specific manner. Examples of minor histocompatibility 
antigens are HA-1, HA-2, HA-3 and HA-8. The significant of these antigens in solid 
organ transplantation becomes apparent in a male to female transplantation 
(Dierselhuis and Goulmy, 2009).    
1.3.4 Autoantibodies 
The formation of antibodies against self-antigens is implicated in the pathogenesis of 
chronic allograft rejection. Autoantibodies can form as a result of graft remodeling or 
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injury following transplantation which might expose cryptic antigenic determinants of 
self-antigens to T-cells inducing activation. In addition, cytokines profile following 
transplantation can reduce the activity and number of self-tolerant T-regulatory cells; 
increasing the autoimmune response (Tiriveedhi et al., 2012a). The development of 
anti-K-α1 tubulin and collagen V antibodies is associated with the pathogenesis of 
chronic lung transplant rejection (Goers et al., 2008; Iwata et al., 2008). Patients 
diagnosed with chronic cardiac vasculopathy can develop autoantibodies to vimentin, 
myosin and collagen V (Nath et al., 2010). In kidney transplantation, the development 
of antibody to angiotensin II type 1 receptor and glomerular basement membrane self-
proteins such as agrin have been shown to induce chronic nephropathy (Joosten et al., 
2005; Dragun et al., 2012).   
 In addition, alloimmune responses such as the development of donor specific HLA 
class I antibody might also result in the formation of autoantibodies accelerating 
chronic allograft rejection (Fukami et al., 2009). Fukami et al. (2009) showed that the 
passive transfer of MHC class I antibody in an animal model of lung transplantation 
induced chronic rejection manifested by irreversible morphological changes of the 
grafts and the formation of antibodies to self-antigens collagen V and  K-α1 tubulin. 
Lung transplanted patients diagnosed with bronchiolitis obliterans syndrome have 
been shown to develop autoantibodies to self-antigens within few months following 
the development of donor specific HLA antibody (Saini et al., 2011). Autoantibodies 
can bind their targets inducing cell signaling and activation. Anti-vimentin antibodies 
induce P-selectin exocytosis from cardiac microvessel endothelial cells, which 
increases the activation and adhesion of platelets to endothelial cells (Leong et al., 
2008). Expression of growth factors, proliferative and inflammatory proteins are also 
increased; accelerating chronic injury (Tiriveedhi et al., 2012b). 
1.4 Mechanism of HLA class I antibody formation 
The process of antibody formation is a process that requires the activation of naive B-
lymphocytes (primary sensitization) or memory B-lymphocytes (second exposure) to 
produce antigen-specific antibodies. Naive B-cells, a part of adaptive immune 
response, mature in the bone marrow and migrate to secondary lymphoid organ, lymph 
node and spleen. In these organs, antigen presenting cells, dendritic cells, present 
foreign antigens to CD4+ T-helper cells which induce the activation of naive B-cells 
in the extrafollicular T-cell area (Stegall et al., 2009). Allorecognition of the 
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mismatched HLA antigens by T-cells occurs by either a direct or indirect mechanisms. 
In the direct pathway, T-cells recognize directly the mismatch HLA antigens 
expressed on the donor passenger antigen presenting cells; CD8+ T-cells recognize 
HLA class I while CD4+ T-cells recognize HLA class II antigens. In the indirect 
mechanism, the recipients’ T-cells recognize peptides from processed donors’ antigens 
presented by the recipients’ antigens-presenting cells (Ali et al., 2013). However, the 
formation of donor specific HLA class I antibodies results mostly due to indirect 
recognition of HLA class I-related peptides presented by recipients’ HLA class II to 
CD4+ T-helper cells, which are necessary for B-cells activation and antibody 
formation. A recent study using an animal model showed that CD4+ T-cells activated 
by the indirect pathway against MHC class I peptides induce an isotype class switch 
and produce long-lived plasma cells maintaining alloantibody production (Conlon et 
al., 2012). 
Activated B-cells differentiate into short-lived plasma cells, plasmablasts, producing 
low affinity antibodies. The formation of a high affinity antigen-specific antibody 
requires the clonal expansion and differentiation of activated B-cells into high affinity 
antibody producing plasma cells. This differentiation occurs in a compartmentalized 
structure called the germinal centers which results from the interaction of activated B-
cells with follicular dendritic cells and T-follicular helper cells. In germinal center, B-
cells undergo a rapid division, somatic hypermutation and affinity maturation to 
produce clones of B-cells specific to target antigen. B-cells expressing new 
immunolglobulin on the cell surface are assessed for antibody affinity by interacting 
with antigen-specific dendritic cells. Clones producing low binding affinity antibody 
receives an apoptosis signal while clones producing a high-affinity antibody receive 
survival signals (Clatworthy et al., 2010).  
Surviving B-cell clones can enter an isotype switching process, for example from IgM 
to IgG, with the aid of helper T-cells. The resultant activated B-cells differentiate into 
either plasma cells producing high affinity antibody or memory B-cells. A small 
proportion of plasma cells migrate to the bone marrow where they maintain the serum 
level of allospecific antibodies (Radbruch et al., 2006). During secondary stimulation, 
memory B-cells, which account 40-60% of peripheral B-cells, convert to plasma cells 
producing a high affinity antibody specific to target antigen (Han et al., 2009). 
Whether the T-helper cells are required for the conversion of memory B-cells to 
plasma cells is unknown. In murine MHC class I mismatched transplantation, 
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germinal center formation and humoral responses can develop in the graft itself in 
addition to secondary lymphoid organs; inducing chronic allograft rejection (Thaunat 
et al., 2005). Mechanism of antibody formation is summarized in Figure 1.1. 
General Introduction 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Mechanism of sensitization and antibody formation. 
Abbreviations: dcell, donor cells. rAPC recipient antigen presenting cell., 
adapted from (Stegall et al., 2009). 
dcell
s 
cells 
Donor HLA class I 
Indirect allorecognition  
B-cell 
activation 
Naive B-cells 
Primary sensitization 
Recipient HLA class II 
Plasmablast 
Low-binding affinity 
antibody 
Activated 
B-cells 
Germinal centre formation 
T Folicular 
helper cells 
Follicular 
dendritic cells 
Long-lived plasma 
cells/high affinity 
antibody 
Memory B-cells 
Secondary sensitization 
General Introduction 
11 
1.5 Mechanisms of antibody action 
The main target of antibodies, whether preexisting or synthesized de novo, is the 
endothelial cells of the transplanted graft. Once antibodies interact with corresponding 
antigens on endothelial cells, they may mediate endothelial damage through either 
complement dependent or complement independent mechanisms (Colvin and Smith, 
2005). This may be related to the ability of specific antibody subclass to fix 
complement. 
1.5.1 Complement-dependent mechanism 
Complement fixation is an important pathway by which circulating allospecific 
antibody induces hyperacute or acute allograft rejection in highly sensitized patients 
(Tinckam and Chandraker, 2006). In pre-sensitized patients, antibodies can bind 
directly to the transplanted graft activating the complement system which induces 
irreversible ischemic damage (Ota et al., 2005). Different IgG subclasses have 
different potential to activate the complement system, with IgG3 the strongest 
complement fixing antibody followed by IgG1, IgG2 and IgG4, respectively. The 
complement system can be activated by either classical, alternative or lectin-dependent 
pathways; however, the contribution of alternative or lectin pathways to allograft 
injury is not fully understood. In the classical pathway, the C1s fragment from C1 
mediates the cleavage of C4 into two fragments C4a and C4b as shown in Figure 1.2. 
The inactivation of C4b can occur in the presence of factor I into C4d which 
covalently binds to tissue as a ‘foot-print’ for complement activation. Activation of the 
‘common pathway’ occurs through C5 cleavage into C5a and C5b. The latter interacts 
with other complement components to form the membrane attack complex (C5b-C9) 
on endothelial cells causing cell lysis. In animal models, C4d deposition has been 
correlated with the level of circulating alloantibody as well as morphological changes 
to transplanted allograft (Minami et al., 2006; Qian et al., 2006). Therefore, an agent 
that impedes complement activation such as anti-C5 monoclonal antibody can improve 
allograft survival as shown in previous study (Wang et al., 2007a). In addition to 
formation of the membrane attack complex, complement fragments initiate cascade of 
events enhancing inflammatory responses and leukocyte migration to the transplanted 
graft.  
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Figure 1.2: Antibody-mediated classical complement activation. 
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Complement fragments such as C3a/C5a are chemoattractants that increase the 
expression of different endothelial adhesion molecules such as E-selectin, vascular cell 
adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1), and 
enhance the production of various cytokines (IL-6, IL-1α) and chemokines (CXCL8, 
CCL2). These secretory proteins recruit inflammatory cells (neutrophils) to 
transplanted grafts and accelerate the rejection process (Colvin and Smith, 2005). In 
addition, complement fragments bind to corresponding receptors on endothelial cells 
and can be recognized directly by neutrophils or dendritic cells which express 
corresponding surface receptors for these fragments (Deitch and Mancini, 1993). 
Accumulation of soluble-sublytic doses of the C5b-C9 complex may also induce 
endothelial cell activation and adhesion molecule expression. Inflammatory responses 
driven by complement components can induce endothelium injury, exposing the 
basement membrane to the circulation. This effect activates the adhesion of circulating 
platelets and increase the secretion of von Willebrand factor enhancing thrombosis 
formation and vascular occlusion (Wehner et al., 2007).  
1.5.2 Complement-independent mechanism 
Antibody can mediate allograft rejection independent of the complement system by 
two different mechanisms these are; antibody-dependent cell mediated cytotoxicity 
(ADCC) or by direct endothelial cell activation. Fc-receptors on natural killer (NK) 
cells and macrophages are involved in ADCC (Lee et al., 2007). The interaction of 
Fcγ-receptors on NK cells (FcγRIII, CD16) with the Fc fragment of the 
immunoglobulin bound to the corresponding antigens on the endothelium results in 
NK cell activation. This binding enhances the production of various cytokines such as 
IFN-γ and TNF-α, expression of the T-bet transcription factor, release of cytotoxic 
granules such as perforin and granzyme B and the activation of death receptors. This 
results in cell apoptosis and lysis of antibody-coated cells and activation of 
macrophages’ phagocytic process (Cornell et al., 2008). This mechanism plays a role 
in the development of hyperacute, acute and chronic rejection (Uehara et al., 2005).  
In xeno-transplantation, this mechanism has a significant impact in inducing an 
immediate hyperacute rejection in the presence of non-complement fixing anti-Gal 
antibody (Yin et al., 2004), while the depletion of NK cells prolongs the graft survival 
and reduces acute antibody-mediated rejection (Chen et al., 2006a). The contribution 
of NK cells in the development of chronic-antibody mediated rejection has been 
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examined in animal models. Passive transfer of MHC class I antibody to NK cell-
deficient mice significantly reduced the development of chronic vasculopathy of 
transplanted hearts either in the presence or absence of complement (Hirohashi et al., 
2012). This effect results from the interaction of the Fc-fragment with Fc-receptors on 
NK cells as confirmed using F(ab)2-fragments. In kidney transplant patients, the 
expression of NK cells-related transcripts was significantly increased in biopsies 
diagnosed with chronic antibody-mediated rejection and not on those diagnosed with 
T-cell mediated rejection (Hidalgo et al., 2010). 
1.6 Antibody-mediated graft accommodation 
In 1980, a group of scientists showed condition for organ survival following ABO-
incompatible kidney transplantation, a transplantation normally associated with 
hyperacute rejection. They demonstrated that kidneys transplanted from A or B blood 
group donors to O blood group recipients, after removal of recipients’ circulating anti-
ABO antibodies by plasmapheresis or immunoprecipitation, survived and functioned 
normally without any signs of rejection. In addition, when the antibodies levels 
returned to normal levels or higher, the organ functioned normally without any 
deterioration. This condition is termed as organ accommodation (Lynch and Platt, 
2008). Graft accommodation is different from immunological tolerance, where a 
recipient’s immune system becomes unresponsive to the transplanted graft as is the 
case of self-antigens (Koch et al., 2004). In xeno-transplantation, depletion of 
complement along with immunosuppressive treatments induced accommodation of 
hamster hearts transplanted into rats. The accommodated organs showed expression of 
anti-apoptotic genes, including Bcl-2, Bcl-xl and A20 and the hemoxygenase enzyme. 
In addition, the expression of non-complement fixing IgG antibodies and Th2 helper 
cell-associated cytokines such as IL-4, IL-10 and IL-13 was detected in 
accommodated organ, while rejected organs showed Th1 helper cell-associated 
cytokines such as IL-2, IFN-γ and TNF-α along with other classes of IgG antibodies 
(Bach et al., 1997). An in vitro study using endothelial cells showed similar results 
(Hancock et al., 1998). 
Allograft accommodation has been reported in a situation of a sensitization to HLA 
class I antigens. Antibody concentration plays a fundamental role in inducing this 
phenomenon. Highly sensitized patients who have undergone preconditioning 
treatment to remove circulating HLA class I antibodies showed up-regulation of anti-
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apoptotic protein, Bcl-xl in the accommodated kidney allografts (Salama et al., 2001). 
In addition, exposure of HUVEC endothelial cells to sub-saturating concentration of 
HLA antibodies from those patients induced the expression of Bcl-xl, reduced the 
expression of adhesion molecules and protected the cells against complement-
mediated cell lysis (Salama et al., 2001). By using human aortic endothelial cells, 
treatment with a sub-saturating concentration of HLA class I antibodies provided 
protection against cell lysis induced by saturating concentration of antibody in the 
presence of complement; while exposure to saturating levels of antibodies induced 
apoptosis through caspase-3-dependent mechanism. In addition, accommodated cells 
showed an increase in the expression of protective genes such as Bcl-2, Bcl-xl and 
heme-oxygenase-1 and a phosphorylation of pro-apoptotic gene Bad at serine residues 
inhibiting its activity. Furthermore, sub-saturating concentration of antibody induced a 
significant decrease in the expression of adhesion molecules ICAM-1 and VCAM-1. 
This resulted in a decrease in the adhesion of leukocytes to stimulated endothelial cells 
under static conditions (Narayanan et al., 2004).  
Expression of other antioxidant genes in endothelial cells stimulated with sub-
saturating concentration of HLA class I antibody has also been reported. Human aortic 
endothelial cells stimulated with sub-saturating concentration of HLA class I 
antibodies expressed ferritin and were protected against complement attack (Iwasaki et 
al., 2010). In a model of heart transplantation in sensitized recipients, pre-exposure to 
a low concentration of HLA class I antibodies induced a significant reduction in the 
expression of adhesion molecules, cytokines and chemokines and significant increase 
in the expression of the hemoxygenase-1 and anti-apoptotic genes (Fukami et al., 
2012). 
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1.7 Human leukocyte antigen system 
1.7.1 Human leukocyte antigen classes  
Human leukocyte antigens (HLA) are highly polymorphic cell-surface glycoproteins. 
They are encoded by a region located on the short arm of chromosome six. The HLA 
system is a part of the MHC which was identified originally in mice as a gene dense 
area involved in graft rejection (Klein, 1986). Over 200 genes are located in this 
region and more than 40 genes encode the human leukocyte antigens. The comparable 
region for leukocyte antigens in mice is located in chromosome 17 and called H-2 
(Klein, 1986). The MHC locus in human, consisting of 3.5 million base pairs, codes 
for two different classes of HLA antigens (class I and class II) and other 
immunological proteins. The region codes for HLA class I and class II antigens 
consists around one third of this region spreading over that sequence. This region also 
codes for various proteins responsible for various immune responses apart from the 
HLA system. These proteins are encoded by genes on HLA class III region. These 
include complement components, some hormones and various intracellular peptides 
involved in antigen processing. The presence of these genes in the MHC region might 
suggest a functional association or a shared transcriptional regulation (Klein and Sato, 
2000). 
1.7.2 Human leukocyte antigen structures 
HLA class I and class II are different on a structural and functional basis, the structure 
of both molecules is shown in Figure 1.3. HLA class I consists of α-polypeptide heavy 
chain that non-covalently binds to a light chain, β2-microglobulin, to form a 45 kDa 
molecule. The heavy chain is encoded on HLA region located on chromosome 6 while 
β2-microglobulin is encoded on chromosome 15. The single membrane bound heavy 
chain consists of three alpha domains which are divided into the peptide-binding 
domains α1 and α2 and an immunoglobulin like domain α3. The α3 domain is non-
covalently bound to β2-microglobulin. The heavy chain is anchored in the cell 
membrane by a membrane spanning region (25 amino acids) following the α3 region, 
followed by a short cytoplasmic tail (30 amino acids). The α1 and α2 domains, 
through their N-terminal domains, fold together to form α-helical sides and eight anti-
parallel β-pleated sheet floors which can bind 8-10 amino acids or peptide protein 
fragments (Bjorkman et al., 1987). HLA class II genes on chromosome 6 encode for
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Figure 1.3: Location and structure of human leukocyte antigens. 
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both α and β polypeptide chains. Each molecule contains four domains: the peptide 
binding domain (α1 and β1), the immunoglobulin like domain (α2 and β2), the 
transmembrane region and the cytoplasmic tail. There are several genes that encode 
classical and non-classical HLA class I molecules. HLA-A, B and C are classical 
molecules which are involved in antigen presentation, and HLA-D, E, F, G, H, J, K 
and L are some of the non-classical HLA molecules which are less involved in 
peptides presentation (Klein and Sato, 2000). Both HLA class I and II occur in a 
multiple alleles diversity. The polymorphic regions are mainly found in the peptide 
binding groove resulting from amino acid substitution in α1 and α2 regions for class I 
and α1 and β1 regions for class II. This substitution and polymorphism occurs as a 
result of sequence diversity in the second exon for class II and in the second and third 
exon for class I. In January 2012, around 7130 classical HLA class I and class II 
alleles were reported in the IMGT/HLA database (report v.3.7.0, 
http://www.ebi.ac.uk/imgh/hla/index.html). At least three isotypes of HLA class I 
antigens are expressed by individual cells with two allelic forms for each isotype 
forming a maximum of six classical HLA class I molecules expressed on the cell 
surface. HLA class II molecules follow the same pattern of the expression in which six 
HLA class II antigens are expressed on the cell surface. Therefore, individuals can 
express 12 HLA antigens, six for HLA class I and six for HLA class II. This highly 
polymorphic characteristic of HLA system ensures efficient immune responses against 
various types of antigenic peptide. 
1.7.3 HLA class I assembly and antigen precursors 
The fully structured HLA class I molecules on cell surfaces are formed by sequential 
steps involving the formation of heavy and light chain heterodimers followed by 
peptide loading. The formed class I molecule is then transported to the cell surface to 
present peptides to circulating T-cells. The loading peptides play an important role in 
maintaining the stability of HLA class I heterodimer which is rapidly dissociated in 
the absence of peptides (Townsend et al., 1989; Ljunggren et al., 1990). HLA class I 
molecules can be loaded with two types of peptides. Normally, endogenous cytosolic 
proteins are trimmed into small peptides and uploaded into HLA class I molecules. By 
expressing self-peptides, HLA class I molecules continuously familiarize the 
circulating cells with intracellular proteins, especially newly synthesized proteins. This 
occurs during the continuous turn-over process for class I antigens in which various 
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proteins are loaded each time into newly synthesized HLA class I antigens (Heath et 
al., 1989; Jardetzky et al., 1991; Corr et al., 1992). In addition, extracellular proteins 
can be internalized into the cytosol by phagocytosis, processed and presented by HLA 
class I molecules in a process called cross presentation (Segura and Villadangos, 
2011). When cells become infected with virus, class I molecules are loaded with 
peptides from virus proteins allowing the cells to be identified by cytotoxic T-cells. 
The circulating T-cells are able to discriminate between HLA class I molecules loaded 
with self peptides and those loaded with foreign peptides. The educational process of 
naive T-cells to discriminate between self and non-self peptides occurs in the thymus 
where the negative and positive selections occurs using self HLA class I molecules 
displaying various self peptides (Bevan, 1977; Van Kaer et al., 1992).    
The process of HLA assembly occurs in different cell compartments and is started by 
the synthesis of heavy and light chains. Synthesized heavy chains are translocated into 
the lumen side of the endoplasmic reticulum (ER) and bound to a membrane 
chaperone called calnexin (CNX). This binding enhances the formation of intrachain 
disulfide bonds and chain folding. The heavy chain has two intrachain disulfide bonds: 
one is within the transmembrane IgG-like domain and the other at the peptide binding 
groove, connecting the α2 region to the β-sheet forming the floor of the groove 
(Williams, 2006). The folded heavy chain then binds to β2-microglobulin forming a 
class I heterodimer. The formation of the heterodimer is followed by the replacement 
of CNX with other protein called calreticulin (CRT). The heterodimer with the CRT is 
then integrated into peptide loading complex that is containing various proteins for 
peptide loading. This complex contains transporter associated with antigen processing 
(TAP), tapasin and ER thiol-oxidoreductase ERp57. All these proteins are involved in 
the assembly of HLA class I in the ER by a process called complex assembly pathway 
(Cresswell et al., 2005).  
In this process, intracellular proteasome degrades various cytosolic proteins into small 
peptides suitable for the loading into the groove of the class I molecules. These 
peptides are transported from the cytosol into the ER lumen in association with TAP 
heterodimer. This contains two subunits TAP1 and TAP2 which belongs to the 
transmembrane protein family called ATP-binding cassette family responsible for 
protein transportation across cellular membranes in an ATP-dependent manner 
(Scholz and Tampe, 2005). Each of these subunits contains a cytosolic domain and a 
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transmembrane domain containing multiple membrane spanning regions. Each 
cytosolic domain of TAP1 and TAP2 is attached to ATP molecule; forming a 
conformational unit. This unit is hydrolyzed during the translocation process to 
provide energy required for this process (van Endert et al., 2002). Peptides 
translocated into the ER might also be trimmed by ER associated aminopeptidase 
(ERAAPs) into 8-10 peptides that are suitable for HLA class I peptide binding pocket 
(Serwold et al., 2002). 
The peptides and heterodimer are brought into close proximity for loading process. 
The tapasin protein plays an important role in tethering the TAP complex to the heavy: 
light heterodimer. The tapasin binds the transmembrane domain of TAP1 and TAP2 
stabilizing TAP1/TAP2 heterodimer and maintaining efficient peptides transport 
(Leonhardt et al., 2005; Procko et al., 2005). The tapasin, through its N-terminal 
residue, interacts also with the HLA heterodimer through α2 and α3 regions of heavy 
chain, connecting the heterodimer to the TAP complex (Lehner et al., 1998). CRT and 
thiol oxido-reductase ERp57 have a role in maintaining an optimal function for the 
peptide loading complex and in promoting HLA class I folding (Gao et al., 2002; 
Garbi et al., 2006; Ireland et al., 2008). CRT is a lectin that specifically binds to the 
carbohydrate side chain of HLA molecules via monoglucosylated N-linked glycans 
(Williams, 2006). ERp57 forms a conjugate with the tapasin protein to provide 
protection for the heavy chain-disulfide bond at α2 region from the reductive activity 
of the ERp57 reductase before peptide loading (Kienast et al., 2007). Following the 
interaction of class I heterodimer with disulfide linked tapasin and ERp57 the peptide 
loading is occurred. Fully structured HLA class I structure is then dissociated from the 
complex and transported to the cell surface through Golgi apparatus in a process 
require ATP degradation (Knittler et al., 1999). Figure 1.4 shows a diagram for HLA 
class I assembly. 
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Figure 1.4: HLA class I molecule assembly. 
ER, Endoplasmic Reticulum, ERAAP, ER associated aminopeptidase, 
CNX, calnexin, CRT, calreticulin, B2m, B2-microglobulin, TAP, 
transporter associated with antigen processing, ERp57, ER thiol 
oxidoreductase, adapted from (Cresswell et al., 2005). 
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1.8 HLA class I antibody and endothelial cell signaling 
1.8.1 Mechanism of HLA class I antibody signaling 
The mechanism by which HLA class I molecules transmit intracellular signaling upon 
cross linking by antibody is still a matter of debate. This is attributed to the fact that 
HLA class I molecules contain only a short cytoplasmic tail that do not attach to any 
cytoplasmic signaling motif such as G-protein or intrinsic kinases. Therefore, different 
studies have suggested that the activation of cell signaling mediated by HLA class I 
molecules occurs through the interaction with other transmembrane molecules which 
have a capacity to trigger intracellular signaling pathways (Jindra and Reed, 2007). 
Early studies showed that HLA class I molecules are able to interact with insulin 
(Ramalingam et al., 1997)
 
and epidermal growth factor receptors (Schreiber et al., 
1984) augmenting their signaling processes. In addition, deletion of the 
intracytoplasmic domain of HLA class I molecules from Jurkat T-cells did not effect 
their capacity to transduce signaling after cross linking with antibodies (Gur et al., 
1999). However, a recent study showed that cross linking HLA class I antigens with 
corresponding antibodies induced cell signaling through interaction with cell-surface 
ß4-integrin expressed by endothelial cells. The interaction with integrins was mediated 
by the cytoplasmic tail of HLA class I antigens. This result contradicts previous 
finding on T-cells. In addition, knockdown of this integrin induced inhibition in cell 
signaling and proliferation in response to cross-linking with HLA class I antibody 
(Zhang et al., 2011b).  
1.8.2 HLA class I antibody and Akt pathway 
Akt is a serine/threonine kinase that is responsible for phosphorylation of target 
proteins at serine and threonine residues. It is also referred to as protein kinase B and 
was originally identified as an oncogene in a mouse leukemia virus, AKT8 (Bellacosa 
et al., 1991). Three isoforms of Akt have been identified with specific tissue 
distributions which are Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ. Akt1 is 
predominant in brain, heart and lung while Akt2 is expressed in skeletal muscle and 
embryonic fat, and Akt3 is mostly expressed in brain, kidney and embryonic heart 
(Altomare et al., 1995; Brodbeck et al., 1999). The activity of Akt proteins is highly 
regulated by its phosphorylation at two residues; threonine 308 and serine 473. This 
phosphorylation is mediated primarily by phosphatidylinositol-3-kinases (PI3Ks) 
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attached to tyrosine kinase or G-protein coupled receptors. Upon exposure to stimuli, 
activation of PI3Ks results in the phosphorylation of cell-membrane phospholipid, 
phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 3,4,5-triphosphate 
resulting in the recruitment of 3-phosphoinositide dependent-protein kinase (PDK) and 
Akt to the cell membrane. PDK translocation to the cell membrane results in the 
phosphorylation of Akt at serine and threonine residues in stimuli dependent manner. 
PDK might interact with other cellular proteins to induce the phosphorylation of Akt 
at serine residue such as integrin-linked kinase (Delcommenne et al., 1998). In 
endothelial cells, the Akt pathway is downstream of many cytokines, growth factors 
and various cellular stimuli, regulating the activity of various proteins involved in cell 
survival, apoptosis, proliferation and angiogenesis (Fujio and Walsh, 1999; Jiang and 
Liu, 2009; Li et al., 2012).  
Exposure of human aortic endothelial cells to mouse HLA class I antibody induces the 
phosphorylation of Akt at serine residue 473 and threonine residue 308 (Jin et al., 
2004; Narayanan et al., 2004). The phosphorylation of Akt in turn induces elevation of 
the expression of the pro-survival protein Bcl-2, suggesting enhancement of cell 
survival signals. The pro-survival activity of Bcl-2 is regulated by the phosphorylation 
of pro-apoptotic gene Bad at serine residues 112 and 136 by Akt, enhancing their 
dissociation from Bcl-2 proteins and binding to 14-3-3 cytoplasmic protein, resulting 
in the inhibition of cell apoptosis. Human cardiac allograft biopsies from patients 
diagnosed with antibody-mediated rejection also showed immunostaining for Bcl-2 
expression (Jin et al., 2004). However, the protective effect of Akt might be correlated 
with antibody concentration, where low concentration of antibody is responsible for 
inducing cell-survival signaling (Jin et al., 2004). Moreover, pre-exposure of human 
aortic endothelial cells to sub-saturating concentration of HLA class I antibody 
provides a protection against the damaging effects induced by the exposure to 
saturating concentration of HLA class I antibody in a mechanism involving the 
expression of anti-apoptotic genes Bcl-2, Bcl-xl and hemoxygenase-1 as well as Bad 
phosphorylation at serine residues 112 and 136. These might occur as a result of the 
activation of Akt at serine residue 473 (Narayanan et al., 2004). 
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1.8.3 HLA class I antibody and mammalian target of rapamycin (mTOR) 
pathway 
Mammalian target of rapamycin (mTOR) is a large serine/threonine kinase complex 
with central function in cell growth and proliferation signaling network. mTOR exists 
in two different multi protein kinase complexes. mTORC1 consists of mTOR protein 
kinase, regulatory associated protein (raptor) and G protein Beta subunit Like protein 
(GBL). The kinase activity of this complex is inhibited by rapamycin, an 
immunosuppressive drug used as an anti-proliferative agent. The second complex is 
mTORC2 which consists of mTORC2, sin1, GBL and rictor, and its kinase activity is 
insensitive to rapamycin treatment (Sarbassov et al., 2005). Activation of these 
complexes leads to the increase in ribosomal biosynthesis and translation of mRNAs 
to proteins essential for transition from G1 to S phase, which enhances cell cycle 
progress and proliferation (Hidalgo and Rowinsky, 2000).  
Ligation of HLA class I molecules on endothelial cells by corresponding antibodies 
enhances mTORC1/C2 complexes assembly, promoting cell proliferation. HLA class I 
antibody induces mTORC1 phosphorylation at serine residue 2448 which, in turn, 
phosphorylates p70 S6 kinase (S6K) at threonine residues 389, 421 and 424 leading to 
the phosphorylation of two downstream regulatory proteins, S6 ribosomal protein 
(S6RP) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) (Jindra et al., 
2008c). Conversely, mTORC2 mediates the phosphorylation of Akt at serine residue 
473 and the expression of Bcl-2 protein (Jindra et al., 2008c). In addition, the 
activation of mitogen-activated protein kinase such as extracellular regulatory kinase 
(ERK1/2) has been shown to occur downstream of mTORC2 in response to cross 
linking of HLA class I molecules with antibodies (Jindra et al., 2008b). ERK is a 
serine/threanine kinase involved in cell proliferation, differentiation, survival and 
arrangement of actin cytoskeleton (Chang et al., 2003; Jindra et al., 2008a).
 
The 
phosphorylation of mTOR, S6K, S6RP, ERK, and Akt has been detected in 
endothelial cells from cardiac transplanted allografts in mice transfused with donor 
specific MHC class I antibodies after transplantation (Jindra et al., 2008a). 
1.8.4 HLA class I antibody and cytoskeleton proteins  
Endothelial cytoskeleton proteins are crucial not only in maintaining cell shape and 
integrity but also in mediating cell responses to extracellular stimuli. The cytoskeleton 
of endothelial cells consists of actin microfilaments, microtubules and intermediate 
General Introduction 
25 
filaments. These structures are essential for maintaining cell-cell and cell-matrix 
interactions, regulating endothelial permeability and mediating cell migration and 
proliferation. These proteins are connected to various intracellular proteins creating an 
intracellular network signaling (Prasain and Stevens, 2009). Actin in resting 
endothelial cells is present in the cortical fiber rim, which is reorganized to form stress 
fiber in response to inflammatory agonists, therefore, reducing cell-cell adhesion 
(Dudek and Garcia, 2001). The attachment of endothelial cells to the extracellular 
matrix is mediated by the formation of focal adhesion regions where transmembrane 
integrins bound to extracellular matrix are attached to intracellular actin through 
various linking proteins. Reorganization of endothelial cytoskeleton and the formation 
of stress fiber might occur in response to extracellular stimuli such as growth factors 
and cytokines. Focal adhesion kinase (FAK) is a cytoplasmic non-receptor tyrosine 
kinase that is responsible for focal adhesion assembly. It is involved in the 
organization of actin cytoskeleton and regulation of growth factor and integrin 
signaling, cell survival, proliferation and cell migration (Wu, 2005). This protein 
induces cell proliferation through phosphorylation and interaction with other signaling 
molecules such as src family kinase proteins, src and fyn, and paxillin (Schaller, 
2001).  
Emerging studies show the crucial role of endothelial cytoskeleton-related proteins in 
cell signaling-mediated by HLA class I antibodies. Ligation of HLA class I antigens 
with antibodies has been shown to phosphorylate src protein kinase, fyn, paxillin and 
PI3K/Akt in FAK dependent manner (Jin et al., 2002; Jin et al., 2007). Exposure to 
HLA class I antibodies induce the formation of actin stress fiber and cell proliferation 
which is abrogated in the absence of FAK (Jin et al., 2007). In addition, disturbance of 
the actin cytoskeleton by chemical agents inhibits the ability of HLA class I antibodies 
to induce FAK phosphorylation, which may suggest the importance of cell 
cytoskeleton in HLA class I molecule-mediated signaling (Jin et al., 2002). Moreover, 
ERK1/2 and other proteins belong to Rho GTPase family are essential for the 
formation of endothelial stress fiber in response to HLA class I antibody (Lepin et al., 
2004; Ziegler et al., 2012a). Recently, a number of endothelial cytoskeleton proteins 
has been identified after treatment with HLA class I antibody, although the exact role 
of these proteins in the development of allograft rejection is still not clear (Ziegler et 
al., 2012b).        
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1.8.5 HLA class I antibody and growth factors 
HLA class I antibodies induce cell proliferation by mediating expression of various 
growth factors and their receptors. Expression of platelet-derived growth factor, 
epidermal growth factor, insulin-like growth factor 1, and basic fibroblast growth 
factor (FGF) increases in airway epithelial cells in response to HLA class I antibody, 
inducing fibroblast proliferation and development of bronchiolitis obliterans syndrome 
(Jaramillo et al., 2003). A previous study showed that ligation of HLA class I 
molecules with antibodies increases the expression of fibroblast growth factor 
receptors in smooth muscle cells (Bian et al., 1998). This effect is enhanced by IFN-γ 
treatment, which increases the expression of HLA class I molecules (Bian and Reed, 
1999). Furthermore, cross linking of HLA class I antigens on endothelial cells 
stimulates the redistribution of FGF receptors from intracellular stores to the plasma 
membrane in a concentration dependent manner (Harris et al., 1997). Binding of FGF 
to its receptors enhances auto-phosphorylation of a tyrosine residue in the cytoplasmic 
domain of the receptor which in turn may activate mitogen activated protein kinases 
(MAPK) and nuclear transcription factors involved in cell proliferation. Kerby et al. 
showed an increase in the expression of both FGF and FGF receptor in the vessels of 
cardiac and renal allografts undergoing chronic rejection (Kerby et al., 1996).  
Further study by Bieri et al. (2009) showed that clustering of HLA class I molecules 
by antibodies induced a production of vascular endothelial growth factor from 
activated endothelial cells, which might activate vascular endothelial growth factor 
receptor in an autocrine mechanism. Activated receptors can either enhance cell 
proliferation or increase membrane permeability through degradation of VE-cadherin, 
which results in impaired adherence at junctions (Bieri et al., 2009).  
1.9 HLA class I antibody induce activation of transcription factors  
Exposure of endothelial cells to anti-HLA class I antibody can induce the activation of 
various transcription factors. The activation of these factors could induce genes 
responsible for either cell protection or cell damage. Activation of transcription factors 
during antibody-mediated rejection might lead to modulation in the expression of 
related genes contributing to modulation of allograft function. Various transcription 
factors are activated in response to stimulation with HLA class I antibody including; 
nuclear factor- B (NF-B) (Smith et al., 2000), E2F (Nath et al., 1999), Nf-E2-
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related factor 2 (Nrf2) (Iwasaki et al., 2010) and cAMP Responsive Element Binding 
protein CREB (Naemi et al., 2011). 
1.9.1 HLA class I antibody and NF-B 
Treatment of human umbilical vein endothelial cells (HUVEC) with monoclonal HLA 
class I antibody (W6/32) and allospecific class I antibody from sensitized patients 
induced NF-B activation which was augmented by cross-linking with rabbit anti-
mouse antibodies (Smith et al., 2000). Nuclear factor-B is a transcription factor that 
is normally sequestered in the cytosol as an inactive hetero- or homo-dimer. Five 
different proteins can be combined to form these dimers which are termed, p50, p52, 
p65 (RelA), Rel B and c-Rel; p50/p65 is the most common dimer. The catalytic 
activity of NF-B is inhibited by a family of 7 inhibitory proteins. The predominant 
inhibitory protein is IKBα which binds the p50/p65 dimer. NF-B-mediated gene 
transcription is a sequential process involving the phosphorylation and subsequent 
separation from inhibitory proteins followed by translocation to the nucleus, where it 
up-regulates various genes (May and Ghosh, 1998). The contribution of activated NF-
B to the transcription of cytokines, chemokines, growth factors, adhesion molecules, 
and cytoprotective enzymes, highlights its role in organ transplantation (Tsoulfas and 
Geller, 2001). NF-B can be activated early after transplantation in response to 
oxidative stress during ischemia/reperfusion injury. In addition, pro-inflammatory 
cytokines such as TNF-α and IL-1, which might be induced after transplantation, can 
also enhance NF-B activation (Li and Verma, 2002). However, this activation can 
induce either organ dysfunction or organ protection.  
In ischemia reperfusion injury, NF-B is elevated after a few hours of reperfusion and 
accompanied by up-regulation of iNOS activity, suggesting cytoprotective mechanism 
(Hur et al., 1999). In contrast, genes associated with endothelial cell activation after 
exposure to allospecific antibodies mostly contain an NF-B binding site. These genes 
have a role in leukocyte migration and inflammation during allograft rejection and 
include E-selectin, ICAM-1, VCAM-1, IL-6, CXCL8 and CCL2 (Hou et al., 1994; 
Jahnke and Johnson, 1994; Parry and Mackman, 1994). The transcription of VCAM-1 
in response to cytokine stimulation was mediated by the binding of NF-B and 
interferon regulatory factor-1 (IRF-1) to their consensus sequences on the promoter of 
the VCAM-1 gene (De Caterina et al., 2001). However, this effect might be cell type 
and stimulus specific. In bovine aortic endothelial cells, stimulation with TNF-α 
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produced an up-regulation of VCAM-1 mediated by CREB activation through p38 
MAPK (Ono et al., 2006). On the other hand, cell surface expression of endothelial 
ICAM-1 is mediated by CREB and NF-B binding in response to TNF-α stimulation 
(Hadad et al., 2011). 
1.9.2 HLA class I antibody and E2F transcription factor 
Cross linking HLA class I molecules with antibodies has been associated with the 
activation of transcription factor, E2F. E2F is a family of transcription factors 
consisting of nine subclasses. They regulate the expression of various genes involved 
in cell cycle progression, apoptosis and cell differentiation. E2F-1 is the most 
prominent member mediating both apoptosis and cell proliferation. The transcriptional 
activity of this protein is regulated by binding to retinoblastoma (Rb) proteins (Chen et 
al., 2009). HLA class I antibody-induced E2F activation by inhibiting the activity of 
Rb protein, rendering the E2F factor active to enhance the expression of proliferative 
proteins (Nath et al., 1999). However, further studies are needed to explore the effects 
of this activation. 
1.9.3 HLA class I antibody and c-Jun transcription factor 
C-Jun is a transcription factor that is a member of activator protein-1 complex. It is 
present as either a homodimer or heterodimer with other members such as ATF-2 or c-
Fos. They regulate the expression of various genes involved in cell proliferation, 
apoptosis, fibrosis, differentiation and inflammation (Angel and Karin, 1991). The 
catalytic activity of c-Jun is regulated by the phosphorylation by c-Jun N-terminal 
kinase. Activation of c-Jun factor has been correlated with the inflammation and 
fibrosis associated with many human kidney diseases (De Borst et al., 2007). In 
cellular rejection, the phosphorylation of this factor has been observed in leukocytes 
infiltrating kidney allografts, and both endothelial cells and infiltrating leukocytes in 
the case of antibody-mediated rejection (Kobayashi et al., 2010). In addition, the 
degree of c-Jun phosphorylation in peritubular endothelial cells from chronic 
antibody-mediated rejection biopsies correlates negatively with allograft function 
(Kobayashi et al., 2012). Inhibition of c-Jun activation by inhibiting c-Jun N-terminal 
kinase activity prolonged allograft survival in a model of cardiac transplantation 
(Tabata et al., 2007). 
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1.9.4 HLA class I antibody and Nf-E2-related factor 2 
Exposure of endothelial cells to HLA class I antibodies is associated with activation of 
the oxidative stress-dependent transcription factor, Nf-E2-related factor 2 (Nrf2) 
(Iwasaki et al., 2010). Endothelial cells transfected with this factor are resistant to 
complement cytotoxicity in the presence of HLA class I antibodies through inducing 
the expression of heme oxygenase-1 and ferritin H (Iwasaki et al., 2010). Nrf2 is a 
basic leucine zipper transcription factor that regulates the transcription of oxidative 
genes containing a consensus region for Nrf2 binding, antioxidant responses element 
(ARE). The predominant genes which are controlled by this factor are NADPH 
oxidoreductase, glutathione-s-transferase, glutamyl-cysteine synthase, glutathione 
peroxidae and HO-1 (Ruiz et al., 2013). Activation of these genes provides a 
protection against oxidative stress induces lung and renal injury (Cho et al., 2004; Kim 
and Vaziri, 2010). An in vivo study showed that Nrf2-deficient mice exhibited 
remarkable inflammation in their lungs in response to hypoxic or bleomycin injury 
(Thimmulappa et al., 2006). In addition, Nrf2 factor might also regulate the expression 
of various genes that have a role during inflammation and leukocyte migration. 
Ischemic Nrf2-deficient mice expressed high level of pro-inflammatory proteins 
including CCL2, TNF-α and cyclo-oxygenase-1 (Ichihara et al., 2010). In a similar 
manner, up-regulation of endothelial Nrf2 induced a protection against oxidative stress 
and abolished the ability of TNF-α to induce the expression of CCL2 and VCAM-1, 
leading to reduction in the adhesion of monocytes to endothelial cells (Chen et al., 
2006b). Summary of all currently known signaling induced by HLA class I antibody is 
shown in Figure 1.5.  
1.10 cAMP Responsive Element Binding protein (CREB)  
CREB is a nuclear transcription factor that belongs to the basic leucine zipper (bZIP) 
superfamily. This group contains CREB isoforms and two other factors, cAMP-
responsive element modulators (CREM) and activating transcription factors (ATF), 
which are collectively called the CREB family (Sandoval et al., 2009). Members of 
this group are both activators and repressors of the transcription process. For example, 
the binding of some isoforms of CREM proteins to DNA blocks the transcription 
process and functions as a negative regulator of CREB by competing with the CREB 
for binding to the specific sequence on DNA. This blockade occurs as a result of the 
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Figure 1.5: Summary of the published data on endothelial cell 
signaling induced by HLA class I antibody. 
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missing domains responsible for transcription activation in the repressor CREM 
(Shaywitz and Greenberg, 1999).  
There are more than 100 target genes for CREB binding. They are proteins responsible 
for a wide range of cell functions such as metabolic regulation, proliferation, 
apoptosis, differentiation, immune regulation, neuronal activities, hematopoiesis and 
transcription (Persengiev and Green, 2003). Cell cycle proteins such as cyclins, growth 
factors, c-fos transcription factor and apoptosis-associated genes such as 14-3-3 
protein and Bcl-2 are all regulated by CREB binding (Zhang et al., 2005). 
Consequently, different studies elucidate a potential role of CREB in the pathogenesis 
of diverse range of diseases (Chiappara et al., 2007; Mroz et al., 2007). 
1.10.1 CREB structure 
In humans, mature CREB is 43 kDa protein encoded by gene containing 11 exons. 
According to the number of expressed exons, there are three isoforms of CREB which 
are uniformly expressed in all somatic cells. They are CREB-α, CREB-∆ and CREB-β. 
CREB-α contains an extra 14 amino acid residues at the beginning of the chain called 
the α-peptide compared to CREB-∆, the most abundant form of CREB. CREB-β lacks 
the first 40 amino acid residues which are present on the other two types (Waeber and 
Habener, 1991). Regulation of gene expression by CREB is facilitated by the presence 
of different domains in the functional protein. CREB has a basic DNA binding 
domain, leucine zipper dimerization domain and three transcription domains. DNA 
binding domain includes mainly sequences of basic amino acid residues, lysine-
arginine, in the c-terminal chain. CREB binds to the cis-regulatory element on the 
promoters of various inducible genes called cAMP responsive element (CRE). This 
element contains either the 8-9 base pair palindromic consensus sequence, 
TGACGTCA or, in some genes, a shorter sequence, CGTCA. CREB binds to 
palindromic CRE with a Kd of 1 nM and to short CRE with a Kd of 5 nM 
(Johannessen et al., 2004). After its binding, CREB dimerizes to form either a 
homodimer or heterodimer with other transcription factors, although it is unknown 
whether this dimerization occurs before or after DNA binding. The dimerization 
between two transcription factors relies on the leucine zipper domain. This domain is 
conserved between CREB members and contains repeated residues of leucine 
(Hoeffler and Habener, 1990).  
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In the amino terminus, two glutamine rich domains (Q1 and Q2) are present which are 
separated by the kinase inducible domain (KID). KID, also known as the 
phosphorylation box, contains different phosphorylation sites that can be a target for 
multitude of kinases. The glutamine rich domains, next to the binding domain, are 
necessary for binding the components of the transcription complex such as 
transcription factor II D (TFIID) and facilitate the accumulation of RNA polymerase. 
This binding might mediate the transcription activity of CREB, even when in its 
unphosphorylated state. The most critical and well characterized phosphorylation site 
is at serine residue 133 (Gonzalez et al., 1991). The phosphorylation of this amino 
acid by various kinases induces a conformational change in the structure of the 
transcription domain, which enhances the binding of coactivator protein called CREB-
binding protein (CBP). Activation of CREB by growth factors, oxidants and G-protein 
coupled receptor is mediated by phosphorylation at this residue (Chrivia et al., 1993).  
1.10.2 Activation of CREB 
Phosphorylation of CREB is mediated by the activation of protein kinase A (PKA) 
enzyme in cAMP-dependent manner. Stimulus receptors such as neurotransmitter, 
growth factors and hormone receptors are attached to the cytoplasmic GTP molecules. 
Upon stimulation, GTP is able to bind and activate adenylyl cyclase which converts 
ATP to cAMP. Following cAMP production, the two catalytic subunits of PKA 
dissociate from the two regulatory subunits and translocate to the nucleus.  In the 
nucleus, PKA phosphorylates CREB at serine residue 133 (Gonzalez and Montminy, 
1989). Although different studies suggest that phosphorylation of this site does not 
affect the DNA binding capacity of CREB, this phosphorylation potentially stimulates 
the transactivation potential of CREB. Substitution of serine 133 residue with alanine 
produces transcriptionaly inactive CREB upon PKA stimulation (Brindle et al., 1993).  
In addition to PKA, CREB can be phosphorylated by multitude of kinases such as 
calcium-moduline kinases (CaMK), mitogen/stress kinase (MSK), RSK and protein 
kinase C. The phosphorylation by PKA, MSK, RSK and CaMKIV is associated with 
an increase in the transcriptional potential of CREB (Sun et al., 1994; Deak et al., 
1998). Because some of these kinases are Ca
2+
-sensitive proteins, CREB might also 
induce cellular gene transcription in response to a calcium influx. Moreover, some 
types of adenylyl cyclase are cAMP independent/ Ca
2+
-dependent which render other 
stimuli independent on G-coupled protein receptors able to enhance CREB activation. 
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In neurons, Ca
2+ 
influx induced by the binding of neurotransmitters interacts with 
different cell proteins such as Ca
2+
-binding protein calmodulin (CaM) inducing the 
activation of CaMKI, CaMKII and CaMKIV, which all have the capacity to activate 
CREB (Enslen et al., 1995).  
Moreover, Ca
2+
 has been shown to activate various mitogen activated protein kinases 
such as Ras/ERK and PI3K/Akt pathways which end with CREB phosphorylation (Du 
and Montminy, 1998). These signaling transduction pathways might be mediated by 
different MAPK such as RSK1/3 and MSK1/2. Although Akt can activate and 
phosphorylate CREB, it is still unknown whether Akt directly phosphorylates CREB 
or works through other intracellular mediators. Furthermore, some of the stress-
inducible kinases such as P38-MAPK are activated in response to stress and activate 
MSK1/2 which in turn phosphorylates CREB.  
1.10.3 CREB function and disease 
CREB is a key modulator of various cell functions such as proliferation, apoptosis, 
survival, glucose metabolism, circadian rhythms and synaptic plasticity-associated 
with memory. All these functions imply CREB as a key effector in the pathogenesis of 
various diseases including cancers, asthma, diabetes, neuronal disorders and vascular 
diseases (Mayr and Montminy, 2001).  
In immune regulation, CREB regulates the differentiation of various cell lineages such 
as T and B-cells, allocating CREB as a central regulator of the adaptive immune 
response. CREB regulates the expression of pro-inflammatory genes such as IL-2, IL-
6, TNF-α, cyclooxygenase 2 and macrophage migration inhibitory factor (Brenner et 
al., 2003; Hughes-Fulford et al., 2005). In macrophages, CREB promotes survival 
signaling enhancing immune responses against invading harmful agents (Park et al., 
2005). Autoimmunity-induced cytokine secretion has been shown to be a causative 
factor for the destruction of pancreatic islet β-cells through downregulation of CREB 
activity leading to type-1 diabetes. This reduction in CREB activity has also been 
reported in both aging and hypertension. 
CREB also modulates survival and proliferation processes in response to pro-growth 
or pro-survival signals. In its role as a proliferative agent, CREB induces the 
expression of endothelial cell cycle genes such as cyclin D1 and cyclin A in response 
to growth factors stimulation (Devi et al., 2011). In hematopoietic cancers, over-
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expression and phosphorylation of CREB in acute myeloid leukemia patients was 
associated with a poor prognosis (Pigazzi et al., 2007). This effect occurs as a result of 
the ability of CREB to enhance proliferation and cell survival upon stimulation with 
hematopoietic growth factors. CREB has also been shown to enhance the expression 
of the pro-survival gene, Bcl-2, in response to growth factor stimulation and ischemic 
conditions (Meller et al., 2005).  
Upregulation of CREB during hypoxia and oxidative stress implies that it has 
cytoprotective effect under these conditions. CREB is also important for the regulation 
of lipid and glucose metabolism particularly during fasting, by modulating the activity 
of insulin and glucagon hormones. Through its ability to induce the expression of 
cytochrome C gene, CREB also regulates the mitochondrial respiration process. In 
addition, CREB might regulate the transcription of other transcription factors such as 
C/EBPβ, Erg1 and Nurr1 (Shaywitz and Greenberg, 1999). A recent study highlighted 
the role of endothelial CREB in maintaining normal endothelial barrier function after 
exposure to inflammatory mediators. Stimulation of CREB-deficient endothelial cells 
with growth factor and histamine induced exaggerated endothelial cell permeability 
(Chava et al., 2012).      
1.11 Leukocyte migration in transplantation  
Leukocyte migration is a major characteristic that is observed at different stages of 
organ transplantation. This infiltration occurs early after reperfusion of the 
transplanted allograft, during the development of acute rejection and has an 
implication for the pathogenesis of graft vasculopathy, the main feature of chronic 
rejection. Leukocyte migration into extravascular tissue is a multistep process 
requiring direct contact between circulating leukocytes and activated or inflamed 
endothelial cells. This process is characterized by the contribution of distinct types of 
adhesion molecules expressed on both leukocytes and endothelial cells. The 
expression of these adhesion molecules might be augmented during inflammatory 
responses enhancing leukocyte adhesion and migration. In addition, the production of 
chemoattractant cytokines, chemokines, by transplanted grafts plays a crucial role in 
directing recipients’ leukocytes to the grafts. These chemokines might also mediate 
leukocyte activation by enhancing the exocytosis of cytotoxic inflammatory mediators, 
inducing allograft damage (Fairchild, 2005). Traditionally, the main three steps for 
leukocyte migration were leukocyte rolling, adhesion and transmigration. However, 
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the discovery of integrins and their ligands as well as chemokines and their receptors 
has added more steps to this cascade. Chemokine-induced integrin activation, integrin-
mediated firm adhesion or arrest and intraluminal crawling are added to define 
sequentially the adhesion process. In addition, the transmigration process has been 
expanded to include paracellular migration, intracellular migration and migration 
through basement membrane (Parish, 2005). 
1.12 Mechanism of Leukocyte extravasation 
1.12.1 Selectin-mediated rolling  
Rolling of circulating leukocytes on endothelial cells require an interaction between 
cell surface selectins and their carbohydrate ligands expressed on both leukocytes and 
endothelial cells (Zarbock et al., 2011). Selectins are heavily glycosylated cell surface 
proteins that bind cell surface oligosaccharide or glycosylated ligands. There are three 
members that belong to the selectin family; L-selectin, E-selectin and P-selectin. L-
selectin is constitutively expressed by most leukocytes. However, E-selectin is up-
regulated on endothelial cells in response to stimulation with pro-inflammatory 
cytokine. P-selectin is stored in intracellular Weibel-Palade bodies and rapidly 
secreted to the endothelial and platelet cell surface in response to stimulation (Zarbock 
et al., 2011). P-selectin glycoprotein ligand-1 (PSGL1) is a dominant ligand for all 
selectins and it is expressed on all leukocytes and certain types of endothelial cells 
(Zarbock et al., 2009). The binding of selectins with their ligands is essential for 
leukocyte rolling on endothelial cells under flow conditions and it is supported by the 
applied shear stress. Under flow, the adherent cells roll on the endothelium according 
to the selectin transporter phenomena, in which a new bond between selectin and 
ligand is formed before the old bond is broken (Yago et al., 2007). Ligation of 
selectins or their ligands on leukocytes triggers activation of various signalling 
pathways such as phosphoinositide-3 kinase and p38-mitogen activated protein 
kinases. The activation of these pathways enhances the activation of other adhesion 
proteins on leukocytes which are integrins. Integrins on leukocytes participate in 
leukocyte rolling and is also involved in leukocyte firm adhesion mediated by 
chemokines (Wang et al., 2007b). 
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1.12.2 Integrin-mediated adhesion 
Integrins are cell-surface heterodimers of non-covalently bound α and β chains with a 
wide range of biological functions in addition to leukocyte trafficking, such as 
development and cell binding to extracellular matrix. The presence of 18 α chains and 
8 β chains creates around 24 intergrin combinations with cell type and ligand 
specificity (Herter and Zarbock, 2013). Integrins that are involved mostly in leukocyte 
adhesion include α4ß1 integrin, which is also called very late antigen 4 (VLA-4, 
CD49d/CD29). VLA-4 binds vascular adhesion molecule-1 (VCAM-1, CD106) on 
endothelial cells and the ß2 integrin, lymphocyte function associated antigen-1 (LFA-
1), that binds intracellular adhesion molecule-1 (ICAM-1, CD54). VLA-4 integrin is 
expressed by monocytes, T-cells and lymphocytes, while LFA-1 mostly expressed on 
lymphocytes (Kuwano et al., 2010). Constitutively expressed α4β1 and β2 integrins on 
circulating leukocytes are in an inactive form with low binding affinity to 
corresponding ligands. Signalling results from selectin-mediated rolling converts the 
intergin to intermediate binding affinity to their ligands. However, the high affinity 
and avidity of integrins to their ligands is achieved by chemokines secreted by 
activated endothelial cells inducing firm adhesion (Lefort and Ley, 2012).  
Chemokines are highly basic low molecular weight proteins. They have fundamental 
roles beyond inflammation such as organ development, angiogenesis, haematopoiesis 
and tumor metastasis (Mortier et al., 2012). Up to 50 different chemokines have been 
identified which include inflammatory and homeostatic chemokines. They are 
structurally classified in human into four distinct groups based on the numbers of the 
amino acids (X) between the first two cysteines (C) at the amino terminal. The 
chemokine families are; C, CC, CXC and CX3C. The CC group contains chemokines 
CCL1 to 28, CXC group contains chemokines CXCL1 to17, C group contains XCL1 
and 2 and only one chemokine in the last group, CX3CL1 or fractalkine (Nomiyama et 
al., 2010). Chemokines bind to seven trans-membrane G-protein coupled chemokine 
receptors (GPCR) expressed on effecter cells. There are up to 22 chemokine receptors 
has been identified (Nomiyama et al., 2010). 
Chemokines secreted by endothelial cells during inflammation bind to negatively 
charged cell surface glycosaminoglycans such as heparan sulfate. This binding is 
crucial in localizing the chemokines on the endothelial cell surface and preventing the 
diffusion of chemokines into the blood stream (Wang et al., 2005; Gangavarapu et al., 
2012). Binding of chemokines to corresponding receptors induces a rapid leukocyte 
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arrest within milliseconds, especially under shear stress conditions. Leukocyte arrest 
results from integrin activation mediated by chemokines; is an inside-out signaling, 
while integrin binding to corresponding ligands is an outside-in signaling (Kinashi, 
2005). Inside-out signaling involves the activation of various intracellular signaling 
pathways such as phospholipase C and GTPase enzymes (Hyduk et al., 2007). This 
signaling induces a conformational change in integrins resulting in exposure of the 
ligand-binding pocket. This also induces the redistribution of integrins increasing 
integrin clustering and avidity. In addition, the binding of integrins to their ligands, for 
example the binding of LFA-1 to ICAM-1, initiates an outside-in signaling on 
integrin-expressing cells. This involves the activation of a cascade of signaling 
pathways such as focal adhesion kinase, src and Syk families. This signalling 
strengthens leukocyte adhesion and induces cytoskeleton changes essential for 
leukocyte arrest and crawling (Abram and Lowell, 2009). 
1.12.3 Leukocyte crawling and extravasation 
Following firm adhesion, adherent cells ‘crawl’ on blood vessel endothelial cells 
mediated by cell surface adhesion molecules mainly ICAM-1 (Schenkel et al., 2004). 
The crawling step is essential for leukocytes to seek a proper site for extravasation and 
is dependent on luminal chemokine expression and shear flow. Leukocytes 
transmigrate to the site of inflammation after crossing three barriers; endothelial cells, 
basement membrane and pericytes (Cinamon et al., 2004). Adherent leukocytes induce 
the formation of endothelial projections called transmigratory cups that are rich in 
ICAM-1 and VCAM-1 molecules. These projections initiate the migration of 
leukocytes in either paracellular or transcellular mechanisms (Muller, 2011). In 
paracellular transmigration, adherent leukocytes migrate through the junction of 
endothelial cells. This process is mediated by contraction of endothelial cells reducing 
endothelial-endothelial cell contacts. In addition, endothelial junction adhesion 
molecules such as platelet endothelial cell adhesion molecules (PECAM-1 or CD31), 
junctional adhesion molecule-A (JAM-A) and CD99 are redistributed and localized to 
the luminal surfaces (Muller, 2003). This movement creates an adhesive gradient 
guiding the adhered leukocytes to the site of extravasation. In addition, cross linking 
of junction molecules induces a signaling pathway resulting in the degradation of VE-
cadherin on adjacent cells (Schulte et al., 2011). In transcellular migration, adherent 
leukocytes cross the endothelial cell by forming a gateway in the cell itself. This type 
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of migration occurs in more restricted manner in the central nervous system and only 
in some kind of inflammation (Muller, 2011).  
The adherent leukocytes squeeze between the endothelial cells starting the penetration 
of the basement membrane to the site of inflammation. The basement membrane 
contains laminin proteins and collagen type IV, which are connected by various 
molecules such as heparan sulphate and proteoglycan perlecan (Hallmann et al., 
2005). Chemokines bound to the luminal heparan sulfate guide the adherent 
leukocytes to cross the basement membrane. Adhered leukocytes bind to laminins 
through integrins and secrete protease and heparanase enzymes enhancing basement 
membrane degradation at particular sites. A summary of this process is shown in 
Figure 1.6. 
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1.13 Role of endothelial cells in rejection 
Endothelial cells are vessel lining cells with wide range of fundamental physiological 
functions such as vascular permeability, coagulation and homeostasis. In 
transplantation, endothelial cells represent the first contact between the recipients’ 
immune system and donor graft beginning at the time of organ reperfusion. Graft 
endothelial cells play a fundamental role in different aspects of transplant biology 
either as an initiator of rejection or as participant and a target during rejection. HLA 
molecules on endothelial cells are able to present foreign antigens to circulating 
leukocytes, initiating alloimmune responses toward transplanted graft. In addition, 
inflammatory responses driven by endothelial immunogenicity disturb normal 
endothelial homeostatic functions and modulate their adhesive properties promoting 
leukocyte adhesion and migration to the transplanted graft.    
1.13.1 Endothelial cells as an initiator of rejection 
Endothelial cells in vivo express both HLA class I and HLA class II antigens (Page et 
al., 1992). Therefore, graft endothelial cells also express donor HLA molecules on 
their cell surfaces. This expression suggests that endothelial cells can initiate T-cell 
allorecognition, exposing graft antigens to the recipient’s immune system. The 
absence of co-stimulatory molecules on endothelial cells, such as CD80 and CD86, 
renders the memory T-cells but not naive T-cells the main responder cells (Shiao et 
al., 2005). This depends on HLA match grade and degree of disparity between the 
donor and recipients. Endothelial cells can activate memory CD4+ T-cells by a direct 
allorecognition mechanism as observed using immunodeficient mice transplanted with 
human skin graft. Activated cells proliferate in response to allogeneic endothelial cells 
producing inflammatory cytokine such as IFN-γ and IL-2 and causing vessel injury 
(Shiao, 2007). The production of inflammatory cytokines by activated T-cells is 
sufficient to induce allograft rejection after renal and cardiac transplantation (Tellides 
and Pober, 2007). The activation of memory CD4+ T-cells by direct allorecognition is 
observed exclusively on endothelial cells but not by epithelial cells or fibroblasts 
stimulated with IFN-γ (Samsonov et al., 2012). Memory CD8+ T-cells can also 
recognize allogeneic antigens on endothelial cells inducing cell migration to 
transplanted graft and maturation of CD8+ T-cells into cytolytic cells (Biedermann 
and Pober, 1998; Walch et al., 2013). It was reported that memory T-cells targeting 
infectious agents might be able to cross-react with allogeneic HLA antigens expressed 
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on donor endothelial cells inducing allograft rejection (Adams et al., 2003). In 
addition to direct recognition, antigenic fragments shed from apoptotic endothelial 
cells can be processed and presented by host antigen presenting cells inducing 
activation of both naïve and memory T-cells. T-cells activated by indirect mechanism 
produced a wider range of inflammatory cytokines including IFN-γ, IL-2, IL-4 and IL-
5 (Samsonov et al., 2012). The expression of inflammatory cytokines induces 
production of other cytokines by endothelial cells which in turn activate different T-
cell subsets (Briscoe et al., 1995). Furthermore, another study showed that endothelial 
cells can capture soluble foreign antigens and present these to antigen presenting cells 
thus accelerating the graft recognition (Vora et al., 1994).     
1.13.2 Endothelial cells as a mediator of rejection 
 Endothelial cell activation following transplantation results in the disruption of the 
endothelial homeostatic balance and induces proinflammatory changes augmenting the 
adhesive properties of the endothelium. Activation of endothelial cells might occur 
into two phases; a rapid early response (type I) or a slow response (type II). The rapid 
responses do not require protein synthesis, as endothelial cells secrete stored proteins 
from weibel-palade bodies to the cell-surface. Production of prostaglandin or NO by 
endothelial cells and translocation of P-selectin from stores to the cell surface are 
examples of this response (Pober and Sessa, 2007). Endothelial cells-derived from 
large vessels stimulated with HLA class I antibodies demonstrated a rapid 
translocation of P-selectin to the cell surface (Valenzuela et al., 2013a). In type II 
endothelial activation, new proteins are synthesized in response to inflammation such 
as in response to inflammatory cytokines TNF-α or IFN-γ. The expression of cell-
surface adhesion molecules and chemokines is induced, enhancing endothelial-
leukocyte interaction. Endothelial cells are able to synthesize various adhesion 
molecules, including VCAM-1 and ICAM-1 in a cytokine-dependent manner. 
Endothelial cells can also produce different chemokines such as CCL2 and CCL5 
inducing the adhesion of circulating monocytes which express corresponding receptors 
CCR1/CCR2 and CCR5, respectively (Grandaliano et al., 1997). In addition, 
endothelial cells can also express CXCL9, CXCL10 and CXCL11 inducing the 
adhesion of T-cells expressing CXCR3 (Manes et al., 2006). Exposure of endothelial 
cells to HLA class I antibodies induces the synthesis of adhesion molecules and 
different chemokines as will be discussed in chapter five.  
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Graft vessel thrombosis is one of the major characteristics observed during acute 
cellular rejection and antibody-mediated rejection (Shimizu and Colvin, 2005). The 
role of endothelial cells in maintaining blood flow and regulating the coagulation 
cascade highlights the contribution of endothelial dysfunction in inducing thrombosis. 
Under resting conditions, endothelial cells prevent platelet adhesion and express tissue 
factor pathway inhibitors maintaining continuous blood flow. In addition, expression 
of negatively charged cell-surface heparan sulphate repels negatively charged proteins 
such as albumin and clotting factors and facilitates the binding of anti-thrombin III, 
inhibiting thrombin activation (Platt et al., 1990). During inflammation, and especially 
during type II activation, endothelial cells synthesize and express pro-coagulant 
proteins such as tissue factor and fibrinogen-like protein 2 and lose the expression of 
some anti-coagulants such as thrombomodulin (Pober and Sessa, 2007). In addition, 
shedding of heparan sulphate during inflammation enhances the binding of platelets 
and clotting factors. Exposure of endothelial cells to donor specific antibodies has 
been shown to be associated with the shedding of heparan sulfate (Saadi and Platt, 
1995).   
1.13.3 Endothelial cells as a target during rejection    
Circulating leukocytes, antibodies, complement and non-immune agents might all 
contribute to allograft rejection and graft endothelial dysfunction. Host cytotoxic T-
cells directly recognize foreign HLA class I/peptide complexes displayed on graft 
endothelial cells, inducing apoptosis. This direct recognition is the main mechanism 
involved in acute cellular rejection (Meehan et al., 1997). Biopsies diagnosed with 
acute cellular rejection show evidence of the presence of cytolytic T-cells and mRNA 
related to these cells (Strehlau et al., 1997). The endothelial-cytolytic T-cell contact 
leads to endothelial lysis mediated by activation of endothelial death receptors or 
secretion of cytotoxic molecules such as perforin and granzyme B. The perforin 
permeates the cell membrane facilitating the entry of granzyme B into endothelial cells 
enhancing activation of the caspase pathway and cell apoptosis.   
The infiltration of NK cells to a transplanted allograft post-transplantation also has a 
role in inducing endothelial injury by ADCC as described earlier in this chapter (Hsieh 
et al., 2002). Expression of adhesion and chemotactic proteins induces infiltration of 
monocytes and their maturation to macrophages as observed in acute cellular and 
antibody mediated rejection (Wyburn et al., 2005). Macrophages also enhance the 
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development of capillary regression by inducing endothelial apoptosis. The latter may 
be mediated by the generation of TNF-α and reactive oxygen species such as nitric 
oxide enhanced also by the presence of IFN-γ (Martinez et al., 2008). Neutrophil 
recruitment is also associated with both antibody-mediated rejection and T-cell 
mediated rejection. Activated neutrophils produce reactive oxygen species and 
degradative enzymes contributing to endothelial cell injury (Morita et al., 2001). 
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1.14 Aim of the project 
In this project, the ability of HLA class I antibody in inducing the activation of 
allograft endothelial cells was examined. Since all previous studies were performed on 
large vessel-derived endothelial cells, this study was extended to examine the 
activation of microvascular endothelial cells. This includes the phosphorylation of 
various proteins and expression of adhesion molecules and chemokines.This study was 
performed using two sources of HLA class I antibody. Mouse monoclonal HLA class I 
antibody (W6/32) and allospecific antibody from patients who had a circulating HLA 
class I antibody at the time of the rejection of their transplanted kidneys were used. 
Characterization of endothelial cells was carried out first and then the activation of 
endothelial cells was assessed. The thesis was divided into chapters as follow: 
 Chapter one: General introduction; 
 Chapter two: General material and methods; 
 Chapter three: Characterization of endothelial cells and purification of mouse 
monoclonal antibody (W6/32); 
 Chapter four: Examination of activation of endothelial cell signaling; 
 Chapter five: Expression of endothelial cell surface adhesion molecules and 
chemokines; and examination of leukocyte migration and adhesion, and 
 Chapter six: Endothelial cell activation using allospecific antibodies.  
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2. Chapter Two- General Material and Methods 
2.1 General practice 
All laboratory work has been performed in a containment level II laboratory under the 
University Health and Safety policy. COSHH and BIOCOSH forms have been 
reviewed and signed before starting work. Procedures of cell culturing were performed 
in containment level II microbiological safety cabinets. The latter were routinely 
cleaned with 70% ethanol prior to use and periodically cleaned by "mycoplasma off" 
spray. All tissue culture equipment was sprayed with 70% ethanol before use. For 
routine culture, all cell lines were grown in plastic tissue culture flasks (Corning, UK) 
in two sizes (25 and 75cm
2
). All cell types were cultured in specific medium according 
to ATCC recommendations and were incubated in a humidified atmosphere of 5% 
CO2 at 37C. Adherent cell lines were placed horizontally in the incubator to allow for 
cell adherence while suspension cell lines were grown in vertical flasks. All culture 
media were supplemented with 10% Foetal Bovine Serum (FBS), 100 U/ml penicillin, 
100μg/ml streptomycin (Sigma) and 4 mM L-glutamine (Sigma). For a specific 
purpose where specified, cells were incubated in media containing 0.2% FBS and 1% 
Bovine Serum Albumin (BSA).  
2.2 Culture media 
2.2.1 MCDB-131 media 
MCDB-131 is the media that has been optimized to support the growth of Human 
Microvascular Endothelial Cells (HMEC-1). This medium (Sigma, M8537-1L) was 
purchased in a powder form containing L-glutamine. The content of each vial was 
dissolved in 900 ml of sterile water containing 15.7ml of 7.5% sodium bicarbonate 
(Sigma, S8761). Complete medium was prepared by adding FBS (10%), 10 ng/ml 
Epidermal Growth Factor (EGF) (Peprotech), 1μg/ml of hydrocortisone (Sigma), 100 
U/ml penicillin and 100 μg/ml streptomycin. To obtain sterilized media, the medium 
was passed through sterile 0.2μm filters using a vacuum pump. 
2.2.2 RPMI 1640 media 
RPMI 1640 medium (Sigma, 5886) was used to support the growth of suspension cell 
lines. Cells were normally grown in this medium after the addition of 10% FBS 
(whole serum or IgG stripped serum), 4 mM L-glutamine, penicillin (100 U/ml) and 
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streptomycin (100 μg/ml). Medium supplemented with 1% BSA was used in some 
experiments as specified. 
2.2.3 DMEM media 
This media (Sigma, D5546) was used to support the growth of the EA.hy926 
endothelial cell line. Complete media was obtained after the addition of 10% FBS, 4 
mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 μg/ml).  
2.2.4 DMEM F12 media 
DMEM F-12 Ham's media (Sigma, D6421) was used to grow adherent epithelial cell 
lines. Cells were normally grown in this medium after the addition of the supplements; 
10% FBS, 4 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 μg/ml).  
2.3 Cell lines and primary cells 
2.3.1 Human microvascular endothelial cell line (HMEC-1) 
This cell line is a model for microvascular endothelial cells generated from the 
transfection of human dermal microvascular endothelial cells (HMEC) with a PBR-
322-based plasmid containing the coding region for the Simian Virus 40 A gene 
product, large T antigen, for immortalization purpose (Ades et al., 1992). These cells 
were cultured in horizontal 75-cm
2
 flasks using complete MCDB-131 media in a 
humidified 5% CO2 atmosphere at 37
ο
C. SV40 transformed endothelial cells retained 
the characteristic cobblestone morphology of the confluent primary endothelial cells 
and maintained the expression of endothelial cell markers such as CD31 (PECAM-1) 
molecules. The modulation of the expression of adhesion molecules by inflammatory 
cytokines renders HMEC-1 cells a good model to study endothelial-leukocyte 
interaction occurring in micro-blood vessels. They also express a high level of HLA 
class I antigens and low level of HLA class II molecules. All experiments related to 
stimulation with HLA class I antibody in this project were performed using this cell 
line. Confluent monolayer cells were routinely sub-cultured every 3-4 days. Adherent 
cells were washed twice with sterile phosphate buffered saline (PBS) and detached 
using trypsin-EDTA and split in the ratio 1:3 or 1:4 depending on cell density. 
General Materials and Methods 
47 
2.3.2 Human large vessels endothelial cell line (EA.hy926) 
EA.hy926 is an immortalized cell line that represents an experimental model of large 
vessel endothelial cells. These cells were formed by fusion of human umbilical vein 
endothelial cells (HUVEC) and human lung carcinoma cells (A549) (Edgell et al., 
1983). The cells were cultured in 75-cm
2
 flask horizontally in complete DMEM media 
in a humidified 5% CO2 atmosphere at 37
ο
C. The cells maintain the major 
characteristic of primary endothelial cells such as the expression of CD31. Confluent 
monolayer cells were routinely sub-cultured every 2-3 days. Adherent cells were 
washed twice with sterile PBS and detached using trypsin-EDTA and split in the ratio 
1:4 or 1:5 depending on cell density. Because the cells are a fusion of two cell types, 
the choice of this cell line for our project was unfavorable since the expression of 
more than six HLA class I antigens on the cell surface is suspected. These cells were 
used as a comparison between microvascular and large vessel endothelial cells. 
2.3.3 Human kidney epithelial cell lines (HK-2 & HKC-8) 
HKC-8 and HK-2 are human renal proximal tubular epithelial cells transfected with 
adenovirus 12-SV40 (Racusen et al., 1997) and human papilloma virus (HPV 16) 
E6/E7 genes (Ryan et al., 1994), respectively. These cells were grown in DMEM F-12 
media supplemented with 10% FBS, 4 mM L-glutamine, penicillin (100 U/ml) and 
streptomycin (100 μg/ml) in a humidified 5% CO2 atmosphere at 37
ο
C. Confluent 
monolayer cells were routinely subcultured every 2-3 days. Adhered cells were 
washed twice with sterile PBS and detached using trypsin-EDTA and split in the ratio 
1:4 or 1:5 depending on cell density. 
2.3.4 Human embryonic kidney 293 cell line (HEK 293 cells) 
This cell line produced by transformation of human embryonic kidney cultured cells 
by adenovirus 5 DNA, which incorporates 4.5 kilobases from its genome into 
chromosome 19 (Graham et al., 1977; Louis et al., 1997). The cell line is widely used 
in transfection experiments due to the ease in cell culturing and transfection. In this 
project, the cell line was used to optimize a transfection protocol and validate different 
transfection reagents. The cells were grown in complete RPMI 1640 media and sub-
cultured into 4 or 5 flasks by washing with PBS and detached by trypsin-EDTA. 
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2.3.5 Hybridoma cell line (W6/32) 
This is a hybridoma cell line produced from a fusion between mouse myeloma B-cells 
(lymphoblast) and B-cells from spleens of immunized mouse with membrane from 
human tonsils (Barnstable et al., 1978). These cells produce a mouse IgG2a isotype 
immunoglobulin in culture media which recognize a monomorphic antigenic 
determinant common to HLA-A, B and C class I antigens. The antibodies recognize 
HLA class I molecules expressed on all nucleated cells and platelets (Barnstable et al., 
1978). They were grown in 200-cm
2
 flask vertically in RPMI-1640 media containing 
10% IgG stripped FBS (PAA, A15-706), 4 mM L-glutamine, penicillin (100 U/ml) 
and streptomycin (100 μg/ml) in a humidified 5% CO2 atmosphere at 37
ο
C. The cells 
were left to grow for around two weeks before the conditioned media was collected. 
The remaining cells were subcultured into 3 or 4 flasks depending on cell density. The 
collected media was filtered through 0.2μm filter and frozen (-20οC) for subsequent 
antibody purification.  
2.3.6 RAJI B cell line  
This is a B human cell line of hematopoietic origin derived from 40 years old Nigerian 
patient with Burkitt's lymphoma (Pulvertaft, 1964). They were grown in 75-cm
2
 flask 
vertically in RPMI 1640 media containing 10% FBS, 4 mM L-glutamine, penicillin 
(100 U/ml) and streptomycin (100 μg/ml) in a humidified 5% CO2 atmosphere at 
37
ο
C. The cells were split every 4-6 days into 2-3 flasks depending on cell density. 
Because the cells express a high level of HLA class II antigens, they were used as a 
positive control in HLA class II molecules staining experiments. 
2.3.7 Human monocytic cell line (THP-1) 
This is a human monocytic cell line established from the peripheral blood of a 1 year 
old human male with acute monocytic leukemia (Tsuchiya et al., 1980). THP-1 cells 
express Fc and C3b receptors and lack the expression of surface and cytoplasmic 
immunoglobulin. The cells can be differentiated into macrophage-like cells using 
various chemical agents such as phorbol 12-myristate 13-acetate (PMA). 
Characterization of the cells showed their expression of CD49d (leukocyte marker) 
and chemokines receptors; CCR5, CXCR4 and CXCR2. They were grown in 75-cm
2
 
flask vertically in RPMI 1640 media containing 10% FBS, 4 mM L-glutamine, 
penicillin (100 U/ml) and streptomycin (100 μg/ml) in a humidified 5% CO2 
atmosphere at 37
ο
C. 
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2.3.8 MOLT-16 T-cell line 
This cell line is a human T cell derived from the peripheral blood of a 5-year-old girl 
with T cell acute lymphoblastic leukemia (Minowada et al., 1984). The cells express 
CXCR4, CCR1 and CXCR3 chemokine receptors. They were grown in 75-cm
2
 flask 
vertically in RPMI 1640 media containing 10% FBS, 4 mM L-glutamine, penicillin 
(100 U/ml) and streptomycin (100 μg/ml) in a humidified 5 % CO2 atmosphere at 
37
ο
C. The cells were split every 4-6 days into 2-3 flasks depending on cell density.  
2.3.9 Peripheral blood mononuclear cells (PBMC)  
The preparation of PBMC was performed freshly when needed from blood taken from 
healthy volunteers. Isolation of viable mononuclear cells was performed using a 
density gradient separation solution, Lympholyte-H (Cedarlane laboratories). Blood 
(15 ml) was collected in 50 ml conical tube containing heparin at final concentration 
25 IU/ml. The blood was diluted with an equal volume of RPM1 1640 media without 
any additives. Lympholyte reagent was added into diluted blood in ratio 1:2 
underneath the blood layer gently avoiding the mixing of the two layers. The tubes 
were centrifuged at 800 g for 20 minutes with no brake at room temperature. After 
centrifugation, three layers were formed; a red pellet containing red blood cells and 
dead cells, top plasma layer and interface layer containing mononuclear cells. The 
interface layer was collected into fresh tube and washed three times with PBS at 500 g 
for 5 minutes each. The cells were then counted and re-suspended in 1% BSA RPMI 
1640 media at final concentration of 2 million cells per ml and incubated in 25 cm
2 
flask horizontally for 1 hour.      
2.4 Cell counting 
When required, cells were counted using an improved Neubauer chamber 
haemocytometer. Ten microliter of cells suspended in an appropriate volume of media 
was inserted onto the chamber covered with a suitable glass slide. Cells within the 25 
squares of the chamber were counted. At least two areas were counted and the mean 
multiplied by 10
4
 were considered the number of cells in one milliliter. 
2.5 Cell cryopreservation 
In order to maintain a stock of the cell lines and to retain cells from an early passage, 
cryopreserved cells were frozen in liquid nitrogen. Cells in their log growth phase (70-
80% confluent) were re-suspended in freezing medium, which consists of 10% 
General Materials and Methods 
50 
dimethylsulphoxide (DMSO-Sigma) in complete media or FBS. Cells were counted 
and frozen in different batches of 5-10 million cells per vial in cryovials (Corning, 
UK). The vials were placed in a Mr. Frosty container (isopropyl alcohol) which 
maintains a gradual reduction in temperature, 1
0
C every minute when stored at -80
0
C 
overnight. On the second day, the cells were transferred into a liquid nitrogen tank for 
long-term storage. For cell recovery, cells were thawed by rapid incubation in a 37C 
water bath. Once thawed, the cells were transferred immediately into 10-15 ml of fresh 
pre-warmed medium.  
2.6 Mycoplasma screening 
Mycoplasma infection is one of the major risk factors affecting cells in tissue culture. 
This is due to the difficulty in realizing the presence of this type of infection which 
induces biochemical alteration of cell metabolism. This results in morphological and 
molecular changes at later stage (Macpherson, 1966). During this project, a routine 
test was performed to ensure the absence of mycoplasma infection in all cell cultures 
by using a Luminometric assay. This assay was performed on culture supernatant of 
cells grown for at least 48 hours by using a Mycoalert kit (Lonza, LT37-618). In this 
assay, the lyophilized reagent and lyophilized substrate were solubilized in 0.6 ml of 
the assay buffer. A plain assay buffer was used as a negative control while the positive 
control was prepared by adding 0.3 ml of the assay buffer into lyophilized positive 
control. The reagents were allowed to stand for 15 minutes at room temperature to 
equilibrate.  Two ml of cell supernatant was centrifuged at 200 g for 5 minutes to 
pellet any cells. 100 µl of cell supernatant, positive control and assay buffer were 
added into eppendorf tubes and mixed with 100 µl of reagent. After 5 minutes 
incubation, integrated readings for one second were recorded (reading A). After that, 
100 µl of substrate was mixed into each tube and incubated for 10 minutes before 
recording (reading B). The ratio between reading B and A was calculated and the 
results interpreted in accordance with this guide: < 1 Negative, 1-1.2 Borderline, > 1.2 
Positive. All cell lines in this project were negative for mycoplasma infection as the all 
readings were less than 1. 
2.7 Flow cytometry  
2.7.1 General principle 
A flow cytometer is an instrument that has a wide range of applications including: 
analysing the expression of cell surface or intracellular molecules, estimating the 
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heterogeneity in a particular cell population, and defining the purity of an isolated cell 
preparation. These applications are based on the capability of this machine to analyse 
different physical and chemical characteristics of a single particle including cells, 
microorganisms and even chromosome preparations. The instrument detects these 
characteristics for each particle separately while it passes through a laser light source 
following hydrodynamic focusing on a very small nozzle using pressurized isotonic 
sheath fluid stream. The cells passing through the laser scatter the light in different 
directions according to their size and granularity; which can be detected by different 
detectors. One detector is in front of the light beam captures forward angle light scatter 
(FSC) and one on the side which captures side scatter (SSC). The FSC represents cell 
size and the latter represents cell granularity, a larger size and more granular cells 
produce higher forward and side scatter signals, respectively. In addition, using 
different fluorescence dyes which can bind specific cell component or intercalate 
within DNA or RNA can be detected by a specific system on the instrument. Once the 
bound dye intersects the laser light, it is excited to a higher energy state and emits light 
at a higher wavelength, called the emission spectra, upon returning to the ground state. 
The emitted fluorescence light is collected via optics and directed to a series of filters 
each one responsible for the detection of a narrow range of wavelengths. Each of these 
detectors, which are called photomultiplyer tubes, can change photon energy into an 
electrical signal which is recorded by the computer system as fluorescence intensity 
for each event.  
In the immunofluorescence technique, a fluorescence dye is conjugated to an antibody 
specific for a particular antigen and the fluorescence intensity produced is correlated 
positively with the amount of that antigen. In this project, three fluorescence dyes 
were used which are fluorescein isothiocyanate dye (FITC) which has excitation-
emission spectra 488-530/30 and propidium iodide and phycoerythrin (PE) which have 
excitation-emission spectra 488-585/40. As the emission spectra of FITC overlaps the 
emission spectra of the PE, therefore, a compensation step is performed in experiments 
where both dyes were used simultaneously. This step involves the subtraction of the 
contribution of each dye from the other by running each fluorchrome separately first.      
2.7.2 Indirect immunofluorescence 
In indirect immunofluorescence staining method, a specific antigen is identified by 
using a fluorescently conjugated secondary antibody that recognizes a primary 
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antibody bound to that antigen. In this method, adherent cells were washed twice with 
PBS and detached by using enzymatic free-PBS based cell dissociation buffer at 37
ο
C 
for 15 minutes. Detached cells were re-suspended in complete media and centrifuged 
at 500 g for 5 minutes. Cells were counted and 2 x 10
5
 cells were used per tube. The 
cells were washed once with 2% FBS in PBS before staining with primary or isotype-
control antibodies. These antibodies were used at concentrations recommended by the 
manufacturer and incubated at 4
ο
C for 20 minutes. Then, the cells were washed twice 
with 2% FBS-PBS solution at 500 g for 5 minutes. Secondary antibodies were added 
and again the cells were incubated at 4
ο
C for 20 minutes. Finally, the cells were 
washed twice with PBS/FBS solution at 500 g for 5 minutes and re-suspended in 200-
400 μl PBS/FBS. Cells were scanned on flow cytometry machine using FACSDiva 
software acquiring 10,000 events.   
2.7.3 Direct immunofluorescence 
In this method, one step staining is performed using one antibody specific to the 
examined antigen rather than using primary and secondary antibodies. In direct 
staining, an antibody specific to the antigen of interest is conjugated directly to 
fluorescence dye and the fluorescence intensity of the labeled cells is recorded by flow 
cytometry. 80 % confluent cells were treated with a particular stimulus either at 
different concentrations for one time point or at a constant concentration for various 
time points. After treatment, the cells were detached using cell dissociation buffer and 
pelleted by centrifugation at 500 g for 5 minutes. 1 X 10
5
 cells were incubated with 
fluorescence-conjugated antibodies or isotype control at 4
ο
C for 20 minutes. Before 
analysis, cells were washed twice with 2% FBS in PBS and re-suspended in 200-400 
μL of this solution and analyzed on flow cytometer machine using linear scale for FCS 
and SSC. 
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2.8 Western blotting 
2.8.1 General principle 
Western blotting or protein immunoblotting is a widely used method to detect a 
specific protein in a mixture which might be a tissue homogenate or cell lysate. This 
analytical technique is based on the separation of proteins by gel electrophoresis 
followed by protein transfer onto a suitable membrane to be accessible and detectable 
by specific-antibodies. The separation can be performed on the basis of isoelectric 
points, molecular weight, electric charge or a combination of these factors. In this 
project, the separation was based on the molecular size by using a reducing agent and 
a detergent, Sodium Dodecyl Sulphate or SDS. β-mercaptoethanol is a reducing agent 
that cleaves the disulfide bonds between cysteine residues converting the tertiary 
structure of the proteins into linear polypeptide chains, while SDS maintains the 
denatured form of the proteins and coats the proteins with negative charge enabling 
the separation according to the molecular size. Separated proteins are transferred into a 
membrane where the specific protein is determined by indirect immunochemistry. 
Polyvinylidene fluoride or PVDF is the most hydrophobic membrane that is used to 
immobilize the separated proteins in the transfer process. This membrane is 
characterized by its capacity to bind various amino acids non-specifically and can 
tolerate probing with different antibodies. The non-protein bound areas of the 
membrane are blocked before probing with primary protein specific antibody. After 
incubation, a secondary antibody conjugated with an enzyme, fluorophore or isotope is 
added. The chemiluminescence method depends on the label on the secondary 
antibody. Horseradish peroxidase (HRP) is one of the most common and safe 
conjugates and was used in this project. The detection of this enzyme, which correlates 
with the abundance of the examined protein, is determined indirectly by the addition 
of a peroxide-luminol based reagent. The peroxidase enzyme catalyzes the oxidation 
of the luminol, resulting in the emission of the light. The emitted light can be captured 
by a camera imager device or by the exposure to X-ray film.  
2.8.2 Preparation of cell lysate 
Cells were stimulated as required and lysed immediately using lysis buffer consisting 
of cell lytic solution (Sigma) supplemented with protease inhibitor tablets (Roche, 
USA) and kept in aliquots in (-20
0
C). The phosphatase inhibitor solution (Thermo 
scientific, USA) was added in the experiments of the determination of phosphorylated 
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proteins. Around 40 μl of lysis buffer was added per million cells with continuous 
mixing. Cell lysates were incubated for 10 minutes on ice with gentle hand shaking 
every 5 minutes. To ensure complete cell lysis and protein extraction, samples were 
sonicated using an MSE Soniprep 150 sonication. The sonication was performed twice 
separated by cooling in ice for one minute to avoid heating causing protein 
denaturation. The samples were centrifuged at 15000 g for 15 minutes to pellet cells 
debris and either used immediately or stored at -80
0
C.  
2.8.3 Determination of protein concentration 
The protein concentration of each sample was estimated colorimetrically using a 
BiCinchoninic Acid (BCA) protein assay kit (Pierce, USA) in accordance with the 
manufacturer’s instructions. This assay is based on the biuret method in which Cu1+ 
ions produced by a reduction of Cu
2+
 ion under an alkaline condition by sample 
proteins are determined using the BCA reagent. The addition of the latter forms a 
coloured, water-soluble complex with Cu
1+
 ions that shows a strong absorbance at 562 
nm. The extent of the colour on sample is proportional to the amount of the protein 
presence. The concentration of the unknown protein was evaluated from a bovine 
serum albumin standard curve which was run in parallel with unknown samples. Ten 
microlitres of standard samples ranging from 125-2000 μg/ml or from unknowns were 
mixed with 200 μl of a working solution in a 96 microwell plate. The working solution 
was prepared prior to use by mixing reagent A (BCA in alkaline buffer) with reagent 
B (4% cupric sulfate) in a ratio of 50:1. The plate was incubated at 37
0
C for 30 
minutes before recording the absorbance at 490 nm.  A linear regression analysis of 
the standard curve was calculated and the unknown protein concentration was 
determined by interpolation. Figure 2.1 represents an example of a standard curve used 
to determine the protein concentration of unknown samples during this project. 
2.8.4 SDS-PAGE electrophoresis 
SDS-PAGE is Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis. SDS-
PAGE gels consist of a stacking gel on the top of a resolving gel. The amount of 
acrylamide in the resolving gel determines the percentage of that gel and its pore size. 
In this project, 10% gel was used to separate large proteins such as an antibody, and 
12% was used for smaller proteins with 60-40 kDa molecular weight. The following
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Figure 2.1: Standard curve of protein concentration. 
Different known concentrations of BSA were mixed with the BCA reagent provided in 
BCA assay kit as explained in the methods. After 30 minutes incubation, the 
absorbance was measured at 490 nm. The linear regression was determined between 
the concentration and the absorbance. The standard curve was used for the 
determination of the protein concentration of unknown samples. 
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constituents, all from Sigma, were mixed to prepare 5 ml resolving gel solution and 3 
ml stacking gel solution sufficient to cast one gel and added to glass and alumina 
plates: 
Resolving gel (12%) Stacking gel 
2ml of 30% acrylamide solution 0.5ml of 30% acrylamide solution 
1.3ml of 1.5M Tris-HCl, pH 8.8 380l of 1 M Tris-HCl, pH 6.8 
1.6ml deionised water 2.1ml deionised water 
50l of 10% (w/v) SDS 30l 10% (w/v) SDS 
50l of 10% (w/v) ammonium persulphate 50l 10% (w/v) ammonium persulphate 
2μl of N,N,N,N – 
tetramethylethylenediamine 
 
3μl of N,N,N,N – 
tetramethylethylenediamine 
 
The resolving gel was left to polymerize for around 30 minutes after the addition of a 
butanol layer on the top of the gel to prevent air disturbance. After polymerization, the 
butanol was washed by deionized water and the stacking gel was added on the top. 
The stacking gel was left to polymerize after insertion of the combs. To prepare cell 
lysates, samples were mixed with laemmli loading buffer (12% sodium dodecyl 
sulfate, 60 % (v/v) of 20 % glycerol, 30 % (v/v) β-mercaptoethanol, 0.0012 % 
bromophenol blue, 0.375 M Tris-base pH 6.8) and boiled for 5 minutes before loading 
on the gel. The addition of β-mercaptoethanol in the loading buffer was excluded in 
non-reducing conditions where the intact structure of desired protein is required. The 
gels were immersed in running buffer consists of 3g/L Tris base, 14.4g/L Glycine and 
1g/L SDS at pH 6.8. In parallel, prestained protein marker (Fementas, SM0671) was 
run on the same gel each run as a guide for the molecular weight of the studied 
proteins. Gels were run at room temperature at 30 mA for each gel using mini vertical 
electrophoresis unit (SE260, GE Life Sciences). 
2.8.5 Gel staining 
In some experiments, staining of separated proteins on gel was required to ensure the 
presence of purified proteins. For this purpose,  Coomassie  staining consisting of 10% 
(v/v) acetic acid, 10% (v/v) Isopropanol and 0.1% (w/v) Coomassie Blue powder was 
used to visualize the separated protein. After 20 minutes incubation at room 
temperature on the rocker, the gels were destained in three sequential steps using three 
different solutions. The stained gels were mixed with destain 1 consisting of 25% 
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propanol with 10% acetic acid for 10 minutes before the addition of destain 2. After 
the removal of destain 1, destain 2 consisting of 10% propanol and 10% acetic acid 
was added to the gel and washed many times until the clear bands were obtained. The 
gels were stored in destain buffer 3 containing 10% acetic acid until acquisition of the 
image using Alphaimager software of AlphImager gel documentation system (Alpha 
innotech, USA). 
2.8.6 Wet Protein transferring 
After protein separation, the proteins were transferred to PVDF membrane. This 
membrane was equilibrated in absolute methanol for ten seconds followed by washing 
with distilled water twice for 5 minutes each. After washing, the membranes were 
soaked in transfer buffer consisting of 3g Tris base, 14.4g glycine and 100ml methanol 
made up to 1L in distilled water 10 minutes before performing the transfer sandwich. 
The gels and transfer electroblotting cassette were soaked in transfer buffer before 
being assembled. Protein transfer was performed either overnight at 30 V or for 2 
hours at 250 mA using a transfer tank (TE22, GE Life Sciences).  
2.8.7 Immunoblotting 
After transfer, the PVDF membrane was washed once with PBS containing 0.1 % 
tween 20 (TPBS) for 5 minutes to remove the transfer buffer before blocking. To 
block the non-specific binding, the membrane was blocked with 3 % BSA for 
phosphorylated proteins or 5% milk for other proteins in 0.1 % TPBS at room 
temperature for 1 hour before probing with primary antibody. Primary antibody was 
diluted in the blocking buffer at a concentration recommended by a manufacture and 
added to the membrane. This was incubated overnight at 4
ο
C with continuous shaking 
on a rocker. After incubation with primary antibodies, the membrane was washed 
three times with 0.1 % TPBS for 5 minutes each. A HRP-conjugated secondary 
antibody was added for 1 hour at room temperature with continuous shaking. After 
three washes with TPBS, peroxidase activity was detected by using Pierce enhanced 
chemiluminscent (ECL) substrate (Thermo-Scientific) for 5 minutes. The detection of 
bound antibodies was dependent on the oxidation of the luminol in the substrate by 
HRP conjugated to the secondary antibody and consequent emission of light. The 
resulting bands were visualized by exposure of the membrane to Kodak film (Sigma) 
using ready to use developer and fixer (Tentenal, Germany). The exposure time was 
varied according to the expression of the desired protein, starting with 2 minutes 
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exposure as a guide. As a loading control, membrane was stripped at room 
temperature for 30 minutes using stripping buffer consisting of; 1.5 % glycine, 0.1 % 
SDS and 1 % Tween 20 (v/v) followed by washing with TPBS and reprobed with 
loading control specific antibody by the same procedure.   
2.9 Molecular biology  
Precautions should be taken when DNA isolation and amplification is performed. 
DNA isolation and amplification in a standard way occurs in two different areas to 
avoid contamination of the original samples with an amplified sequence. This 
principle is applied when performing critical analysis such as tissue typing in 
transplantation. All reagents used for this procedure should be at a high degree of 
purity and designed for molecular biology use. These reagents are also RNase free 
which provide protection during the RNA isolation process. All reagents used for 
RNA isolation in this project were molecular biology grade available commercially. 
All areas used for RNA isolation where decontaminated by using RNase removal 
spray (Sigma). All pipettes were decontaminated by exposure to UV light for 30 
minutes prior to use. Filter sterile tips and autoclaved sterile Eppendorfs were used 
during the whole process.  
2.9.1 General principle of RNA isolation 
Isolation of RNA allows study of the modulation of a gene expression following 
exposure to a particular stimulus or its modulation during the development of diseases. 
In this project, RNA was extracted using guanidinium-thiocyanate-phenol-chloroform. 
This method was developed by Chomczynski and Sacchi in 1987 (Chomczynski and 
Sacchi, 1987). In this method, cells were lysed in a mixture of guanidinium 
isothiocyanate and phenol mixture. The former acts as a denaturing solution that 
separates rRNA from ribosomes and it denatures cell proteins including RNase 
enzyme to ensure RNA integrity. The presence of phenol dissolves the proteins and 
lipids leaving water soluble materials in the aqueous phase. The addition of 
chloroform followed by centrifugation results in the formation of upper aqueous phase 
and lower pink phase separated by interphase containing a high amount of DNA. At 
acidic pH, the isolated RNA retains in the upper phase while lipids and proteins are 
present in organic phase along with phenol and chloroform. The precipitation of RNA 
from the aqueous phase is achieved by the addition of propanol. The extraction 
process is terminated by washing with 70% ethanol and dissolving in RNase free 
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water. A commercial reagent, Tri-reagent (Sigma), based on this principle was used in 
this project. This reagent has a high capacity to extract RNA from samples in 
comparison with other methods such as column based method.  
2.9.2 Procedure of RNA Isolation 
Tri reagent was used to isolate total RNA from cells according to manufacturer’s 
instructions. The addition of this reagent at a rate of 1 ml per 5x106 cells for 5 minutes 
at room temperature resulted in a complete dissolution of the cells. When lysing cells 
in a 12 well plate, 250 μl of Tri reagent was used and the volumes of all further 
solutions were adjusted accordingly.  After incubation, 200 μl of chloroform (Sigma) 
was added per 1 ml of the reagent and the mixture was mixed vigorously by hand for 
15 seconds. The mixture was then allowed to stand at room temperature for 2-3 
minutes. After centrifugation at 12000 g for 15 minutes at 4
ο
C, the upper colourless 
aqueous layer was isolated into freshly autoclaved Eppendorfs avoiding disturbance of 
the interfacial layer.  Soluble RNA in this layer was precipitated by the addition of 250 
μl of isopropanol (Sigma) per 1 ml of Tri reagent. After 10 minutes incubation at room 
temperature, samples were centrifuged at 12000 g for 10 minutes at 4
ο
C. The RNA 
pellet was then washed with 75% (v/v) ethanol at an equal volume of the used Tri 
reagent and centrifuged at 7500 g for 5 minutes. Isolated RNA was left to dry before it 
was re-suspended in 10 μl of RNase free water.   
2.9.3 Analysis of RNA concentration and purity 
A Nanodrop spectrophotometer was used for determination of RNA concentration and 
purity. The machine measures the absorbance at 230, 260 and 280 nm and calculates 
these values as a guide to nucleic acid purity and concentration. One microliter of 
extracted RNA was applied to the Nanodrop after blanking with 1 μl of RNase-free 
water. The concentration was obtained in ng/μl. RNA absorbs light at a wavelength of 
260 nm and the optical density relates proportionally to the amount of RNA in 
samples. Contaminant proteins and organic chemicals in isolated RNA samples absorb 
light at 280 and 230 nm, respectively. Therefore, the purity of isolated RNA sample 
was evaluated by examining 260/280 and 260/230 ratios. The reading around 2 for 
both of the ratios is considered as a pure sample free from protein and phenol 
contamination and suitable for cDNA synthesis. Figure 2.2 shows an example of RNA 
concentration measurement and purity using the Nanodrop. 
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2.9.4 Analysis of RNA integrity 
For analysis of RNA integrity, isolated RNA was run on 1.5 % agarose gels containing 
ethidium bromide. For a mini gel, 0.75 g of agarose was dissolved in 45ml of distilled 
water and 5 ml of 10X Tris-acetate EDTA electrophoresis buffer or TAE (48.4 g of 
Tris base, 11.4 ml glacial acetic acid and 3.7g of EDTA dissolved in 1L). Dissolving 
the agarose was achieved by gentle boiling in a microwave for 2 minutes with 
avoidance of extra heating. The solution was left to cool slightly under running tap 
water followed by the addition of 3 µl of ethidium bromide at final concentration 0.5 
μg/ml. The gel was allowed to solidify for around 15 minutes at room temperature. For 
preparation of RNA sample, 1µg of RNA was suspended in RNase free water and 
mixed with 3 µl of 5 X loading buffer consisting of 50% Glycerol, 1mM EDTA (pH 
8.0) and 0.4% Bromophenol blue in a total volume 15 µl. The sample was run using 
1X TAE running buffer at 100 V for around 20 minutes, until the dye front reached the 
third quarter of the gel. Around 10 µl of 1 kb DNA ladder was run in parallel to check 
the size of the products. Figure 2.3 shows an example of intact RNA. The intact RNA 
was confirmed by the presence of 28S and 18S rRNA subunits and the absence of 
smeared RNA.   
2.9.5 cDNA synthesis. 
Isolated RNA was reverse transcribed reversibly to complementary DNA (cDNA) 
using RT first strand kit (Qiagen).  This kit contains all the components required for 
cDNA synthesis, including oligo dT, a random hexamer primer mixture, assay buffer, 
reverse transcriptase enzyme, dNTP and RNAase free water. Each reaction was 
performed in a total volume of 20 μl using 5 μg RNA adjusted to the maximum 
volume 10 μl with RNAase free water. Ten μl of cDNA solution containing 1 μl 
primer, 4 μl assay buffer, 3μl reverse transcriptase enzyme and 2 μl RNAase free 
water was mixed with 10 μl of RNA and transcribed in a thermocycler (G-storm) at 
42C for 15 minutes followed by rapid heating at 95C for 5 minutes. The resultant 
cDNA was used as a template for q-PCR reactions. 
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Figure 2.2: Examination of RNA purity and concentration using a Nanodrop 
instrument. 
The system was initialized and blanked with 1 μl of RNase free water followed by 1 μl 
of RNA sample. The concentration and purity ratios were recorded for each sample.    
                                           
 
 
 
             
 
Figure 2.3: Examination of the integrity of isolated RNA. 
The integrity of isolated RNA was verified by running on 1% agarose gel from three 
random samples. The efficiency of the isolation was assessed by the presence of intact 
rRNA 28S and 18S subunits.  
28S rRNA 
18S rRNA 
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2.10 Real time-polymerase chain reaction 
2.10.1 General principle 
Quantitative polymerase chain reaction or q-PCR is a precise technique for 
measurement of changes in gene expression. In this method, a specific sequence of 
DNA is amplified in a geometric way to produce many copies of the original sequence. 
The amplified product can be measured either at the end point of the reaction in 
"traditional" PCR or during the amplification process in the real-time PCR method. The 
latter has many advantages that overcome the traditional PCR in the context of the 
processing time and accuracy. In a way that traditional PCR is more qualitative method 
in determining the presence or absence of a particular gene of interest at the end point of 
the reaction, q-PCR is able to detect small differences in the level of the expression 
between examined samples. In contrast to traditional PCR, in q-PCR the amplification 
and quantification occur simultaneously. An ideal amplification plot has an exponential, 
linear and plateau phases, in which the amplicon is quantified as the amplification is in 
progress and reaches plateau when the reaction components are depleted. The PCR 
product is determined in the exponential phase and crosses the threshold level in a cycle 
called the threshold cycle. The detection process in this method requires the presence of 
fluorescent reagents that detect the amount of the amplified product. These reagents are 
either sequence specific or non-sequence specific. An example of sequence specific 
reagent is the 5' nuclease probe such as the Taqman assay, while the non-sequence 
specific reagents are the DNA double stranded intercalating dyes such as SYBR green 
or Evagreen.   
2.10.2 Taqman assay  
In this project, Taqman primer-probes (or 5' nuclease assay) was used to determine the 
modulation in the expression of genes of interest. In this assay, a set of two primers and 
probe in the presence of exonuclease activity of Taqman DNA polymerase are used. 
The DNA probe is a non-extendable sequence that is labelled with a fluorescence 
reporter at the 5' end and quencher at the 3' end. This probe is able to bind 
complementary sequence on the desired gene in either an exon boundary spanning or 
non-exon spanning manner. In the intact probe, the presence of the quencher in the close 
proximity to the reporter enables the former to absorb the fluorescence light emitted by 
the latter preventing the emission of any light. In the first step of the amplification 
process, the reaction mixture is heated to 95
0
C for 15 seconds which is required for 
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optimal activation of the DNA Taq polymerase enzyme. In the second step, the 
hybridization of the two oligonucleotide primers and probe to the complementary 
sequence on the DNA strand occurs at lower temperature of around 40-60
0
C for one 
minute; this is called the annealing step. DNA synthesis is initiated as the polymerase 
extends the primers using the deoxynucleotide triphosphate (dNTPs) forming new 
complementary strands in the 5' to 3' direction. The elongation process occurs at around 
72
0
C for 1-2 minutes and requires the addition of optimum salt and MgCl2 
concentrations which are required for enzyme activity. As the polymerase reaches the 
probe, the exonuclease activity of the enzyme cleaves the hybridized probe enhancing 
separation of the reporter from the quenchers. This separation eliminates the quencher 
role allows the reporter fluorescence to be detected by real-time instrument. This 
thermal cycle is repeated between 30-40 times before the reaction is ended. During the 
exponential phase each cycle doubles the amount of the original sequence ending with 
2
n
 copies, where n is the number of cycles.    
2.10.3 Primer efficiency 
PCR efficiency is defined as the rate at which a PCR product is generated. This is 
represented as a percentage value with a maximum PCR amplification efficiency almost 
100%. If the PCR amplicon is doubled during each cycle, that reflects a 100% 
efficiency. This value is estimated from a standard curve specific for each primer which 
is prepared by serial dilutions of cDNA sample. In this curve, a log of input nucleic 
acids on X-axis is plotted against CT values on the y-axis. The gradient of the semi-log 
regression is determined to evaluate the amplification efficiency by this equation: 
efficiency = 10^ (-1/gradient)-1. The gradient value equals to -3.32 represents 100% 
amplification efficiency. A value that is more negative than this value reflects an 
amplification process less than 100 % while more positive value reflects sample quality 
or pipetting problems. In this project three human primer probes with FAM fluorophore 
and TAMRA as a quencher were used which are glyceraldehyde 3-phosphate 
dehydrogenase or GAPDH (HS9999905-m1), CXCL8 (HS00174103-m1) and 18S 
(HS99999901_s1). Figure 2.4 shows the efficiency curves for these primers performed 
using 10 times serial dilution from cDNA sample.  
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Figure 2.4: The standard curve for tenfold dilution series of cDNA for (A) 18S, 
(B) GAPDH and (C) CXCL8 transcripts. 
The efficiency of GAPDH and 18S primers was confirmed by using ten serial dilutions 
from cDNA prepared from 5 μg of untreated HMEC-1 cells. While the efficiency of 
CXCL8 was assessed by using cDNA prepared from 5 μg RNA of 10 ng /ml TNF-α 
treated cells for 3.5 hours. The reactions were run on an Applied Biosystem instrument 
(StepOnePlus) for 40 cycles. For gradient and efficiency values, the data were analyzed 
by linear regression converting x values to a log scale. 
 
 
(A) 
(B) (C) 
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2.10.4 Semi quantitative real time-PCR 
To determine the change in expression of a particular gene at a molecular level a 
quantitative PCR reaction was performed using a cDNA template transcribed from the 
isolated RNA. PCR reaction was prepared in 20 μl total volume by mixing 10 μl of 2X 
master mix, containing Taq man polymerase enzyme and buffers essential for its 
activity, 8 μl distilled water molecular grade, 1 μl of cDNA and 1 μl of desired primer in 
96 wells plate. The mixture was amplified using Applied Biosystem (Step one plus). 
The amplification process was carried out for 40 cycles in the following sequential 
steps:  95
0
C for 10 minutes followed by 40 cycles of 95
0
C for 15 seconds followed by 1 
minute at 60
0
C. Each PCR run contains a target gene in parallel with a housekeeping 
gene. In addition, each run has negative control wells where RNA sample and master 
mix mixture were checked separately for any contamination.  
2.10.5 Data analysis-comparative ∆∆CT value  
Quantification of PCR products can be performed by relative expression of target gene 
compared to control group. The latter requires the measurement of target gene and 
housekeeping gene (constantly expressed between samples) on both control and treated 
samples. For the purpose of this project, relative expression of target gene was used in 
which a comparative ∆∆CT value was calculated and converted to fold change. In this 
analysis, ∆CT value between target gene and housekeeping gene is calculated for both 
control and treated samples, ∆CT= CT target gene - CT housekeeping gene. The ∆CT 
value for the control group is subtracted from the ∆CT value of the treated group, ∆CT 
treated group - ∆CT control group. This value is then converted to fold change or 
relative expression calculated as 2
- (∆CT treated group - ∆CT control group)
. All PCR data analysis in 
this project is performed under this principle using REST 2009 software.   
2.11 Statistical analysis 
All data were plotted using GraphPad prism software version 5. Comparison between 
different groups were verified using one way analysis of variance (ANOVA) followed 
by Bonferonni test as a post hoc test considering the significance at P < 0.05, or two 
way ANOVA followed by Bonferroni post-tests. In this study, * refers to p<0.05, ** 
refers to P<0.01 and *** p<0.001. Comparison between two groups were performed by 
unpaired Student’s t-test at P<0.05. All flow cytometry data were analyzed and graphed 
by WinMDI 2.9 and FACSDiva software using median fluorescence intensity (MFI) 
value from each sample. Densitometric analysis of western blotting data was performed 
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using AlphaImager software of AlphaImager gel documentation system and the ratio 
between analyte and loading control was plotted (Alpha innotech, USA). 
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3. Chapter Three-Characterization of Cell Lines and Antibody 
Purification  
3.1 Introduction 
Macovascular (large vessel) and microvascular (small vessel) endothelial cells show 
similarity in cell morphology and some of their characteristics. However, endothelial 
cells from different blood vessels have a distinct gene regulation and protein expression 
which facilitates their functions. In addition, expression of some types of cell surface 
antigens and adhesion molecules between the two cell types are different. Expression of 
HLA class II antigens in vivo is detectable on microvascular but not on macrovascular 
endothelial cells; suggesting their involvement in antigen presentation (Muczynski et 
al., 2003). Non-stimulated microvascular endothelial cells, in contrast to large vessel 
endothelial cells, show a constitutive expression of ICAM-1 adhesion molecules which 
is up-regulated on both cell types by stimulation with different inflammatory cytokines. 
During inflammation, both of cell types respond differently to some extent to 
extracellular stimuli. In response to TNF-α stimulation, microvascular endothelial cells 
express different types of chemokines and cytokines such as IL-β and CXCL5 which is 
either not expressed or expressed at low level by large vessel endothelial cells (Viemann 
et al., 2006). The interaction between the endothelial cells and leukocytes, in addition, 
occurs mostly in post-capillary vessel which is necessary for leukocyte trafficking. 
Therefore, both of cell types respond differently to the inflammatory responses 
occurring following solid organ transplantation (Taflin et al., 2011).   
Donor specific antibodies can form against HLA class I and class II antigens inducing 
allograft rejection. Polymorphism of these antigens is mainly in the peptide binding 
groove which can be identified by different methods to determine the HLA type and 
antigen specificity. Traditionally, serological typing was used to identify the cell surface 
expression of HLA antigens. In this method, patient lymphocytes are mixed with sera of 
known specificity toward particular HLA antigens; sera were collected mostly from 
multiparous women. After the addition of complement and a vital dye¸ the antigen-
antibody complex is formed activating the complement system and inducing cell death. 
Dead cells with permeable membrane internalize the vital dye (Acridine Orange or 
Ethidium bromide) which is visualized under phase contrast microscopy. By excluding 
and comparing the results between the wells, the HLA type can be identified. However, 
this method is no longer used in HLA typing (Tinckam, 2009). 
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The predominantly used HLA typing nowadays is mainly performed using DNA-based 
methods. These methods are dependent on the amplification of DNA sequence by 
polymerase chain reaction technique followed by different detection methods. The most 
commonly used molecular typing methods: are polymerase chain reaction-specific 
sequence primer (PCR-SSP), sequence specific oligonucleotide probes (PCR-SSOP) 
and direct DNA sequencing. The highly polymorphic regions of HLA molecules are 
encoded by second and third exons in the case of HLA class I and second exon in the 
case of HLA class II. Both PCR-SSP and PCR-SSOP can be performed at low, 
intermediate or high resolution. Low resolution typing gives similar resolution to the 
serological typing with identification of allele groups. The intermediate resolution 
typing provides possibility of group of alleles at more restricted manner. With higher 
resolution typing, additional information about other exons might be achieved by 
adding additional primers (SSP) or additional probes (SSOP) to determine the exact 
HLA type (Nunes et al., 2011). 
Luminex assay is the most commonly used in PCR-SSOP method. Isolated DNA is 
amplified using biotin-conjugated primers specific to either HLA-A, HLA-B or HLA-C 
locus. Amplified products are then denatured and the denatured strands hybridize with 
sequence specific oligonucleotides probes attached to microsphere beads panel. 
Streptavidin-conjugated phycoerythrin is then added and the fluorescence intensity of 
phycoerythrin in each bead is determined by Luminex flow analyzer. HLA alleles are 
then assigned using specific software containing sequences listed in IMGT/HLA 
database. This method is considered slightly expensive compared to other types, since it 
requires a set of beads and Luminex analyzer (Petersdorf, 2008). 
The PCR-SSP is the most widely used PCR-based typing. In this method, a particular 
HLA allele is amplified by using specific sequence primer in a pre-designed 96 wells 
tray. The content of the wells is then analyzed by separation into agarose gel. 
Interpretation of the results is performed by assigning the amplified products in the gel 
with a corresponding primer in the wells. Among the advantages of this method are: 
equipment required, test cost and time to perform the assay. The minimum molecular 
equipment such as thermal cycler and gel electrophoresis are sufficient to perform this 
test with reasonable cost depending on the cost of the primers. The method is 
considered the quickest molecular method that can be used for typing a deceased donor. 
In addition, the typing can be performed with low to high resolution according to the 
primer mix used (Erlich et al., 2001). Therefore, this method was used in this project. 
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The majority of previously published studies on HLA class I antibody have used 
macrovascular endothelial cells (Jin et al., 2004; Jindra et al., 2008c). Therefore, in this 
project the effect of HLA class I antibody on the activation of microvascular endothelial 
cells (HMEC-1) was examined. In addition, microvascular endothelial cells are a good 
model to study leukocyte adhesion and migration. HMEC-1 cells were characterized for 
the expression of endothelial cell markers, CD31 and CD34 and compared to a model of 
macrovascular endothelial cells, EA.hy926 cells. The modulation in the expression of 
HLA class II antigens on both cell types by inflammatory cytokines was also 
determined. Mouse HLA class I antibody, W6/32, was chosen for this project. W6/32 
antibody binds to all HLA class I antigens reacting with the monomorphic determinants 
present in the α3 domain and β2-microglobulin. The hybridoma cell line (W6/32) was 
grown and the antibody was purified from the conditioned media and used in this 
project as will be described in later sections within this chapter.      
3.2 Specific Aims 
In this chapter the characterization of human endothelial cells was performed. This 
includes; 
 The expression of endothelial cell markers, CD31 and CD34; 
 The modulation in the expression of HLA class II molecules by inflammatory 
cytokines IFN-γ and TNF-α; 
 HLA class I and ABO genotyping of HMEC-1 cells, and 
 The purification of HLA class I antibody (W6/32).  
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3.3 Specific materials and methods 
3.3.1 Immunofluorescence staining on chamber slides 
Immortalized endothelial cells (EA.hy926 and HMEC-1) grown in chamber slides until 
confluency as described in section 2.3.1 and 2.3.2 were washed twice with PBS after 
removing the media. Washed cells were fixed with cold methanol at -20
ο
C for 10 
minutes. Once the slides were dried, they were covered with 0.1 % triton X-100 /PBS 
and incubated at 4
ο
C for 10 minutes in a humid atmosphere. After washing twice with 
PBS for 10 minutes, 5% BSA was added and cells were incubated at 4
ο
C for one hour to 
block non-specific binding. Primary mouse anti-human CD31 and CD34 antibodies 
(R&D system) were diluted in BSA at the manufacturer’s recommended concentration 
and cells were incubated at 4
ο
C overnight. After washing three times, secondary 
antibody, rabbit anti-mouse FITC conjugated antibody (Sigma), was added at an 
optimum dilution (1:150) followed by incubation in a dark humid atmosphere for two 
hours at the room temperature. After washing, DAPI was added for five minutes in the 
dark at a final concentration of 2 μg/ml prepared in PBS. After washing three times, 
fluorescence mounting media (DAKO) was added and the slides were covered by cover 
slips and sealed with nail polish solution. Slides were examined by fluorescence using 
an inverted microscope (Leica LCM microscope).   
3.3.2 Treatment of endothelial cell lines with IFN-γ and TNF-α 
Interferon-γ (IFN-γ) and tumor necrosis factor (TNF-α) were supplied as lyophilized 
powder (R&D system). They were reconstituted in PBS in accordance with 
manufacturer’s instructions to make a stock solution of 200 μg/ml and 100 μg/ml, 
respectively. The stock solution was aliquoted and stored at -20
ο
C. For stimulation, cells 
were grown in 12-well plates until 50-70 % confluency. Different concentrations of 
IFN-γ were prepared in complete media just before use, either alone or in combination 
with TNF-α. Cells were washed once with PBS and then treated with cytokine-
containing media. Cells were incubated at 37
ο
C for different time points ranging from 
24-72 hours without media change. After cytokine stimulation, cells were detached and 
analyzed for the expression of HLA class II antigens by flow cytometry. 
3.3.3 Direct immunofluorescence staining for HLA class II expression 
After treatment, healthy cells were washed once with PBS and detached using enzyme-
free cell dissociation buffer (Invitrogen). Cells were counted and 1X10
5
 cells were 
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washed once with 2% FBS in PBS at 500g for 5 minutes. The cells were stained with 
mouse anti-human PE conjugated HLA class II antibody (Abcam) specifically for HLA-
DR, DQ and DP. After 20 minutes incubation at 4
ο
C, cells were washed twice with 2% 
FBS in PBS before analysis by flow cytometry as described in section 2.7.3. Unstained 
cells were used to determine the gates for FSC against SSC and SSC against FL-2 
channel. In parallel, cells stained with isotype control antibody (PE-conjugated mouse 
IgG2a) were used to adjust the background staining. This value was subtracted from the 
median fluorescence of all stained tubes.    
3.3.4 Acid treatment assay 
To produce a cell line without expression of HLA class I molecules, HMEC-1 cells 
were exposed to sodium citrate buffer at pH 3 (Sugawara et al., 1987). This buffer was 
prepared by mixing 0.123M Na2HPO4 containing 1% (w/v) bovine serum albumin with 
0.263 M citric acid and adjusting the pH to 3. Adherent cells were treated with this 
buffer for two minutes before washing with PBS and detachment by enzyme-free cell 
dissociation buffer. Cells were stained with 12 μg/ml of mouse HLA class I antibody 
(W6/32) for 20 minutes at 4
ο
C. Following washing with 2% FBS/PBS, incubation with 
FITC-conjugated rabbit anti-mouse IgG (Sigma) was performed at 4
ο
C for another 20 
minutes. After further washing steps, cells were resuspended in 200 μl FBS/PBS and 
analyzed by flow cytometry. After compensation, propidium iodide was added at a final 
concentration of 2.5 μg/ml to exclude dead cells. The acid treatment induced not more 
than 10% of cell death. 
3.3.5 Effect of trypsin treatment on cell surface HLA class I expression 
To investigate the ability of trypsin to induce proteolytic cleavage and shedding of HLA 
class I molecules expressed by HMEC-1 cells, adherent cells were detached with either 
trypsin or non-enzymatic PBS-EDTA cell dissociation buffer and washed in 2% 
FBS/PBS. Cells were counted and 2X10
5
 cells were stained for the expression of HLA 
class I molecules by W6/32 antibody followed by FITC conjugated rabbit anti-mouse 
IgG as previously described. Cells resuspended in 200 μl FBS/PBS were analysed by 
flow cytometry using FSC/SSC and excitation/emission for FITC dye 488/530. 
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3.3.6 Genotyping of cell lines for the HLA class I  
3.3.6.1  DNA Extraction  
A T 75 cm
2
 flask of 80-90 % confluent endothelial cells was trypsinized and 8 million 
cells were re-suspended in 200 μL PBS. These cells were treated with proteinase K and 
incubated at 50
ο
C for 15 minutes to dissociate the cell membrane. DNA extraction was 
performed using Geno-M6 instrument (QIAGEN) located in the National Health Service 
(Blood and Transplant laboratory (NHSBT), Newcastle). This machine isolates DNA 
from cell lysates through its binding to the silica surface of magnetic particles in the 
presence of a chaotropic salt. The bound DNA is then washed and eluted by elution 
buffer. The DNA concentration was determined by Nanodrop and 60 ng/µl of DNA was 
used for genotyping.  
3.3.6.2 HLA typing using PCR-SSP 
Low to medium resolution typing for HLA class I (A,B,C) and HLA class II (DR,DQ) 
were performed by PCR-SSP using a Bio-Rad HLA SSP kit according to manufacturer's 
instructions. The kit consists of 96 well plates with each well containing dried primer 
mix that identifies a group of alleles. Each well also contains an internal positive control 
primer which amplifies a 1069 bp fragment of human growth hormone to demonstrate 
successful PCR amplification. The concentration of the control primers is lower than the 
allele-specific primer pairs as this could render these bands weak in the presence of 
positive allele-specific product. The HLA class II genotype was also performed in case 
this was needed for a later analysis, but only the HLA class I genotype was used in this 
project. PCR reaction was performed by mixing 748 µl of distilled water, 544 µl of PCR 
cocktail and 8.7 µl of Taq DNA polymerase. 10 μl of the PCR reaction was added to the 
negative control wells before the addition of the DNA sample. 68 µl of DNA sample 
was then mixed with the PCR reaction and 10 µl was added to the remaining wells for 
HLA class I and class II typing. The samples were amplified in thermal cycler using the 
following protocol:  
                        Initial denaturating            96
ο
C      2   minutes 
                        Denaturing                         96
ο
C      10 seconds 
                        Annealing & Extension      65
ο
C     60 seconds  
                         Denaturing                         96
ο
C    10 seconds  
                         Annealing                           61
ο
C    50 seconds 
                         Extension                           72
ο
C     30 seconds 
10 cycles 
20 cycles 
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3.3.6.3 Agarose electrophoresis  
Post-PCR, the PCR product in each well was loaded into 2% agarose gels which were 
prepared by boiling 2 g of agarose in 100 ml of 1X Tris Boric acid EDTA (TBE) until 
completely dissolved. The solution was cooled to < 60
ο
C, and 4 µl of ethidium bromide 
was added to 50 ml of the solution. The solution was then poured into sealed gel trays 
with combs. The gels were left to solidify at the room temperature for 15 minutes. After 
gel solidification, the gels were placed into the gel tank and covered with TBE buffer. 
The PCR products from the wells were pipetted into the gel wells. The gels were 
running at 8 voltage /cm for 15 minutes. A DNA ladder with molecular weight ranging 
from 50-1000 base pairs was used to check the size of PCR products. The gels were 
visualized on UV transilluminator and photographed for documentation and 
interpretation. The results were interpreted using Bio-Rad SSP typing software. In this 
project, three cell lines were genotyped: HMEC-1 endothelial cells, HK-2 and HKC-8 
epithelial cell lines. 
3.3.6.4 ABO genotyping of HMEC-1 cell line by PCR-SSP 
DNA was extracted from HMEC-1 cell line as described previously in section 3.3.6.1. 
Since the ABO antigens are carbohydrates, ABO genotyping is performed by 
determining the presence of glycosyl transferase enzymes located on chromosome 9 
responsible for building the sugar blocks. Specific sequences were amplified by 
traditional PCR in 8 reactions strip containing primers for these enzymes (inno-train, 
Germany). The amplicon was run on 2% agarose gel as described in the previous 
section and interpreted manually using the manufacturer’s sheet.  
3.3.7 Purification of W6/32 antibody 
3.3.7.1 Media collection and processing 
As a source of HLA class I antibody for this project the W6/32 hybridoma cell line was 
grown in medium containing IgG stripped serum as described previously in section 
2.3.5. The media collected and stored at -20
ο
C was thawed and filtered through a 0.2 
μM sterile filter to remove any debris that might block the column during the 
purification process. 
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3.3.7.2 Affinity chromatography 
3.3.7.2.1 General principle 
Affinity chromatography is the most commonly used biochemical technique to purify 
antibody from a complex mixture. This technique is dependent on reversible interaction 
between protein and its ligand in a highly selective way such as between antigen and 
antibody. The bound antibody is then eluted or recovered by using other factors such as 
changes in pH, ionic strength or polarity. The specificity and stability of the system is 
maintained by the use of bispecific ligands that are supported on chromatography 
matrices. These ligands can be naturally derived products, bacterial derived receptors, 
antigens or anti-antibody. The application of bacterial proteins to antibody purification 
is based on the high affinity between the bacterial protein and antibody. The most 
frequently used bacterial protein ligands are Staphylococcal protein A and streptococcal 
protein G, which are extracted from bacterial cell walls of Staphylococcal aureus and 
Streptococcal group C and G, respectively. Both proteins are used in the purification of 
intact antibody and characterized by their capacities to bind different subclasses of 
antibody.  
Protein A contains five domains that can bind different subclasses of immunoglobulin. 
In the case of IgG, the binding to protein A occurs through the Fc region of the antibody 
between the CH2 and CH3 domains. A protein A column has high purification 
efficiency due to its selectivity in binding IgG antibody; in particular, mouse IgG1, 
IgG2b, IgG3 and very high affinity for IgG2a. In this project, bacterial receptor in the 
form of a protein A column was used for the purification of W6/32 antibody (mouse 
IgG2a) from a hybridoma conditioned media as was described in section 2.3.5. Media 
containing antibody was run through the protein A column at a natural pH (8.2). Elution 
with acidic buffer at pH 2 was then used for elution of bound antibody. To avoid 
antibody denaturation and aggregation at low pH, neutralization to a neutral or slightly 
basic pH was performed.    
3.3.7.2.2 Antibody purification using Protein A column 
The fast protein liquid chromatography system (FPLC) was used to purify the HLA 
class I antibody (mouse IgG2a), (Äkta, GE healthcare). Before purification, the protein 
A column (GE healthcare) was washed with 75% ethanol followed by washing with 
filtered PBS solution. The media was kept on ice and passed through a pre-equilibrated 
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protein A column overnight at a rate of 0.5 ml to 1 ml/minute. After running the media, 
the column was washed with PBS and the bound antibody was eluted using 0.1 M 
glycine at pH 2.2. The eluates were collected into 1 ml Eppendorf tubes containing 0.5 
ml of 1M Tris PH 8.8 to prevent antibody degradation. The protein content of each 
fraction was detected by an inbuilt detector which estimates the absorbance of each 
fraction at 280 nm. Figure 3.1 shows the resultant peak that occurs at a high antibody 
concentration. The protein concentration of the fractions was also assessed using a 
Nanodrop. The fractions that contain antibodies were combined together and 
concentrated using a 20 ml centrifuge concentrator tube (Thermo scientific) with cutoff 
100 kDa. The protein concentration of the concentrator was determined by BCA assay 
as it was described in section 2.8.3. Purified antibody was adjusted to 1 mg/ml in sterile 
PBS, aliquoted into small Eppendorf tubes and stored at -20
0
C.  
3.3.7.3 ELISA assay 
The presence of mouse IgG antibody in each fraction was assessed by Enzyme-Linked 
Immunosorbent Assay (ELISA). Eluted fractions were diluted with carbonate coating 
buffer (15 mM Na2CO3, 35 Mm NaHCO3, pH 9.6), 1/10 and 1/100, and incubated 
overnight at 4
ο
C in 96 well plates. The wells were washed three times with 0.1 % tween 
20 in PBS (TPBS) and then blocked with 3% BSA for 30 minutes at the room 
temperature. Anti-mouse HRP antibody (Sigma) was added to the wells at concentration 
(1:5000). After 1 hour incubation at the room temperature, wells were washed three 
times with TPBS. The plate was then developed using a solution containing 0.4 mg/ml 
O-phenylenediamine (OPD) in 50mM citrate at pH 5 in the presence of 0.012% (v/v) 
H2O2. The reaction was stopped after 30 minutes using 2M sulphuric acid and the 
absorbance was recorded at 490 nm. Blank wells contained all reagents except the 
W6/32 antibody. 
3.3.7.4 Reducing SDS-PAGE  
The purification of antibody was confirmed by separation on 10% SDS-PAGE gel 
under reducing condition using β-metcaptoethanol. The addition of this agent 
dissociates the antibody to its heavy and light chains which appear at 55 and 25 kDa, 
respectively. Five μg of antibody was mixed with 2 X loading buffer containing β-
metcaptoethanol and heated for 10 minutes. The sample as well as the prestained protein 
marker was run on 10% SDS-PAGE electrophoresis at 30 mA for around 1.5 hour. The 
gel was stained using coomassie stain and destained as described in section 2.8.5. 
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Figure 3.1: Purification of W6/32 antibody using a protein A column. 
The media was passed through the protein A column at 0.5 ml/minute overnight. The 
bound antibody was eluted by 0.1 M glycine (pH 2.2). The eluted protein in each 
fraction is detected by UV light which gives the absorbance of each fraction at 280 nm. 
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3.3.7.5 Indirect immuno-fluorescence staining for HLA class I expression  
To determine the expression of HLA class I on HMEC-1 endothelial cells, the cells 
were detached using cell dissociation buffer, washed once in 2% FBS/PBS and counted. 
2X10
5
 cells were added into each tube and stained with different concentrations of 
W6/32 antibody ranging from 36 µg/ml to 0.005 µg/ml. After incubation for 20 minutes 
at 4
0
C, cells were washed twice with 2% FBS/PBS. FITC-conjugated rabbit anti-mouse 
IgG antibody was added at a concentration recommended by the manufacturer and 
incubated again for 20 minutes at 4
0
C. After incubation, cells were washed twice with 
2% FBS/PBS and resuspended into 200 µl of FBS/PBS before analysis by flow 
cytometer. 
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3.4 Results 
3.4.1 Expression of CD31 and CD34 on endothelial cells 
Platelet derived endothelial cells adhesion molecule (PECAM-1 or CD31) is a 
transmembrane glycoprotein with molecular weight 130 kDa. It is a member of the 
immunoglobulin superfamily molecules. It is expressed on the surface of platelets, 
neutrophils, monocytes, macrophages and at endothelial intracellular junction. CD31 
plays an important role in facilitating the migration of inflammatory cells during 
inflammation process and is used as an endothelial cell marker. EA.hy926 and HMEC-1 
endothelial cells were shown to express CD31 molecules by the indirect 
immunofluorescence staining as shown in Figure 3.2. To confirm this result, expression 
of CD31 on EA.hy926 cell line was investigated by flow cytometry at various antibody 
concentrations as shown in Figure 3.3. CD34 is a transmembrane glycoprotein with 
molecular weight 110 kDa presents on various cell types including endothelial cells of 
blood vessels but not lymphatic origin, stem cells, leukemic cells and dendritic cells. 
The function of CD34 is not clear; however, its location at cell to cell junction suggests 
a role in leukocyte extravasation to inflammatory sites. In bone marrow, CD34 
facilitates the attachment of stem cells to bone marrow. HMEC-1 cell line expressed 
CD34 at low level as examined by immunofluorescence staining. In contrast, there was 
no CD34 expression on EA.hy926 cell line as shown in Figure 3.2. 
 
 
 
 
 
 
 
 
Characterization of Endothelial Cells  
79 
           EA.hy926 cell line                             HMEC-1 cell line 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Indirect CD31 and CD34 immunofluorescence staining on 
EA.hy926 and HMEC-1 endothelial cells. 
 Cells grown on chamber slides were fixed and stained using mouse anti-human 
antibodies against CD31 and CD34 molecules followed by FITC-conjugated rabbit anti-
mouse antibody. Slides were examined by fluorescence microscope (Leica). The data 
are representative of two independent experiments. 
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Figure 3.3: Expression of CD31 molecules on EA.hy926 cells examined 
by flow cytometer. 
 Panel A shows the expression of CD31 molecules on EA.hy926 cell surface using 
different concentrations of mouse anti-human CD31 antibody. Panel B shows flow 
cytometer histogram for CD31 expression showing unstained (red), secondary antibody 
(blue) and different concentrations of primary CD31 antibody ranging from 100-500 
µg/ml (green, purple, yellow). The data are representative of two independent 
experiments. 
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3.4.2 Expression of HLA class II antigens on endothelial cells stimulated 
with IFN-γ 
Human endothelial cells in vivo express HLA class II antigens at low level and this 
expression is lost in vitro during cell culturing. However, the expression of these 
molecules can be modulated in a concentration and time dependent manner by different 
cytokines. Interferon-γ (IFN-γ) is a proinflammatory cytokine produced by a variety of 
lymphatic lineage cells such as T-cells, B-cells and NK cells. Previous studies have 
shown that IFN-γ can induce the expression of HLA class II molecules on endothelial 
cells (McDouall et al., 1997; Muczynski et al., 2003). As shown in Figure 3.4, 
unstimulated EA.hy926 and HMEC-1 endothelial cells expressed a negligible level of 
HLA class II molecules which is upregulated significantly following stimulation with 
IFN-γ. The increase in the expression was dependent on cytokine concentration as 
shown by using different cytokine concentrations ranging from 0.3 nM to 2.9 nM for 72 
hours. Although the expression of HLA class II molecules on both cell types was 
increased with IFN-γ treatment, HMEC-1 microvascular endothelial cells showed a 
higher response to lower concentration of IFN-γ compared to EA.hy926 cells.  
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Figure 3.4: Expression of HLA class II antigens on EA.hy926 and HMEC-1 
endothelial cells following stimulation with IFN-γ.  
Endothelial cells were incubated with different concentrations of IFN-γ for 72 hours 
before cell detachment. Cells were stained with PE-conjugated mouse anti-human HLA 
class II antibody and analyzed by flow cytometer. A and B show unstained EA.hy926 
and HMEC-1 cells, respectively. C shows isotype control PE-conjugated mouse IgG2a 
on EA.hy926 cells. D and E show examples of staining with HLA class II antibody on 
EA.hy926 and HMEC-1 cells, respectively. F shows positive control using Raji B-cells. 
G Bar chart represents median fluorescence intensity of the two cell types. The data 
were analyzed by two way ANOVA followed by Bonfferoni test. *** p<0.001 
compared to EA.hy926 at the same concentration. The data are representative of three 
independent experiments.  
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3.4.3 Expression of HLA class II antigens on endothelial cells stimulated 
with both IFN-γ and TNF-α 
Tumor necrosis factor-α (TNF-α) is a non-glycosylated protein with molecular mass of 
17 kDa. It is a proinflammatory cytokine secreted by cell types such as mast cells and 
endothelial cells in response to inflammatory stimulus. The modulation in the 
expression of HLA class II antigens on endothelial cells in response to a costimulation 
with IFN-γ and TNF-α was examined on both EA.hy926 and HMEC-1 cells. EA.hy926 
cells were treated with varying concentrations of TNF-α ranging from 0.29 nM to 5.7 
nM with a constant concentration of IFN-γ (1.5 nM) for 72 hours. It was expected that 
the addition of these two cytokines collectively to the endothelial cells would produce a 
synergistic effect on the expression of HLA class II molecules, since both are pro-
inflammatory cytokines. However, this treatment significantly abrogated the ability of 
IFN-γ to induce the expression of HLA class II antigens. In addition, as the 
concentration of TNF-α increases the inhibitory effect increases accordingly, as shown 
in Figure 3.5. The addition of TNF-α at 0.29 and 5.7 nM reduced the expression of HLA 
class II antigens by around 50% and 80%, respectively compared to cells treated with 
IFN-γ only. However, the increase in expression was still statistically significant 
compared to the untreated group. Treatment of HMEC-1 cells with the same cytokines 
combination induced a similar effect as shown in Figure 3.6. 
To confirm these findings, HMEC-1 and EA.hy926 cells were treated with the higher 
concentration of TNF-α (5.7 nM) in combination with different concentrations of IFN-γ, 
5, 10 and 25 nM at different time points. As previously observed, treatment of both cell 
types with different concentrations of IFN-γ did not reverse the inhibitory effects 
mediated by TNF-α at any time point 24, 48 or 72 hours. As the concentration of IFN-γ 
increased the inhibition of expression was reduced. In addition, TNF-α treatment alone 
had no significant effect on the expression of HLA class II molecules on EA.hy926 cells 
but there was a significant increase on HMEC-1 endothelial cells as shown in Figure 3.7 
and Figure 3.8, respectively.  
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Figure 3.5: Expression of HLA class II molecules on EA.hy926 cells following 
stimulation with IFN-γ and TNF-α.  
Cells were incubated with 1.5 nM IFN-γ and different concentrations of TNF-α ranging 
from 0.29 to 5.7 nM for 72 hours followed by flow cytometry analysis. Cells treated 
with combined cytokines were compared to IFN-γ treated group using one-way 
ANOVA followed by Bonferonni test. The data are representative of two independent 
experiments. *** p <0.001. 
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Figure 3.6: Expression of HLA class II molecules on HMEC-1 cells following 
stimulation with IFN-γ and TNF-α. 
Cells were incubated for 72 hours with 1.5 nM IFN-γ combined with TNF-α at different 
concentrations ranging from 0.29 to 5.7nM followed by analysis using flow cytometer. 
The analysis between the groups was performed by one-way ANOVA followed by 
Bonferroni test and compared to IFN-γ treated group. *** p < 0.001. The data are 
representative of two independent experiments.  
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Figure 3.7: Expression of HLA class II molecules on EA.hy926 endothelial 
cells following stimulation with IFN-γ and TNF-α at different time points. 
Cells were incubated for 24, 48 and 72 hours with 5.7 nM TNF-α and different 
concentrations of IFN-γ (5, 10 and 25 nM) before flow cytometry analysis. Statistical 
analysis was performed using two-way ANOVA followed by Bonferonni test compared 
to corresponding untreated group. *** p<0.001. The data are representative of three 
independent experiments.  
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Figure 3.8: Expression of HLA class II molecules on HMEC-1 cell line following 
stimulation with IFN-γ and TNF-α at different time points.  
Cells were incubated for 24, 48 and 72 hours with 5.7 nM TNF-α and different 
concentrations of IFN-γ (5, 10, 25 nM) before flow cytometry analysis. Statistical 
analysis was performed using two-way ANOVA followed by Bonferroni test compared 
to untreated corresponding group. * p<0.05 and *** p<0.001, respectively. The data are 
representative of three independent experiments. 
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3.4.4 Effect of acid treatment on HLA class I expression on endothelial cells  
The effect of acid treatment on HLA class I antigen expression was investigated. 
HMEC-1 endothelial cells were treated with monosodium citrate solution (pH 3) for 2 
minutes. Different citrate concentrations were used to determine the lowest 
concentration that reduced HLA class I expression. Around 80% reduction in the 
expression of these antigens was achieved with concentrations between 0.06 -0.26 M 
when compared to untreated group. Treatment with 0.01 and 0.03 M induced a 
reduction in the antigen expression by 20% and 60%; respectively, compared to 
untreated groups as shown in Figure 3.9. Treatment with citrate solution at the above 
concentrations did not induce more than 10% in cell death as shown by staining with PI; 
however, exposure to citrate concentration higher than 0.26 M induced significant cell 
death (data not shown). Therefore, 0.06 M was used for further experiments.  
The time required to recover the expression of HLA class I antigens post-treatment was 
examined. HMEC-1 cells were treated with 0.06 M of citrate solution for 2 minutes 
after which the solution was replaced with fresh media. The cells were detached at 
different time intervals and stained for the expression of HLA class I antigens using 
W6/32 antibody. As shown in Figure 3.10, the cells gradually regained the expression 
of the cell surface HLA class I antigens, this started within 30 minutes after treatment. 
The complete expression of HLA class I molecules, comparable to untreated cells, was 
seen after 24 hours. The cell viability was assessed by trypan blue at each time point 
before analysis by flow cytometry. HMEC-1 microvascular endothelial cells were used 
for all further experiments. 
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Figure 3.9: Effect of sodium citrate treatment on the expression of HLA class I 
molecules on HMEC-1 cells.  
Adherent HMEC-1 cells were exposed to different concentrations of citric acid solution 
ranging from 0.26 to 0.01 M for 2 minutes. Cells were detached and stained with 12 
μg/ml of W6/32 antibody and analyzed by flow cytometry. Panel A shows unstained, B 
secondary antibody only, C untreated, D 0.26 M treated, E 0.03 M treated, F 0.01 M 
treated and G bar chart of the median fluorescence intensity. The data were compared to 
untreated group by one way ANOVA followed by Bonferroni test. ** p<0.01 and *** 
p<0.001. The data are representative of two independent experiments.    
Unstained MFI 103 
G) 
F) E) D) 
C) B) A) Secondary MFI 116 Untreated MFI 25,185 
0.26 M MFI 5,336 0.03 M MFI 9,479 0.01 M MFI 19,522 
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Figure 3.10: Recovery of the expression of HLA class I antigens on HMEC-1 
cells following sodium citrate treatment.  
Adherent HMEC-1 cells were treated with 0.06 M of sodium citrate (pH 3) for 2 
minutes. Cells were detached and stained with 12 μg/ml of W6/32 antibody and 
analyzed by flow cytometry. The analysis was performed by two-way ANOVA 
followed by Bonferroni test. *** p<0.001. The data are representative of two 
independent experiments run on duplicate.   
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3.4.5 Effect of trypsin treatment on the expression of HLA class I antigen on 
endothelial cells 
Trypsin is a serine protease enzyme that cleaves the polypeptide chains at lysine or 
arginine residues. To assess the effect of trypsin on cell surface HLA class I antigens, 
adherent HMEC-1 cells were detached with either trypsin or PBS-EDTA based cell 
dissociation buffer. Following detachment, the cells were stained with W6/32 antibody 
and examined for the expression of HLA class I antigens by flow cytometry as shown in 
Figure 3.11. There was no significant difference in the expression of HLA class I 
antigens when trypsin was used compared to the detachment using cell dissociation 
buffer. Cells stained with FITC-conjugated anti-mouse secondary antibody were used as 
a negative control.  
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Figure 3.11: Effect of trypsin treatment on the expression of HLA class I 
molecules. 
Adherent HMEC-1 cells were detached using either trypsin or enzyme-free dissociation 
buffer before cell detachment. Cells were stained using W6/32 antibody at 12 μg/ml 
followed by rabbit anti-mouse FITC-conjugated secondary antibody. Histograms show 
A unstained, B secondary antibody only, C staining on trypsin detached cells, D 
staining on dissociation buffer detached cells and E bar chart of median fluorescence 
intensity. The data were analysed by two-way ANOVA. The data are representative of 
two independent experiments.  
B) 
E) 
C) D) 
A)
) 
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3.4.6 HLA class I and ABO genotyping on HMEC-1 cells  
HMEC-1 cells were genotyped for HLA class I (HLA-A, B and C) and ABO blood 
group by PCR-SSP method. The identification of the HLA class I type was performed 
to allow selecting sera from sensitized patients with corresponding antibody specificity. 
Adherent HMEC-1 cells were detached and the DNA was isolated as described in the 
methods section. Amplification was performed with primers specific to group of alleles 
in a tray and the amplicons were run on agarose gel. Figure 3.12 shows the agarose gels 
for HLA-A, B and C. Each well contains a primer that amplifies the human growth 
hormone as a positive control (red arrow). The gel was interpreted by using Biotest 
software to determine the genotype. The HLA class I genotype for HMEC-1 is A*01, 
A*68, B*35, B*58, C*04, C*06.  
To ensure there was no effect of ABO antibodies in the polyclonal sera, The HMEC-1 
cells were genotyped for ABO antigens by PCR-SSP. This was performed to eliminate 
any potential interaction of ABO antibody with the endothelial cells. HMEC-1 DNA 
was amplified using specific primers for ABO transferase enzymes. The amplicons were 
run on agarose gel as shown in Figure 3.13. Each well has a primer that amplifies the 
human growth hormone as a positive control. The amplicon product was run on 1.2% 
gel and interpreted using Biotest software. The cell line is from an "O" blood group 
donor.  
 
 Cell line HLA typing ABO typing 
HMEC-1 cell line 
A*01, A*68 
B*35, B*58 
 C*04, C*06  
 
'O' 
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Figure 3.12: Agarose gel of HLA class I genotyping on HMEC-1 cell line using 
PCR-SSP method.  
The amplicon product from each well was run on 1.2% agarose gel and visualized by 
UV machine. Lanes from 1-25 represents HLA-A genotypes, 26-76 for HLA-B and 77-
93 for HLA-C. HMEC-1 class I typing are A*01, A*68, B*35, B*58, C*04, C*06. 
Interpretation of the data was performed using Biotest SSP typing Software.  
                                    
 
Figure 3.13: Agarose gel of ABO genotype of HMEC-1 cell line using PCR-SSP 
method.  
DNA was extracted and amplified using specific sequence primer for transferase 
enzymes. The amplicon was run on 1.2% agarose gel. Interpretation of the data was 
performed using Biotest SSP typing Software. 
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3.4.7 Purification of W6/32 antibody 
The hybridoma cell line (W6/32) which produces a monoclonal mouse HLA class I 
antibody (IgG2a) was grown in media supplemented with IgG stripped serum as 
described in section 2.3.5. Conditioned media from W6/32 cells was collected and the 
antibody was purified using protein A column as described in the methodology part. 
The concentration of the eluted and concentrated antibody was determined using a BCA 
protein assay kit. The presence of the antibody was confirmed by SDS gel 
electrophoresis and ELISA as shown in Figure 3.14 A and B, respectively. The 
separation on the gel under reducing condition showed clearly two bands for the heavy 
and light chains at 55 and 25 kDa, respectively. To determine the saturating and 
subsaturating concentrations of this antibody on HMEC-1 cells, a titration experiment 
was performed using indirect immunofluorescence staining as shown in Figure 3.14 (C 
and D). The cells were stained with different concentrations of W6/32 antibody 
followed by staining with rabbit anti-mouse FITC-conjugated secondary antibody. 
W6/32 antibody at a concentration was the saturating concentration and concentrations 
lower than 12 µg/ml were sub-saturating concentrations (0.35-6 µg/ml). Cells stained 
with secondary antibody only were used as a negative control. 
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Figure 3.14: Purification of HLA class I antibody (mouse IgG2a) from W6/32 
hybridoma cell line. 
A shows the reduced antibody on 10% SDS-PAGE which separates into heavy and light 
chain bands. B shows ELISA of purified concentrated antibody. C shows titration of 
purified HLA class I antibody on HMEC-1 cells by flow cytometry. D shows flow 
cytometry histogram of the binding of W6/32 antibody to HMEC-1 cells at different 
concentrations. The cells were incubated with FITC-conjugated rabbit anti-mouse IgG 
antibody after staining with W6/32 antibody. Cells stained with the secondary antibody 
only were used as a control. *** p<0.001. The data are representative of two 
independent experiments. 
C) 
B) 
D) 
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3.5 Discussion 
Donor endothelial cells are the first target exposed to recipients’ immune system after 
transplantation. The constitutive expression of polymorphic HLA class I antigens 
renders these cells the main target for either cellular or donor specific antibody 
responses. Endothelial cells from both large and small vessels are crucial in maintaining 
normal allograft function. However, microvascular endothelial cells as an antigen 
presenting cells might have a more potent role in inducing allograft rejection. Functions 
such as leukocyte adhesion and migration may predominantly occur in small vessels 
rather than large vessels where the blood flow is slower facilitating the adhesion and 
migration processes (Aird, 2007). Therefore, human microvascular endothelial cells 
(HMEC-1) were used in this project. Characterization of the cell line and comparison to 
human large vessel endothelial cells (EA.hy926) were carried out. 
 EA.hy926 and HMEC-1 endothelial cells were characterized for the cell surface 
expression of CD31 and CD34 antigens. CD31 is a transmembrane glycoprotein with 
six extracellular immunoglobulin domains and two cytoplasmic immunotyrosine-based 
inhibitory motifs. This antigen is expressed also on other cell types such as neutrophils, 
lymphocytes, monocytes and platelets (Ilan et al., 1999). Although it is widely known 
as a cell-cell adhesion molecule, its role as a cell signaling molecule is emerging. For 
example, CD31 regulates the activation and detachment of other cells such as T-cells 
and platelets (Liu and Shi, 2012). In addition, it has an important role in the regulation 
of leukocyte trafficking to the secondary lymphoid organs during recirculation and 
inflammation (Ma et al., 2012). Inflammatory cytokines enhance the redistribution of 
endothelial CD31 and activation of integrins expressed on leukocytes enhancing their 
transmigration (Romer et al., 1995). In this project, indirect immunofluorescence 
staining showed that both endothelial cell lines examined express CD31 molecules on 
their cell surface, confirming the finding from other groups used other techniques such 
an immmunocytochemistry, flow cytometry and RT-PCR (Ades et al., 1992; Unger et 
al., 2002; Ali et al., 2008).  
CD34 is a transmembrane glycoprotein antigen which is expressed mainly on 
hematopoietic stem cells (Dedeepiya et al., 2012). Studies have also shown that other 
cell types such as endothelial and tumor cells might also express this antigen (Fina et 
al., 1990; Soligo et al., 1991). Although the role of this molecule is not fully 
understood, different studies have suggested a role in regulating leukocyte adhesion and 
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infiltration (Nielsen and McNagny, 2008).  However, the expression of this antigen on 
endothelial cells is highly dependent on the origin of these cells, culturing condition and 
passage number. Some endothelial cells from large veins and arteries such as from 
placenta and lymphatic endothelial cells do not express this antigen and other cells 
might lose this expression after a few passage numbers (Fina et al., 1990; Delia et al., 
1993). In this project, HMEC-1 cells showed a weak positive staining for CD34 but not 
on EA.hy926 cell line. The cell surface expression of this antigen on HMEC-1 cells has 
been previously detected on small subsets of cell population ranging from 10-15% 
(Nisato et al., 2004; van Beijnum et al., 2008). In addition, the cell surface expression 
of this antigen on CD34 negative subsets of HMEC-1 cells has been shown to become 
CD34 positive after re-culturing for 10 days (Siemerink et al., 2012). This result 
suggests that the expression of this molecule on the cell surface is not constitutive and 
regulated by different conditions. Primary vascular endothelial cells lose the expression 
of this molecule after culturing for few passages which can be retained by culturing at 
high density (Delia et al., 1993). This observation might explain the failure to detect a 
positive CD34 population on HMEC-1 cell in other studies (Unger et al., 2002). The 
later study also showed the absence of CD34 antigens on EA.hy926 cells. 
Expression of HLA class II antigens on endothelial cells was determined under resting 
and stimulated conditions. The expression of these molecules is normally restricted to 
antigen presenting cells due to their role in presenting processed extracellular antigens 
to T-helper cells, eliciting series of events leading finally to eradication of harmful 
agents. (Unanue, 1992). Some types of human endothelial cells express HLA class II 
molecules in vivo and lose this expression by culturing. This includes heart and kidney 
microvascular endothelial cells but not large vessel endothelial cells. However, the 
expression in vitro can be up-regulated by stimulation with pro-inflammatory cytokines 
such as IFN-γ (McDouall et al., 1997; Muczynski et al., 2003). IFN-γ is an 
inflammatory cytokine that is secreted by activated T-cells (Th-1) and NK cells in 
response to viral, bacterial infection or inflammation to enhance the differentiation and 
activation of other immune cells. A recent study showed that IFN-γ has the potential to 
induce endothelial to mesenchymal transition implicating a role in fibrogenesis and 
vascular-related disorders. This is mediated by downregualting the expression of VE-
cadherin and upregulating the expression of transformation growth factor-beta2 (TGF-
β2) and endothelin-1 (Chrobak et al., 2013). IFN-γ enhances the expression of HLA 
class II antigens through activation of Janus kinase/signal transducers and activators of 
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transcription (JAK/STAT) pathway. The binding of IFN-γ to its receptor results in the 
phosphorylation of JAK1 and JAK2 kinases which subsequently phosphorylate the IFN-
γ receptor. The phosphorylation of this receptor induces the recruitment and binding of 
cytoplasmic STAT1 protein to the IFN-γ receptor. This binding results in the 
phosphorylation and homodimerization of STAT1. The homodimer translocates to the 
nucleus where it induces the transcription of interferon regulatory factor-1 (IRF-1). This 
factor with STAT1 and other constitutive factors bind to the class II transactivator, 
nuclear transcription factor, promoter inducing its expression (Tsai et al., 2007). In 
addition, a recent study showed the involvement of another factor called B-associated 
transcript-3, adjacent to HLA-B locus, in the expression of HLA class II molecules on 
lymphocytes (Kamper et al., 2012). In this project, the expression of endothelial HLA 
class II molecules in response to either IFN-γ alone or in combination with TNF-α was 
examined.  
Exposure of endothelial cell lines with different concentrations of IFN-γ for 72 hours 
induced a significant increase in the expression of HLA class II antigens as shown by 
direct immunofluorescence staining. Although both cell lines responded to this 
treatment in a dose dependent manner, HMEC-1 cells exhibited a higher level of 
expression at lower doses of IFN-γ than EA.hy926 cells. This might be due to the higher 
sensitivity of microvascular endothelial cells to pro-inflammatory cytokines compared 
to endothelial cells derived from large vessels (McDouall et al., 1997). The up-
regulation in the expression of HLA class II antigens by IFN-γ has been previously 
reported in many studies using macrovascular and microvascular endothelial cells 
(Cunningham et al., 1997; McDouall et al., 1997). Through their ability to express HLA 
class II molecules, endothelial cells can function as an antigen presenting cells to T-cells 
inducing their recruitment (Shiao et al., 2007; Manes and Pober, 2008). The expression 
of HLA class II molecules is linked with the expression of class II transactivator which 
has been detected within hours after IFN-γ treatment in HUVEC endothelial cells (Tsai 
et al., 2007) and HMEC-1 cells (Fritchley et al., 2000).   
The effect of TNF-α stimulation alone or in combination with IFN-γ on endothelial 
HLA class II antigen expression was also examined. TNF-α is a pro-inflammatory 
cytokine secreted by activated T-cells, dendritic cells and macrophages in response to 
inflammatory signals. It can synergise with other cytokines to induce the expression of 
cell surface molecules or chemokines (Cavalcanti et al., 2012; Griffin et al., 2012). In 
this project, treatment of HMEC-1 but not EA.hy926 cells with TNF-α alone induced 
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the expression of cell surface HLA class II antigen. In addition, treatment with a 
combination of IFN-γ and TNF-α significantly decreased the expression of HLA class II 
molecules compared to cells treated with IFN-γ alone. The inhibitory effect was 
dependent on the concentration, as the concentration of TNF-α increased the inhibitory 
effect increased accordingly. In a recent study by Norder and co-workers, TNF-α was 
unable to induce the expression of HLA class II molecule on lymphatic endothelial cells 
(Norder et al., 2012). In addition, the latter study showed no change in the expression of 
HLA class II in the presence of TNF-α with IFN-γ compared to IFN-γ alone as observed 
in our study. Previous studies on HUVEC cells showed the inhibitory effect of TNF-α 
on HLA class II expression induced by IFN-γ (Leeuwenberg et al., 1988; Wedgwood et 
al., 1988). This inhibitory effect might be attributed to the ability of TNF-α to reduce 
the transcription of HLA class II genes as shown by a reduction in murine MHC class II 
β-chain mRNA (Melhus et al., 1991) or through production of nitric oxide (Sicher et al., 
1995). In contrast, a synergistic effect between TNF-α and IFN-γ on HLA class II 
expression has been reported on other human cell types such as tumor cell line 
(Pfizenmaier et al., 1987) and T-cells (Scheurich et al., 1987). It has previously shown 
that the effect of TNF-α on IFN-γ treatment is dependent on the cell type and maturation 
state, as shown by the Watanabe and Jacob (Watanabe and Jacob, 1991). They showed 
that treatment of immature promyelocytic cells with a TNF-α augmented the ability of 
IFN-γ to induce HLA class II expression. However, differentiation of these cells 
inhibited the synergistic effect of TNF-α and IFN-γ. Since endothelial cells might be 
considered as differentiated cells, they may function in a similar way.  
The expression of HLA class I antigens on HMEC-1 cells was confirmed by staining 
with purified W6/32 antibody. The titration experiment showed that 12 µg/ml was a 
saturating concentration for HLA class I antigens on HMEC-1 cells and concentrations 
lower than that were sub-saturating concentrations. Therefore, 12 µg/ml was used for all 
experiments performed using saturating concentration. HLA class I genotyping was 
performed by PCR-SSP to determine the HLA specificity of the cell line. The genotype 
is; A*01, A*68, B*35, B*58, C*04 and C*06 and the cell line from ‘O’ blood group 
donor. Genotyping also included HLA class II genotypes, and two epithelial cell lines 
(HKC-8, HK-2) which can be used in other studies (appendices 10.1, 10.2, 10.3). HLA 
class I antigen expression was not reduced when exposed to trypsin. This suggests that 
the use of trypsin to detach cells for flow cytometry analysis can be performed without 
affecting the expression of HLA class I antigen. Acid treatment produced a significant, 
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but incomplete, cleavage of cell surface HLA class I antigens. In agreement with our 
finding, treatment of platelets with the sodium citrate solution caused approximately 80-
85% of HLA class I cleavage (Zou et al., 2011). Citric acid treatment showed 
specificity for HLA class I cleavage as treated platelets showed a specific class I 
cleavage but normal expression of other cell surface antigens (Neumuller et al., 1993). 
In our study, the expression of HLA class I antigens fully regains after 24 hours of acid 
treatment.  
In this chapter, phenotypic analysis of HMEC-1 endothelial cells was performed and 
compared to that of EA.hy926 cells. HMEC-1 cells do express CD31, HLA class I and 
upregulate HLA class II in response to cytokine stimulation. The W6/32 antibody was 
successfully obtained for this project, with retained binding efficiency to HMEC-1 cells 
as assessed by flow cytometry. 
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4. Chapter Four- HLA Class I Antibodies and Endothelial Cell 
Signalling 
4.1 Introduction 
Protein phosphorylation is an important post-translational modification and an early 
response by which cells regulate different cellular processes in response to various 
extracellular stimuli. This phosphorylation can occur at different amino acid residues 
such as serine, threonine and tyrosine, changing protein activity to either activation or 
deactivation, protein localization and effecting downstream protein targets (Hunter, 
2007).  Different lines of evidence showed that ligation of HLA class I molecules on 
endothelial cells with antibodies is associated with the phosphorylation of various 
intracellular proteins by a mechanism independent to the activation of the complement 
system. These proteins are involved in a variety of signal transduction pathways 
responsible for regulating various endothelial cell functions such as survival, apoptosis, 
proliferation and cell migration. Therefore, in this chapter the activation of cell 
signaling-associated proteins in response to stimulation with HLA class I antibodies was 
examined using human microvascular endothelial cells.   
Phosphorylation of endothelial Akt, ERK1/2, mTOR, cytoskeleton proteins and others 
has been previously reported in response to stimulation with HLA class I antibody as 
discussed in details in section 1.8. In addition, activation of endothelial transcription 
factors such as NF-kB, E2F, c-Jun and Nf-E2-related factor in response to HLA class I 
antibody has also been observed as explained in details in section 1.9. The activation of 
transcription factors suggests a modulation in the expression of endothelial proteins 
upon stimulation. However, all of the cell signaling studies previously performed have 
used human large vessel endothelial cells. Therefore, activation of microvascular 
endothelial cells in response to HLA class I antibody was investigated in this study. 
This includes activation of cell signaling pathways and transcription factors. 
HLA class I antibody is associated with the development of chronic allograft rejection, 
which is characterized by the perivascular fibrosis, neointimal thickness and 
proliferation of endothelial cells and smooth muscles (Zhang et al., 2011b; Trayssac et 
al., 2012). Ligation of HLA class I molecules by antibodies in vitro also induces 
epithelial cell proliferation leading to bronchiolitis obliteraus syndrome, the main 
manifestation of chronic rejection in lung transplantation (Reznik et al., 2000). Cell 
proliferation results from activation of cell-cycle progression proteins downstream of 
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the cell signaling transduction pathways. Activation of mTOR, focal adhesion signaling 
(Jin et al., 2002) and Akt pathways in response to HLA class I antibody showed a 
correlation with endothelial cell proliferation (Jindra et al., 2008a). In addition, an 
increase in endothelial cell proliferation might occur as a result of the expression of 
endothelial growth factors such as vascular endothelial growth factor in response to 
stimulation with HLA class I antibody (Bieri et al., 2009). In addition to the increase in 
the expression of growth factors, cells stimulated with these antibodies show an 
upregulation in the expression of cell surface fibroblast growth factor receptors which 
increased the sensitivity to fibroblast growth factor (Harris et al., 1997; Bian et al., 
1998; Jin et al., 2002). 
Apoptosis is a programmed cell death that is crucial for cell development and 
homeostasis. However, excessive endothelial cell apoptosis in response to extracellular 
stimuli can cause endothelial dysfunction and vascular injury (Winn and Harlan, 2005). 
Narayanan et al. (2004) reported endothelial cell apoptosis in response to stimulation 
with saturating concentration of HLA class I antibody in the presence of complement. 
Apoptotic cell death was inhibited by the pre-exposure to sub-saturating concentration 
of HLA class I antibody. This effect was mediated by the expression of anti-apoptotic 
genes upon exposure to sub-saturating concentration providing protection against a high 
dose of the antibodies (Narayanan et al., 2004). Stimulation of epithelial cells with HLA 
class I antibody induced cell apoptosis after 48 hours from stimulation (Jaramillo et al., 
2003). Using aortic endothelial cells, Yamakuchi and colleagues showed that 
stimulation with HLA class I antibody alone or in combination with complement C5a 
did not induce cell death (Yamakuchi et al., 2007). However, the role of HLA class I 
antibody in inducing microvascular endothelial cell apoptosis independent of 
complement has not been studied.   
In this chapter, the phosphorylation of endothelial cell signaling proteins in response to 
stimulation with HLA class I antibody was investigated. This was achieved using 
proteome profiler phospho-array and western blotting. Both methods are the most 
commonly used methods for detection of phospho-proteins. They share the main 
principle where a phosphorylated analyte is detected by a specific antibody. The array 
contains multi-phospho-antibodies attached to the nitrocellulose membrane which 
provides a quick and convenient method for the detection of a wide range of 
phosphorylated proteins in response to particular stimulus. The method has a main 
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advantage of avoiding using highly hazardous materials such as radioisotops. 
Phosphorylation of Akt, ERK and transcription factor CREB at specific residues in 
response to stimulation with HLA class I antibody was evaluated. In addition, the effect 
of the antibodies in inducing endothelial cell proliferation and apoptosis was also 
assessed. Colorimetric assay for cell proliferation and flow cytometric analysis for cell 
apoptosis were used.      
4.2 Specific Aims 
In this chapter, the potential of HLA class I antibody in inducing activation of 
microvascular endothelial cells was examined. This includes: 
 Activation of signal transduction pathways including; p-ERK, p-Akt and p-CREB; 
 Examining the ability of W6/32 antibody in inducing cell apoptosis, and 
 Assessing the ability of W6/32 antibody to induce cell proliferation. 
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4.3 Specific materials and methods 
4.3.1 Human phosphokinase array on endothelial cells 
Analysing the phosphorylation of kinases and their substrates after exposure to the HLA 
class I antibody was performed using a human phospho-kinase array kit (R&D system). 
The array contains different capture antibodies specific to wide range of phosphorylated 
proteins attached to nitrocellulose membranes. HMEC-1 cells were serum starved 
overnight in 0.2% FBS containing media without EGF or hydrocortisone. The cells 
were then detached using cell dissociation buffer and resuspended into 200 μl of 0.2% 
FBS and incubated at 37
0
C for 2 hours. The cells were then stimulated for 5 minutes 
with either saturating concentration of W6/32 antibody (12 μg/ml) or isotype control 
mouse IgG2a. Stimulation was terminated by the addition of cold PBS followed by 
rapid centrifugation. The cell lysate was obtained as described in the instruction manual 
and 500 μg of protein was used per array (membrane A & B). After blocking for one 
hour with the provided blocking agent, the membranes were incubated with cell lysates 
on the shaker in cold room (4
0
C) overnight. After the washing steps, an antibody 
cocktail specific for each membrane was added and incubated for 2 hours at room 
temperature. Streptavidin-HRP was added to the membrane after three washes. The 
signal produced by HRP activity was detected by using Pierce enhanced 
chemiluminscent (ECL) substrate and Kodak X-ray films. 
4.3.2 Stimulation of endothelial cells for measurement of phosphorylated 
proteins (Akt, ERK and CREB) 
To examine the phosphorylation of cell signalling proteins, HMEC-1 cells were 
incubated overnight with 0.2% FBS containing media without EGF or hydrocortisone. 
The cells were then detached using cell dissociation buffer and and resuspended into 
200 μl of 0.2% FBS and incubated at 370C for 2 hours. The cells were then stimulated 
with W6/32 antibody at either different time points or different antibody concentrations. 
The stimulation was terminated by the addition of cold PBS and the tubes were 
transferred immediately into ice. After centrifugation at 12000g for 3 minutes, the cells 
were lysed by using lysis buffer containing protease and phosphatase inhibitors as 
described in section 2.8.2. Protein concentration was determined using the BCA assay 
as described in section 2.8.3. Between 20 to 40 μg of proteins were separated on 12% 
SDS-PAGE and transferred into PDVF membrane as described in sections 2.8.4 and 
2.8.6, respectively. The membrane was blocked with 3 % BSA in 0.1% TPBS for one 
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hour before incubation with the primary antibodies. Primary antibodies were diluted in 
the blocking solution at the recommended concentration by the manufacturer. The 
primary anti-human antibodies used were: mouse p-ERK1/2 (T202/Y204) (Santa Cruz 
Biotechnology, USA), rabbit T-ERK (BD Bioscience, USA), rabbit monoclonal p-Akt 
(Serine residue 473), rabbit total Akt, rabbit monoclonal p-CREB (Serine residue 133) 
and rabbit total-CREB antibodies (Cell Signaling Technology, USA). The secondary 
antibodies used were: horseradish peroxidase conjugated goat anti-rabbit IgG (Cell 
Signaling Technology, USA) and horseradish peroxidase conjugated rabbit anti-mouse 
IgG (Sigma Aldrich, USA). Membranes were probed with antibodies and developed as 
described in section 2.8.7.  
4.3.3 Stimulation of endothelial cells with forskolin  
Forskolin (7-beta-acetoxy-8,13-epoxy-1-alpha, 6-beta, 9-alpha-trihydroxylabd-14-en-
11-one  Coleonol) is a natural product belonging to the labdane diterpene group and 
produced by Indian plant called Coleus forskohlii. Forskolin is particularly 
characterized by the presence of a tetrahydopyran-derived heterocyclic ring. It has an 
antihypertensive and platelet aggregation effects. It is also widely used to increase the 
level of cAMP through activation of intracellular adenylyl cyclase. The rise in cAMP 
levels leads to the activation of protein kinase A, enhancing the phosphorylation of 
cAMP Responsive Elements Binding protein (CREB) at serine residue 133 (Bhat et al., 
1983). In this project, forskolin was used as a positive control for endothelial CREB 
phosphorylation. Forskolin was dissolved in DMSO to prepare a 100 mM stock (Sigma 
Aldrish, USA). Endothelial cells starved in 0.2% FBS containing media were detached 
using cell dissociation buffer, re-suspended in 200 μl of 0.2% FBS media and incubated 
at 37
0
C for 2 hours. The cells were stimulated with 10, 50 and 100 µM of forskolin for 5 
minutes before the addition of cold PBS. The cells were centrifuged at 12000g for 5 
minutes before adding the lysis buffer. The cell lysates were then prepared and analyzed 
for CREB phosphorylation by western blotting as previously described. 
4.3.4 Using specific inhibitors 
To examine the contribution of a particular cell protein in the activation of downstream 
proteins, a specific inhibitor is normally used. In this project, two inhibitors have been 
used to examine the dependency of CREB phosphorylation at serine residues on the Akt 
and PKA pathways. 
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4.3.4.1 PI3K/Akt inhibitor 
LY294002 is a selective inhibitor for phosphoinositol-3-kinase (PI3K) but not for other 
kinases such as protein kinase C or MAP kinases (Cell Signalling Technology). The 
specificity for PI3K is optimal at a concentration of 50 μM as determined in previous 
study (Vlahos et al., 1994). The inhibitor was dissolved in DMSO at a stock 
concentration of 50 mM. Endothelial cells were incubated with two different 
concentrations of the inhibitor (10 and 50 μM) one hour before the stimulation with 
saturating concentration of W6/32 antibody for 5 minutes. The activity of the inhibitor 
was verified by probing for p-Akt following stimulation with W6/32 antibody in the 
presence of the inhibitor.     
4.3.4.2 Protein kinase A inhibitor 
To assess the contribution of protein kinase A in CREB phosphorylation, a protein 
kinase A (PKA) inhibitor was used. The H-89 inhibitor is a selective and potent 
inhibitor for PKA, (Cell Signalling Technology). In in vitro assay, H-89 has been shown 
to induce a 50% inhibition of PKA phosphorylation at 50 nM (Chijiwa et al., 1990). 
The inhibitor was dissolved in DMSO to make a stock solution at a concentration of 20 
mM. Optimisation of the concentration of H-89 inhibitor was performed by incubation 
of HMEC-1 cells with different concentrations of H-89 inhibitor ranging from 0.05 to 
50 μM followed by stimulation with 10 μM of forskolin. The cells were incubated with 
5 μM of the inhibitor one hour before the stimulation with saturating concentration of 
W6/32 for 5 minutes. To ensure the activity of the inhibitor, reduction in CREB 
phosphorylation by forskolin in the presence of H-89 inhibitor was assessed.  
4.3.5 Trypan blue staining 
Cell viability following serum starvation or following the use of different protein kinase 
inhibitors was determined by staining with trypan blue before stimulation. Staining with 
trypan blue is a quick and efficient way to examine cell viability. Dead cells are 
characterised by the disruption in the cell membrane which facilitates the entrance of 
the blue stain inside the cells; live cells exclude this stain. Cells with 95% viability were 
used for all experiments. 
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4.3.6 Examination of biological functions  
4.3.6.1 Cell proliferation assay 
To assess the ability of HLA class I antibody to induce endothelial cell proliferation, a 
CellTiter 96 AQueous One Solution Cell proliferation assay was used (Promega, USA). 
This assay is a colorimetric method that determines the number of viable cells by using 
a tetrazolium compound (inner salt) and an electron coupling reagent (phenazine 
ethosulfate). The tetrazolium compound mixed with phenazine ethosulfate is reduced by 
NADPH and NADH produced by dehydrogenase enzymes in metabolically active cells 
to produce a soluble colored formazan product which can be measured at 490 nm. 
HMEC-1 cells were counted and 20,000 cells were cultured in 96 wells plate. After 
overnight incubation, cells were treated with a saturating concentration of W6/32 
antibody or isotype control and incubated at 37
0
C for 24 and 48 hours. The number of 
viable cells was determined by adding 20 μl of 5 % phenazine ethosulfate in tetrazolium 
compound to 100 μl of culture media. The plate was incubated for one hour at 370C and 
the absorbance was measured at 490 nm. The efficiency and sensitivity of the 
colorimetric assay was evaluated by seeding different number of cells in complete 
media for 24 hours followed by performing the assay as shown in Figure 4.1. 
4.3.6.2 Cell apoptosis assay 
4.3.6.2.1 General principle 
Apoptosis was defined in 1972 as a programmed cell death essential for eliminating 
unwanted or aged cells from living tissues, or as a part of normal cell turnover (Kerr et 
al., 1972). This phenomenon is a distinctive mode of cell death that is different from 
cell necrosis. In the latter, a rapid and non-specific cell death occurs in response to the 
exposure to high concentration of toxic agents. Each mode of cell death is recognized 
on the basis of biochemical and morphological changes. The main features of cell 
apoptosis are cell shrinkage, DNA fragmentation and formation of blebs in the plasma 
membrane. However, the apoptotic cells preserve cell membrane integrity as well as 
organelle structures. DNA fragmentation occurs as a result of the activation of calcium 
and magnesium-dependent endogenous nucleases. These enzymes catalyze the 
fragmentation of DNA at the sites located between nucleosomes producing mono and 
oligonucleosome fragments. For the apoptotic cells to be phagocytosed, the 
translocation of the phosphatidylserine from the inner side of the cell membrane to the 
outer side occurs as a phagocytic marker for phagocytic cells. In contrast, cell necrosis 
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Figure 4.1: Efficiency of proliferation assay using HMEC-1 endothelial cells. 
Different number of cells was seeded into 96 wells plate. After 24 hours, viable cells 
were assessed using colorimetric proliferation assay as described in the methods. The 
absorbance was measured at 490 nm using ELISA plat reader. A linear regression 
between cell count and absorbance was evaluated. The correlation coefficient of the line 
was 0.9728. Absorbance of the reagent alone was used as a background and subtracted 
from all readings. Each point represents the mean ± standard error of mean. The data are 
representative of two independent experiments. 
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 is characterized by loss of cell membrane integrity with swelling of cell organelles. On 
the basis of these differences, there are many assays that can be used to determine cell 
apoptosis in response to particular stimulus such as colorimetric or radioactive assays, 
DNA ladders, ELISA and flow cytometry (Elmore, 2007). 
The simplest method to detect cell apoptosis is by flow cytometry using DNA 
intercalating dyes. After cell permeabilization, the dye stains the DNA content of the 
cells. Staining of healthy cells from normal culture shows cells at three different phases 
according to DNA contents which are G1, G2 and S phases. The DNA content of cells 
in the G2 phase is a double of that in the G1 phase, while DNA content of cells in the S 
phase is in between the G1 and G2 phases. Apoptotic cells are characterized by the 
presence of DNA content less than that in the G1 phase as a result of DNA 
fragmentation and leakage from the cells. The differences in DNA content at different 
stages occur with different fluorescence intensity on flow cytometry after staining with 
DNA intercalating dye. Different fluorochromes such as Propidium Iodide (PI), DAPI 
and Acridine Orange can be used to stain the DNA and determine the reduction in DNA 
content during apoptosis. Therefore, cells stained with these dyes show two different 
peaks for G1 and G2 phases, where the fluorescence intensity for the G2 peak is double 
of that in the G1. The cells in the S phase will show a range of fluorescence intensity 
that lay between G1 and G2 peaks. The apoptotic cells show low DNA staining and 
appear as a peak with fluorescence intensity lower than that of the G1 population, which 
is the sub-G1 or sub-diploid peak. Due to cell membrane integrity, different dyes will be 
excluded from the apoptotic cells but not from necrotic cells which lose cell membrane 
integrity. Therefore, a detergent such as triton X-100 is used to facilitate the diffusion of 
dyes into cells and enhance the release of fragmented DNA from the nucleus enabling 
detection of the reduction in DNA content. In contrast, necrotic cells do not show an 
immediate reduction in DNA content and the sub-G1 peak is not present. In this project, 
cells were stained with a mixture of PI and triton X-100 to determine the sub-G1 peak 
(Riccardi and Nicoletti, 2006).    
4.3.6.2.2 Staurosporine treatment  
Staurosporine (STS) is a natural product isolated from Streptomyces staurosporeus with 
a wide range of biological activities ranging from antifungal to antihypertensive. The 
main biological activity of staurosporine is inhibition of protein kinase C through the 
prevention of ATP binding to the kinase portion. It is used in research as an apoptosis 
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inducing agent or synchronizing agent. Endothelial cells grown to 80 % confluency in 6 
wells plate were treated with STS at a concentration of 2.5 μM prepared by a serial 
dilution from staurosporine stock (2.1 mM) dissolved in DMSO (Sigma Aldrich).  
4.3.6.2.3 Sub-diploid peak assay 
Endothelial cells were treated with STS dissolved in complete media at either different 
concentrations or different time points. After treatment, cells were washed once with 
PBS and detached using trypsin. Detached cells were washed twice with 2 % FBS in 
PBS and re-suspended in 1 ml PBS/FBS solution. Cells were permeabilized and stained 
using 1 % triton X-100 containing PI at a concentration 0.2 μg/ml. This was added to 
the cells just prior to analysis by flow cytometry. Around 20,000 events were acquired 
on linear scales for FSC, SSC and PI channel. Cells stained with PI only were used to 
exclude dead necrotic cells.   
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4.4 Results 
4.4.1 Human phosphokinase array on endothelial cells following 
stimulation with W6/32 antibody 
A human phosphokinase array was chosen as a screening experiment to examine the 
phosphorylation of endothelial cell signaling proteins in response to stimulation with 
HLA class I antibody (appendix 10.4). The array contains capture antibodies specific for 
phosphorylated proteins attached to a nitrocellulose membrane. These proteins include 
the phosphorylated form of: Akt, mTOR, CREB, MEK1/2, MSK1/2, β-catenin, FAK 
and STAT6. Endothelial HMEC-1 cells were stimulated with a saturating concentration 
(12 μg/ml) of W6/32 antibody or isotype control for 5 minutes followed by preparation 
of cell lysates. As shown in Figure 4.2, HLA class I antibody enhanced the 
phosphorylation of various kinases including p-Akt, p-CREB, β-catenin, FAK, MEK1/2 
and others. Positive spots in both membranes were used to assess the validity of the 
array and as a loading control between the two samples. The phosphorylation of ERK at 
tyrosine 202 and threonine 204 residues, Akt at serine residue 473 and phosphorylation 
of transcription factor CREB at serine residue 133 were chosen for further analysis.   
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Figure 4.2: Human-phosphokinase array of endothelial cells following 
stimulation with HLA class I antibody.  
HMEC-1 cells were treated with saturating concentration (12 μg/ml) of W6/32 antibody 
or isotype control for 5 minutes. The cells were lysed and applied to the array. Panel A 
shows the arrays and panel B shows the densitometric analysis. The density of the dots 
was measured using gel documentation system and AlphaImager software. Statistical 
analysis was performed using two way ANOVA followed by Bonfferoni test at p<0.05. 
*** p<0.001. The data are representative of two independent experiments. 
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4.4.2 Endothelial ERK, Akt and CREB phosphorylation following stimulation 
with W6/32 antibody  
To examine further the ability of HLA class I antibody to induce activation of 
endothelial cell signalling, HMEC-1 cells were treated with HLA class I antibody 
(W6/32) and then analysed by western blotting for the phosphorylation of selected 
proteins. Cells were treated with either saturating concentration of W6/32 antibody (12 
μg/ml) or isotype control mouse IgG2a for different time points or stimulated with 
different concentrations of HLA class I antibody for 5 minutes. The lysates were probed 
for p-Akt at serine residue 473, p-ERK1/2 at tyrosine and threonine residues and p-
CREB at serine residue 133.  
As a positive control, treatment with H2O2 was used for ERK and Akt phosphorylation, 
and treatment with forskolin was used for CREB phosphorylation. Forskolin is well 
known as a PKA activator that is used to investigate CREB phosphorylation. 
Endothelial cells were treated with 100 μM of H2O2 for 5 minutes and lysates were 
probed for p-ERK1/2 and p-Akt antibodies. This concentration was shown to induce 
significant protein phosphorylation. Cell viability was assessed using trypan blue 
staining; 90-95% viable cells were observed and used after forskolin or H2O2 
treatments. For CREB phosphorylation, endothelial cells where stimulated with 10, 50 
and 100 μM of forskolin for 5 minutes followed by probing with p-CREB antibody. As 
shown in Figure 4.3, 10 μM of forskolin was sufficient to induce CREB 
phosphorylation compared to untreated cells. The antibody used for CREB 
phosphorylation also detects other protein belonging to the CREB family, p-ATF1 
shown as second band on the western blot. P-CREB antibody can bind weakly to 
pyruvate dehydrogenase which might explain the third band. According to the size of p-
CREB, the first band is for p-CREB.   
Exposure to a saturating concentration of HLA class I antibody induced ERK1/2 
phosphorylation at tyrosine 202 and threonine 204 residues which peaked at 1 minute 
and declined by 30 minutes as shown in Figure 4.4. The exposure to W6/32 antibody 
also induced the phosphorylation of Akt and CREB at specified residues as shown in 
Figure 4.5 (A and B), respectively. The phosphorylation of Akt increased at 5 minutes 
following stimulation, peaked at 15 minutes and slightly reduced after 30 minutes. The 
phosphorylation of CREB occurred at early time point within 1 minute, peaked at 5 
minutes and declined by 30 minutes following stimulation with HLA class I antibody. 
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Figure 4.3: Phosphorylation of CREB at serine residue (133) by endothelial 
cells following stimulation with forskolin.  
Serum starved HMEC-1 cells were stimulated with different concentrations of forskolin, 
10, 50 and 100 μM for 5 minutes followed by cell lysis and western blotting. The 
membrane was probed for p-CREB using rabbit anti-human p-CREB antibody. The 
membrane was stripped and re-probed with mouse T-CREB antibody as a loading 
control. Densitometric analysis was performed using AlphaImager software. The 
experiment is representative of two independent experiments. 
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Figure 4.4: Phosphorylation of ERK1/2 at threonine 202 and tyrosine 204 
residues by endothelial cells following stimulation with HLA class I antibody. 
Serum starved HMEC-1 cells were treated with a saturating concentration (12 µg/ml) of 
W6/32 antibody or isotype control for various time points before cells were lyzed. Cells 
treated with 100 µM of H2O2 for 5 minutes were used as a positive control. The 
membrane probed for p-ERK using rabbit anti-human p-ERK antibody. The membrane 
was then stripped and re-probed for total ERK (T-ERK). The density of the bands was 
analyzed using AlphaImager software. The data are representative of three independent 
experiments. 
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Figure 4.5: Phosphorylation of Akt and CREB by endothelial cells following 
stimulation with HLA class I antibody.  
Serum starved HMEC-1 cells were treated with saturating concentration (12 µg/ml) of 
W6/32 antibody for various time points before the cells were lyzed. The membranes 
were probed for p-Akt at serine residue 473 (A) and p-CREB at serine residue 133 (B) 
using rabbit anti-human p-Akt and p-CREB antibodies, respectively. Cells treated with 
isotype control mouse IgG2a at the same concentration were used as a negative control. 
Cells stimulated with 100 µM of H2O2 or 10 µM of forskolin were used as a positive 
control for p-Akt and p-CREB, respectively. The membranes were stripped and re-
probed for total Akt (T-Akt) and total CREB (T-CREB). The density of the bands was 
analyzed by AlphaImager software. The data are representative of three experiments.  
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4.4.3 Dose response of endothelial Akt and CREB phosphorylation following 
stimulation with W6/32 antibody 
To investigate whether the exposure to sub-saturating concentrations of W6/32 antibody 
might induce a similar effect on protein phosphorylation, HMEC-1 cells were 
stimulated with different subsaturating concentrations of HLA class I antibody (W6/32) 
ranging from 0.35-6 μg/ml  and examined by western blotting for Akt and CREB 
phosphorylation. The subsaturating concentrations were previously determined using 
flow cytometry as shown earlier in Figure 3.14 (C and D). Endothelial Akt 
phosphorylation showed a dependency on antibody concentration, the level of 
phosphorylation declined at concentration from 0.35 to 1.5 μg/ml compared to that 
between 3-12 μg/ml, as shown in Figure 4.6 (A). In contrast, panel B on the same figure 
shows the phosphorylation of CREB independent to antibody concentration. The 
exposure to the lower concentration of W6/32 antibody used is sufficient to induce the 
phosphorylation of this transcription factor. Corresponding total proteins were used as a 
loading control for each blot.  
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Figure 4.6: Phosphorylation of endothelial Akt and CREB following 
stimulation with different concentrations of HLA class I antibody. 
Serum starved HMEC-1 cells were treated with different concentrations of W6/32 
antibody ranging from (0.35-12 µg/ml) for 5 minutes followed by cell lysate 
preparation. Panel A shows the phosphorylation of Akt at Serine 473 and B shows 
phosphorylation of CREB at serine 133. Cells treated with isotype control (mouse 
IgG2a) were used as a negative control. Cells stimulated with 100 µM of H2O2 and 10 
µM forskolin were used as positive controls for p-Akt and p-CREB, respectively. The 
membranes were stripped and re-probed for T-Akt and T-CREB. The densitometric 
analysis was performed using Alphaimager software. The data are representative of 
three independent experiments. 
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4.4.4 Effect of the PI3K/Akt pathway on CREB phosphorylation induced by 
W6/32 antibody 
The contribution of Akt to CREB phosphorylation in response to HLA class I antibody 
was examined using PI3K/Akt inhibitor, LY249002. The inhibitor was used at two 
concentrations: 10 and 50 μM for 30 minutes before stimulation with a saturating 
concentration of W6/32 antibody. The concentrations of the inhibitor were 
recommended by the manufacturer. Cell viability and toxicity related to the inhibitor 
was assessed by staining with trypan blue before stimulation the cells with W6/32 
antibody. The inhibitor did not induce cell toxicity; 90-95% of cell viability was 
observed after incubation with the inhibitor. The cell lysates were probed for p-Akt and 
p-CREB simultaneously. Probing for p-Akt was used as a control to ensure the activity 
of the inhibitor. The phosphorylation of Akt observed in response to W6/32 antibody is 
reduced significantly in the presence of the LY249002 inhibitor as shown in Figure 4.7 
(A). The presence of LY249002 inhibitor before stimulation with the W6/32 antibody 
did not abrogate CREB phosphorylation at serine residue 133 in both examined 
concentrations as shown in Figure 4.7 (B). The presence of the inhibitor alone did not 
show significant Akt or CREB phosphorylation. This result suggests that stimulation 
with W6/32 antibody activates two distinct pathways and Akt phosphorylation is 
independent to CREB pathway.   
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Figure 4.7: Effect of PI3K/Akt pathway on endothelial CREB phosphorylation 
induced by HLA class I antibody. 
HMEC-1 cells were treated with LY249002 inhibitor at 10 and 50 μM for 30 minutes 
before stimulation with saturating concentration of W6/32 antibody for 5 minutes. Cells 
were lysed and analysed by western blotting. Untreated cells and cells incubated with 
the inhibitor alone were used as negative controls. The membranes were probed for p-
Akt (A) and p-CREB (B). The membranes were then stripped and re-probed for 
corresponding total Akt and CREB. The densitometric analysis was performed using 
Alphaimager software. The data are representative of three independent experiments.  
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4.4.5 Effect of PKA pathway on endothelial CREB phosphorylation induced 
by W6/32 antibody 
Phosphorylation of the transcription factor CREB following stimulation with W6/32 
antibody suggests the involvement of an upstream pathway. It is well known that the 
PKA pathway is mainly responsible for CREB phosphorylation in response to 
stimulation with different stimuli. To examine whether CREB phosphorylation is 
downstream of the PKA pathway, the PKA inhibitor H-89 was used. To optimize the 
inhibitor concentration, HMEC-1 endothelial cells were incubated with different 
concentrations of the PKA inhibitor ranging from 50 nM to 50 μM before stimulation 
with 10 μM of forskolin for 5 minutes. Concentration above 50 μM effected 
significantly the cell viability as determined by trypan blue staining. As shown in Figure 
4.8, both 50 and 5 μM of H-89 inhibited CREB phosphorylation upon exposure to 
forskolin stimulation compared to cells treated with forskolin only. Therefore, 5 μM 
was used in further experiments since it is the lower concentration that inhibits 
significantly CREB phosphorylation in response to stimulation. 
For antibody stimulation, HMEC-1 cells were incubated with 5 μM of PKA inhibitor for 
30 minutes before stimulation with saturating concentration of W6/32 antibody (12 
μg/ml) for 5 minutes. Cells stimulated with the W6/32 antibody following incubation 
with H-89 inhibitor showed a reduction in the extent of CREB phosphorylation 
compared to cells treated with W6/32 antibody alone as shown in Figure 4.9.  
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Figure 4.8: Optimization of the concentration of the PKA inhibitor, H-89 on 
endothelial cells. 
HMEC-1 cells were treated with forskolin 10 μM for 5 minutes either in the presence or 
absence of different concentrations of H-89 inhibitor. The inhibitor was added 30 
minutes before stimulation with forskolin and lysates were probed for p-CREB at serine 
residue 133. The membrane was stripped and re-probed for T-CREB to ensure equal 
loading. The densitometric analysis was performed using Alphaimager software. The 
experiment is representative of two independent experiments. 
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Figure 4.9: Effect of PKA pathway on endothelial CREB phosphorylation 
induced by HLA class I antibody. 
Serum starved HMEC-1 cells were treated with isotype control (mouse IgG2a), 10 µM 
of forskolin or 5 µM of PKA inhibitor (H-89) 30 minutes before the exposure to either 
forskolin or W6/32 antibody (12 µg/ml) for 5 minutes. The cell lysates were probed 
with rabbit anti-human p-CREB antibody at serine residue 133. The membrane was 
stripped and re-probed for total CREB. The density of the bands was measured by 
AlphaImager software. This experiment is representative of three independent 
experiments.  
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4.4.6 Effect of W6/32 antibody on cell proliferation 
The ability of HLA class I antibody to induce endothelial cell proliferation was 
examined. Optimum cell number of HMEC-1 cells (20,000) were seeded into 96 wells 
plate and treated with a saturating concentration (12 μg/ml) of either W6/32 or isotype 
control antibody (mouse IgG2a) for 24 and 48 hours in complete media before 
performing colorimetric proliferation assay. As shown in Figure 4.10, HLA class I 
antibody treated cells did not show any significant difference in the rate of cell 
proliferation compared to isotype treated groups after 24 and 48 hours of stimulation. 
There was no significant difference between these groups and the untreated group (data 
not shown). 
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Figure 4.10: Proliferation assay using endothelial cells following stimulation 
with HLA class I antibody. 
20,000 HMEC-1 cells were treated with a saturating concentration of HLA class I 
antibody (12 μg/ml) or isotype control in complete media for 24 and 48 hours before 
adding the colorimetric proliferation assay reagents. The plate was incubate at 37
0
C for 
one hour and then measured at 490 nm using ELISA plate reader. Data are 
representative of three independent experiments. 
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4.4.7 Optimization of apoptosis of the HMEC-1 cells using staurosporine 
Staurosporine (STS) is a potent inhibitor of various protein kinases especially protein 
kinase C. It is known as an anti-proliferative drug which might cause cell death of 
various human cell types. To examine the apoptosis of endothelial cells in response to 
HLA class I antibody, HMEC-1 cells were first examined for cell apoptosis using STS 
to be used as a positive control. Cells were initially treated with 2.5 µM STS, a 
concentration optimized by our group for Jurkat T-lymphocyte cell line. Unfortunately, 
this dose induced an immediate cell necrosis in HMEC-1 cells. Therefore, different 
concentrations of STS were used to evaluate the optimum concentration which might 
produce a significant percentage of apoptotic cells. Cells were treated with different 
concentrations of STS ranging from 25 nM to 600 nM for 24 hours followed by staining 
with propidium iodide in the presence of permeabilizing agent. As shown in Figure 
4.11, a lower concentration (25-200 nM) caused cell cycle arrest at G1 phase and at a 
higher dose (400-600 nM) cells were arrested at G2 phase. Treatment of HMEC-1 cells 
with DMSO only did not induce a significant change in cell distribution (data not 
shown). This data suggests that STS treatment on HMEC-1 cells has a synchronizing 
rather than an apoptotic effect.   
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Figure 4.11: Optimization of apoptosis on HMEC-1 endothelial cell line using 
staurosporine.  
Cells were treated with different concentrations of staurosporine for 24 hours before 
flow cytometry analysis using PI/triton X-100 solution. Data were analyzed by 
Ventourione software for cell cycle distribution. The data are representative of two 
independent experiments. 
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4.4.8  Optimization of apoptosis on EA.hy926 cells using staurosporine  
As we were unable to elicit apoptosis on HMEC-1 cells following treatment with STS, 
another endothelial cell line, EA.hy926, was used to validate STS treatment and used as 
a comparison to HMEC-1 cells. EA.hy926 cells were treated with 2.5µM of STS for 24 
hours followed by flow cytometry analysis. Incubation of confluent cells in a serum free 
media for 24 hours followed by treatment with STS in complete media induced around 
15 % apoptotic cells after 4, 8 and 16 hours and around 42 % after 24 hours as shown in 
Figure 4.12. To exclude the possibility of non-specific effect of DMSO, cells were 
treated with 4 % DMSO alone and examined by flow cytometry. DMSO did not show 
significant difference from untreated group. 
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Figure 4.12: Optimization of apoptosis on EA.hy926 cells using 
staurosporine. 
Serum starved cells were incubated with 2.5 μM STS or 4 % DMSO at different time 
points before analysis by flow cytometry. Detached cells were stained with PI/triton X-
100 and analyzed by flow cytometry. Data were analyzed by Ventourione software for 
cell cycle distribution. Panel A, B, C, D, E and F show untreated (24 hours), 4, 8, 18, 24 
hours STS-treated and DMSO-treated (24 hours), respectively. Panel G shows the bar 
chart of the percentage of apoptotic cells. Data analysis was performed by two way 
ANOVA followed by Bonferroni test compared to DMSO treated cells at the same 
incubation time. * P<0.05 and *** p<0.001. The data are representative of three 
independent experiments. 
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4.4.9  Effect of HLA class I antibody on cell cycle distribution of HMEC-1 cell 
line 
From optimization experiments, it seems that HMEC-1 cell line is not a good model to 
study cell apoptosis. However, examination of the effect of HLA class I antibody on 
inducing changes in cell cycle of HMEC-1 endothelial cells was assessed. HMEC-1 
cells were treated with a saturating concentration of W6/32 antibody (12 μg/ml) for 24 
hours followed by analysis using flow cytometry. As shown in Figure 4.13, treated cells 
showed no significant changes in cell cycle distribution compared to control group in 
response to HLA class I antibody stimulation after propidium iodide staining. Isotype 
control treated cells showed similar cell cycle distribution to untreated group (data not 
shown). 
 
 
Figure 4.13: Effect of HLA class I antibody on the cell cycle of HMEC-1 cell line. 
Cells were treated with saturating concentration of HLA class I antibody for 24 hours 
before permeabilization with triton X-100 / propidium iodide solution. The cells were 
analyzed by flow cytometry. Interpretation of the data was performed using 
Ventourione software. The data are representative of three independent experiments. 
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4.5 Discussion 
Antibody-mediated rejection is one of the major obstacles against successful long-term 
solid organ transplantation. Donor specific antibody targeting HLA class I antigens 
induces activation of endothelial cells and microvascular inflammation. This results in 
allograft acute rejection and the development of transplant vasculopathy, the main 
manifestation of antibody-mediated chronic rejection (Sis, 2012). In a mechanism 
independent on the complement system, HLA class I antibody is able to induce 
activation of large vessel endothelial cells (Jindra et al., 2008c). Cross linking of HLA 
class I antigens induces a rapid phosphorylation of various endothelial cell signaling 
mediators; modulating their normal functions. In this chapter, the activation of 
endothelial cell signaling pathways in response to stimulation with HLA class I 
antibody was examined. 
In this study, treatment of endothelial cells with saturating concentration (12 μg/ml) of 
HLA class I antibody induced the phosphorylation of different cell signaling proteins 
such as Akt, FAK, Src, β-catenine, CREB and others assessed using human phospho-
kinase array. Although these mediators regulate endothelial cell functions, the role of 
some of these kinases in inducing endothelial dysfunction during rejection is not fully 
investigated. Cross linking of HLA class I antigens by saturating concentration of HLA 
class I antibody enhanced ERK phosphorylation at Thr202/204 residues as determined 
by western blotting. It is a serine/threonine kinase that mediates the activation of 
proliferative and cell differentiation genes (Chang et al., 2003). The phosphorylation of 
ERK has also been observed in primary human aortic endothelial cells treated with the 
same antibody in a mechanism involving the activation of mTORC2 (Jindra et al., 
2008b). In addition, in this study, HLA class I antibody induced Akt phosphorylation at 
serine residue 473 in a time and dose dependent manner. The expression of β4-integrin 
on endothelial cells is shown to be responsible for signaling mediated by HLA class I 
molecules (Zhang et al., 2011b). HMEC-1 endothelial cells express a high level of β4-
integrin as reported previously which might explain the cell signaling (Xu et al., 1994). 
Akt is a serine/threonine kinase that maintains the balance between cell proliferation 
and apoptosis depending on cell type and stimulus (Fatrai et al., 2006). The 
phosphorylation of Akt on aortic endothelial cells by HLA class I antibody has been 
previously shown as a downstream consequence of mTORC1 activation, following 
phosphorylation by exposure to HLA class I antibody (Jindra et al., 2008c). In a 
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previous study, maximum activation of Akt phosphorylation after stimulation with HLA 
class I antibody has been detected at a lower concentration of antibody (0.01 μg/ml) (Jin 
et al., 2004). It was assumed that the Akt phosphorylation at lower concentrations of 
antibody promoted cell survival by up-regulating the expression of anti-apoptotic 
proteins; enhancing organ accommodation rather than rejection. However, in this 
project, the extent of Akt phosphorylation was reduced at lower antibody concentration. 
Whether this contributes to protective mechanism or not is not obvious. However, large 
vessel endothelial cells and microvascular endothelial cells might response differently to 
different antibody concentrations.  
In this study, the phosphorylation of endothelial transcription factor CREB in response 
to stimulation with W6/32 antibody was also observed. Using HMEC-1 endothelial 
cells, CREB phosphorylation at serine residue 133 occurred in a time dependent manner 
and was less sensitive to antibody concentrations. CREB is a nuclear transcription factor 
that belongs to the basic leucine zipper (bZIP) superfamily. It regulates a wide range of 
crucial biological functions such as cell proliferation, survival, inflammation and 
differentiation via modulating the expression of various genes (Ichiki, 2006). In 
response to growth factor stimuli, CREB is responsible for enhancing cell survival 
through up-regulation of anti-apoptotic genes such as Bcl-2 (Bonni et al., 1999; Riccio 
et al., 1999) and cell proliferation by enhancing the expression of cyclin D1 (Lee et al., 
1999; D'Amico et al., 2000; Nagata et al., 2001) and cyclin A (Desdouets et al., 1995).  
CREB activation has a role in providing protection during oxidative stress through 
expression of antioxidant mediators such as manganese superoxide dismutase, 
thioredoxin and heme oxygenase-1 (Kronke et al., 2003; Chiueh et al., 2005). Various 
kinases might phosphorylate CREB in cell type and stimuli dependent manners such as 
ERK, MAPK, Akt and PKA as discussed in details in section 1.10.2. The 
phosphorylation in our system is independent on Akt signalling and depends on the 
PKA pathway as shown by using pathway specific inhibitors. Only one previous study 
has reported the phosphorylation of PKA in aortic endothelial cells stimulated with sub-
saturating concentration of HLA class I antibody, but not when stimulated with a 
saturating concentration (Narayanan et al., 2006). This group also showed that the 
activation of PKA was associated with a protection of endothelial cells against lysis by 
complement. The possibility that CREB protects cells from a sub-saturating 
concentration of antibody still needs to be elucidated.  
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Proliferation of smooth muscle and endothelial cells is one of the major histological 
signs of chronic antibody-mediated rejection (Zhang et al., 2012). Therefore, the effect 
of HLA class I antibody in inducing microvascular endothelial cell proliferation was 
examined. HMEC-1 cells treated with a saturating concentration of HLA class I 
antibody did not show any significant difference in the proliferation rate compared to 
isotype-treated cells after 24 and 48 hours of stimulation. In contrast, human aortic 
endothelial cells stimulated with 1 µg/ml of HLA class I antibody showed a significant 
increase in cell proliferation compared to control group after 72 hours stimulation 
(Jindra et al., 2008c). This was also observed using HUVEC cells treated with W6/32 
antibody and allospecific antibody (Smith et al., 2000). This difference might be 
attributed to the use of microvascular endothelial cell lines or might suggest the inability 
of microvascular endothelial cells to proliferate in response to HLA class I antibody.  
Staurosporine is an alkaloid isolated from bacterium Streptomyces staurosporeus which 
has an indol-2,3-α-carbazol chromophore. It has a wide range of clinical activity 
ranging from antifungal to antitumor effects (Omura et al., 1977). Its effect is attributed 
to its ability to inhibit a catalytic domain of protein kinase C enzyme which mediates 
phosphorylation of various intracellular proteins involved in cell growth and 
differentiation (Tamaoki and Nakano, 1990). In the research field, STS has been shown 
to induce apoptosis in embryonic neuronal cells (Wiesner and Dawson, 1996), causing 
nuclear changes in MOLT-4 cell line (Falcieri et al., 1993) and HL-60 cells (Bertrand et 
al., 1993), cell differentiation (Okazaki et al., 1988)
 
and inhibition of cell cycle 
progression (Bruno et al., 1992) and metastasis of tumor cells (Schwartz et al., 1990). In 
this project, STS was used to assess the ability of EA.hy926 and HMEC-1 cells to 
undergo apoptotic cell death, provide a positive control in apoptosis experiments using 
HLA class I antibody. 
Treatment of HMEC-1 with doses of STS ranging from 25 to 200 nM caused an arrest 
of the cell cycle at G1 phase while treatment with higher doses (400-600 µM) arrested 
the cells at G2 phase. In contrast, treatment of EA.hy926 cells with 2.5 µM STS induced 
around 41% of cell apoptosis after treatment for 24 hours. Previous results showed that 
treatment with STS produced both effects in a cell type and cell cycle dependent manner 
(Bernard et al., 2001).  Treatment of fibroblasts with STS showed a similar effect to that 
observed on HMEC-1 cells. Treatment with lower doses of STS (10 ng/ml) arrested 
cells at the G1-phase whilst treatment with higher doses of STS induced cell cycle arrest 
at the G2-phase (Abe et al., 1991). For EA.hy926 cells, apoptotic cell death was 
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observed previously using STS at different time points and concentrations (Mosnier and 
Griffin, 2003). This suggests that STS can be used as a cell synchronizing agent in some 
types of endothelial cells and as an apoptosis inducing agents in the others. Therefore, 
HLA class I antibody was assessed for its ability to induce a modulation in endothelial 
cell cycle rather than apoptosis. Exposure to these antibodies at a saturating 
concentration for 24 hours did not produce any changes in the cell cycle compared to 
isotype control. This might also confirm the proliferation result, since the increase in the 
proliferation rate suggests an increase in S and G2-phases which is also not observed.   
In conclusion, exposure of human microvascular endothelial cells to HLA class I 
antibody induces phosphorylation of various intracellular signaling proteins such as 
ERK, Akt and transcription factor CREB. The phosphorylation of CREB shows 
sensitivity to PKA but not to the Akt pathway suggesting activation of two independent 
pathways. Although the stimulation with HLA class I antibody did not induce 
endothelial cell proliferation or apoptosis, the activation of these pathways suggests a 
modulation of endothelium function after exposure to HLA class I antibody. Therefore, 
expression of adhesion molecules and chemokines by stimulated endothelial cells was 
examined. 
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5. Chapter Five-HLA class I Antibodies and Endothelial-
Leukocyte Interaction  
5.1 Introduction 
In solid organ transplantation, the presence of circulating donor specific HLA 
antibodies is associated with a high incidence of acute cellular rejection (Musat et al., 
2011). In addition, detection of these antibodies along with cellular rejection in renal 
transplantation is a marker of poor prognosis of allograft survival compared to grafts 
with antibody-mediated rejection or cellular rejection alone (Everly et al., 2009). 
Infiltration of mononuclear cells is not only observed in cellular-mediated rejection but 
is also one of the main characteristic of microvascular inflammation during antibody-
mediated rejection and predicts poor allograft outcome (Tinckam et al., 2005; Molne et 
al., 2006; Fahim et al., 2007; Papadimitriou et al., 2010). In a mouse model, passive 
transfer of MHC class I antibodies into mismatched recipients induces 
monocyte/macrophage infiltration independent of the Fc fragment of the antibody 
(Jindra et al., 2008a). Infiltrating macrophages can induce endothelial cell proliferation 
by secreting growth factors and cytokines promoting the development of vasculopathy 
(Schubert et al., 2008). The mechanism by which endothelial cells induce monocyte 
adhesion in response to HLA class I antibodies is not fully understood. 
Leukocyte migration is a multistep process mediated by the expression of adhesion 
molecules and chemokines by endothelial cells. The expression of these mediators is 
increased at different stages following transplantation. During ischemia reperfusion, the 
expression of cytokines and chemokines such as IL-2, IL-6, CCL2 and CCL5 increased 
after 30 minutes of allograft reperfusion in an animal model of pancreas transplantation 
(Lunsford et al., 2013). In cellular rejection, the expression of CCL21 chemokine 
increased in biopsies from kidney patients and is involved in inducing cell fibrosis 
(Zhou et al., 2013). Antibody-mediated rejection is also characterized by the expression 
of different chemokines and adhesion molecules. In a mouse model, passive transfer of 
MHC class I antibody to mismatched antigens induced the expression of VCAM-1, 
ICAM-1, IL-6, IL-1β, CXCL8 and IL-12 (Fukami et al., 2012). Chemokine expression 
is also involved in the development of graft vasculopathy, the main feature of chronic 
rejection (Ruster et al., 2004). In addition, the detection of soluble adhesion molecules 
VCAM-1 and ICAM-1 can be used as a marker for early acute rejection and predicts 
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poor outcome following kidney transplantation (Connolly et al., 2011; Reinhold et al., 
2012).   
In blood vessels, intravascular flow is necessary for inducing leukocyte migration in a 
process called chemorheotaxis. In this process, shear stress applied by the blood flow is 
essential for leukocyte trafficking into inflammatory sites in the presence of 
immobilized chemokines (Luscinskas et al., 2001). Apical chemokines immobilized on 
the endothelial cell surface play an essential role in inducing stable leukocyte arrest, 
while luminal chemokines are essential for inducing leukocyte transmigration (Weber et 
al., 1999; Cinamon et al., 2001). Shear stress is defined by the magnitude of the force 
exerted by the blood flow to the specific area on the blood vessels, and is expressed as 
dyne cm
-2
. According to the type of blood vessels and their inflammatory status, the 
blood flow applies shear stress ranging from 1 dyne cm
-2 
in post-capillary venules to 
more than 10 dyne cm
-2 
in arteries (Fidkowski et al., 2005). Typically, from 1-6 dyne 
cm
-2
 is a physiological range for leukocyte recruitment in post-capillary and 0.5 dyne 
cm
-2  
is optimal for in vitro leukocyte adhesion (Verdier et al., 2009).  
Shear stress applied by blood flow is crucial in maintaining optimum function of cell 
surface selectins and integrins (Laudanna and Alon, 2006). In addition, lymph node-
related chemokines such as CXCL12 induce efficient integrin activation and cell 
adhesion under shear forces compared to that in a shear-free environment. Endothelial 
chemokines under flow induce conformational changes to the cell surface integrins, 
enhancing their binding to corresponding endothelial ligands (Woolf et al., 2007). 
Furthermore, blood flow enhances a synergistic effect between different chemokines 
compared to the effect of each chemokine independently in static adhesion assays 
(Schreiber et al., 2007).  
Examination of leukocyte migration in response to particular chemokines is 
traditionally performed under static conditions. Static chemotaxis assays using transwell 
chambers, such as Boyden chambers, can be used for a migration assays without 
applying any shear stress. These assays can be used to assess the ability of the cells to 
migrate in response to chemokine gradients, without assessing cell adhesion and 
migration in the presence of physiological shear stress. Although both chemotactic 
effects and chemokinetics can be analyzed in this assay, diffusion of chemokines after a 
few hours impairs the chemokine gradients and impedes further cell migration (Toetsch 
et al., 2009). By using flow based assays, these limitations are overcome; remodeling in 
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vivo leukocyte adhesion that is not present under static condition. Therefore, in this 
project the role of activated endothelial cells in inducing leukocyte adhesion and 
migration was examined using both static and flow based assays.  
In this chapter, the potential of HLA class I antibody to induce the expression of 
mediators responsible for leukocyte adhesion and migration was examined. This 
includes the expression of endothelial cell surface adhesion molecules; VCAM-1, 
ICAM-1 and E-selectin in addition to the expression of inflammatory cytokines and 
chemokines. The expression of adhesion molecules was determined using flow 
cytometry while the expression of inflammatory cytokines was evaluated using human 
protein cytokine array and q-PCR. Furthermore, the mechanisms responsible for the 
expression of these molecules were assessed. This was performed by examining the 
contribution of cell signaling pathways Akt and PKA/CREB in the expression of 
adhesion molecules and chemokine using pathway-specific inhibitor and CREB-
knockdown. The ability of activated microvascular endothelial cells to induce monocyte 
adhesion and migration was also determined using static chemotaxis and in vitro flow-
based adhesion assays.  
5.2 Specific Aims 
The role of HLA class I antibody (W6/32) in inducing the expression of mediators 
involved in leukocyte adhesion was examined. This involves: 
 Evaluating the expression of cell surface adhesion molecules following stimulation 
with W6/32 antibody; 
 Assessing the contribution of the PI3K/Akt pathway in the expression of endothelial 
adhesion molecules; 
 Evaluating the expression of cytokines and chemokines by endothelial cells 
following the exposure to saturating concentration of W6/32 antibody; 
 Examining the pathways responsible for the expression of CXCL8 in response to 
W6/32 antibody 
 Examining the efficiency of W6/32 antibody-treated endothelial cells in inducing 
human monocytes (THP-1) migration using static chemotaxis assay, and 
 Assessing the potential of F(ab)2 fragments in inducing the adhesion of THP-1 cells, 
under physiological flow condition. 
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5.3 Specific materials and methods 
5.3.1 Stimulation of endothelial cells for adhesion molecules expression 
Expression of the adhesion molecules E-selectin, ICAM-1 and VCAM-1 on endothelial 
cells was examined following stimulation with tumor necrosis factor (TNF-α). Adherent 
HMEC-1 cells were grown in 12 well plates until reach 50-60% confluence. The cells 
were then washed once with PBS and the media was changed to media containing TNF-
α at different concentrations. HMEC-1 cells were stimulated with TNF-α at 
concentrations ranging from (0.1-20 ng/ml) for 16 to 72 hours without media change. 
Stimulated cells were detached using cell dissociation buffer and 1X10
5
 cells were 
stained with PE-conjugated mouse anti-human E-selectin, VCAM-1 and ICAM-1 
antibodies (eBioscience) and analysed by flow cytometry. Cells stained with isotype 
control (mouse IgG1) were used as a negative control. For stimulation with W6/32 
antibody, adherent cells were incubated with a saturating concentration of W6/32 
antibody (12 μg/ml) or isotype control (mouse IgG2a) in complete media at different 
time points ranging from 8 hours to 72 hours. The cells were then analyzed using flow 
cytometry.    
5.3.2 Stimulation of endothelial cells for measurement of cytokine and 
chemokine expression  
To assess the ability of endothelial cells to produce inflammatory cytokines and 
chemokines in response to W6/32 antibody cells were stimulated with this antibody and 
examined for the expression of these mediators at the protein level. A human cytokine 
array (R&D system) containing 36 different anti-cytokine antibodies attached to a 
nitrocellulose membrane was used. HMEC-1 cells at 50% confluence were stimulated 
with saturating concentration of W6/32 antibody (12 μg/ml) or isotype control for 72 
hours. Supernatant was collected and analysed against the cytokine array according to 
the manufacturer’s instruction. In brief, membranes were blocked for 1 hour at room 
temperature with blocking buffer provided in the kit. Conditioned media from W6/32 or 
isotype treated cells were mixed with biotinylated detection antibody cocktail and 
incubated for 1 hour at room temperature. The samples were then added to the blocked 
membranes and incubated overnight at 4
ο
C with continuous shaking. After incubation, 
membranes were washed three times followed by incubation with streptavidin-HRP. 
The membranes were incubated at room temperature for 30 minutes followed by three 
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washes. Blots were developed using ECL substrates and Kodak films. The density of 
the dots was measured using AlphaImager software.   
5.3.3 Stimulation of endothelial cells for expression of CXCL8 
Endothelial cells (HMEC-1) were grown in 12 wells plate until confluence. Cells were 
stimulated with saturating concentration 12 μg/ml of either isotype control or W6/32 at 
different time points or with different antibody concentrations ranging from (0.4-12 
μg/ml) for 3.5 hours. After stimulation, the cells were washed once with PBS and RNA 
was isolated as described in section 2.9.2 using 250 μl of Tri reagent per well. The RNA 
concentration and purity was assessed by Nanodrop as described in section 2.9.3. Two 
to five μg of RNA was used for cDNA synthesis. The latter was performed using one 
step cDNA systhesis kit as described in section 2.9.5. The resultant product was used in 
a q-PCR reaction as described in section 2.10.4 using human CXCL8 and GAPDH 
specific primer-probes.  
5.3.4 Transient transfection (siRNA technology) 
5.3.4.1 General principle 
The RNA interference is a physiological regulatory pathway which occurs in the 
cytoplasm of most eukaryotic organisms. In this process, small double stranded RNA 
mediates the downregulation of different proteins at the post-transcriptional level. The 
key mediators in this process are small endogenous RNA sequences with around 21-28 
nucleotides; they are small interfering RNA (siRNA) and microRNA. From this 
pathway, the ability to silence a specific gene by using an exogenous siRNA in a 
transfection process has emerged. In this machinery, a long double stranded RNA, 
exogenous or endogenous, is cleaved by the Dicer enzyme, a ribonuclease belonging to 
the RNase III family, generating a short double stranded siRNA of around 22 
nucleotides. This sequence is incorporated into the RISC complex (RNA induced 
silencing complex) producing a single stranded siRNA in a reaction catalyzed by RNA 
helicase enzyme. The production of single stranded siRNA induces activation of RISC 
complex which activates the nuclease enzyme, inducing degradation of mRNA that is 
complimentary to the siRNA as shown in Figure 5.1. Transfection of siRNA induces 
transient, sequence specific knock down which is applicable for 3-5 cell divisions (Kim, 
2003). 
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Figure 5.1: Mechanism of siRNA action in degradation of target mRNA. 
 Source: (Kim, 2003). 
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The transfection of siRNA into cultured cells can be performed using different 
transfection reagents and methods. Transfection can be achieved using biological, 
chemical or physical methods. The chemical agents that can be used involve; cationic 
polymer, calcium phosphate and cationic lipid based reagents. In this project, siRNA 
transfection was performed using the chemical method (lipid-based transfection agent) 
and physical method (electroporation). In the former, a complex is formed between 
negatively charged siRNA and a cationic lipid attached to liposomes. The latter contains 
long hydrophobic chains and a positively charged head group which encapsulates the 
siRNA by lipid bilayer preventing its degradation and facilitating its uptake to the cells. 
Adherent cells can be transfected by these agents either in their adherent state 
(traditional transfection) or by reverse transfection. In reverse tranfection method, cells 
are transfected while they are in suspension and the transfection occurs at the time of 
cell attachment, minimizing the transfection time and increasing transfection efficiency. 
In electroporation method, the cells are exposed to electrical pulse forming pores in the 
cell membrane facilitating the entrance of siRNA. In general, successful transfection 
depends on many factors and might require optimization. Factors such as cell type, 
passage number, method used and the half-life of the target protein need to be all 
considered.          
5.3.4.2 Transfection efficiency using cy3 labelled GAPDH siRNA and lipid 
based reagents 
Fluorescently labelled siRNA is used as a guide in monitoring siRNA uptake as well as 
its distribution and localization during the transfection process. Additionally, it can be 
also used to assess the efficiency of the knockdown of the desired gene. Human silencer 
cy3 labelled GAPDH siRNA (Applied Biosystems) was supplied in lyophilized form. It 
was resuspended in RNAase free water to 10 μM concentration. A lipid based 
transfection reagent, siPORT NeoFX (Applied Biosystems) was used to perform the 
transfection process using manufacturer’s instruction. In brief, 50% confluent HMEC-1 
cells were trypsinized and counted. 9X10
4
 cells were added per well in 12 wells plate, 
re-suspended in 900 μL of HMEC-1 media without antibiotics. For reagent preparation, 
the complex formation between siRNA and the reagent was performed using HMEC-1 
media (MCDB-1 media) without any additives. The siRNA was used at concentrations 
30, 50 and 100 nM. For complex formation, 50 μL of media was mixed with 3 μL of 
labelled GAPDH siRNA to final concentration of 30 nM in Eppendorf tube. In a second 
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Eppendorf tube, 50 μL of media was mixed with 3 μL of siPORT NeoFX transfection 
reagent. The contents of the two Eppendorfs were mixed together and left for 10 
minutes at room temperature. After incubation, 100 μL of siRNA mixture was added to 
the cells in the wells with gentle shaking. After 24 hours of incubation, cells then were 
washed once with PBS and fresh media was added. The cells were examined by 
fluorescence microscope (Leica, Germany) at excitation 547 nm and emission 563 nm 
at 24, 48 and 72 hours. Cells transfected with 30 nM of labelled GAPDH siRNA for 24, 
48 and 72 hours are shown in Figure 5.2, while transfection with different siRNA 
concentrations for 24 hours is shown in Figure 5.3.   
5.3.4.3 Transfection efficiency using cy3 labelled GAPDH siRNA and 
electroporation technique 
For transfection by electroporation, 0.5 million cells trypsinized from 50% confluent 
HMEC-1 culture were suspended in PBS. The cells were transfected with labelled 
siRNA for GAPDH at final concentration of 30 nM. The electroporation process was 
carried out using a Nucleofector I instrument (Amaxa, Lonza). Suspended cells and 
siRNA were exposed to electric pulses recommended by the manufacturer for similar 
cell lines and saved as M-03 program. The cells were resuspended in 1 ml of media 
without antibiotics and grown in 12 well plates. After 24, 48 and 72 hours, cells were 
visualised using inverted fluorescence microscope (Leica) at excitation 547 nm and 
emission 563 nm as shown in Figure 5.4. Electroporation caused excessive cell death. 
Therefore, transfection using lipid-based reagent was chosen for further experiments.  
5.3.4.4 Evaluation of knockdown efficiency using different lipid based 
reagents and non-fluorescently labelled GAPDH siRNA  
Fluorescently labelled GAPDH siRNA showed successful transfection of HMEC-1 
cells. However, fluorescently labelled GAPDH siRNA showed a low efficiency in 
knocking down GAPDH at a protein level as assessed by western blotting (data not 
shown). Therefore, a non-fluorescently labelled silencer select GAPDH siRNA was 
chosen. The choice of this sequence was made according to manufacturer’s 
recommendation which is supposed to be effective in knocking down a target sequence 
at lower siRNA concentrations between 5-20 nM. Silencer select GAPDH siRNA 
(Applied Biosystems) was supplied in purified and dried form. It was reconstituted in 
RNAase free water at 5 μM stock solution. To optimize the transfection protocol, the 
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Figure 5.2: Time course of the transfection with cy3 GAPDH siRNA into 
HMEC-1 cells using lipid based transfection reagent. 
HMEC-1 cells were transfected with 30 nM of cy3-GAPDH siRNA using NeoFX 
siPORT transfection reagent and visualized by fluorescence microscopy (Leica) at 
excitation 547 nm and emission 563 nm after 24, 48 and 72 hours of transfection.  
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Figure 5.3: Transfection of cy3 GAPDH siRNA at different concentrations into 
HMEC-1 cells using lipid based transfection reagent. 
HMEC-1 cells were transfected with 30, 50 and 100 nM of cy3-GAPDH siRNA using 
NeoFX siPORT transfection reagent and visualized by fluorescence microscope (Leica) 
at excitation 547 nm and emission 563 nm after 24 hours of transfection.  
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Figure 5.4: Transfection of cy3 GAPDH siRNA into HMEC-1 cells using the 
electroporation technique. 
HMEC-1 cells were resuspended in PBS and transfected with 30nM of cy3-GAPDH 
siRNA using Nucleofector I instrument with M-03 program. The images were captured 
by fluorescence microscope after 24, 48 and 72 hours of transfection.  
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HEK cell line described in section 2.3.4 was used. This cell line is a good model to 
achieve an efficient transfection and gene silencing as previously shown by our 
laboratory. Therefore, knocking down of GAPDH in this cell line was assessed in 
parallel with HMEC-1 cells. Four different lipid based transfection reagents were tested 
which were supplied by different manufacturers including; siPORT NeoFX transfection 
reagent (Applied Biosystems), lipofectamine (invitrogen), interferin siRNA transfection 
reagent (PolyPlus-transfection) and Ribocellin siRNA delivery reagent 
(BioCellChallenge). All reagents were tested using HEK cells and HMEC-1 cells except 
the last reagent was tested on HMEC-1 only. The 2X10
5
 of HMEC-1 cells were 
transfected reversely with 5 nM of GAPDH siRNA in 12 wells plate using four different 
reagents, following the manufacturer’s instructions for each reagent. The cells were 
incubated at 37
0
C for 48 and 72 hours incubation. The knockdown efficiency was 
determined at mRNA level after 48 hours of transfection and at protein level following 
72 hours. Media was changed to fresh transfection media (without antibiotics) after 24 
hours of transfection.  
5.3.4.5   Knockdown efficiency at mRNA level 
To determine the efficiency of silencing GAPDH at mRNA level, real time-PCR using a 
Taqman assay was performed as described in section 2.10.4. After 48 hours of 
transfection, HEK and HMEC-1 cells were washed once with PBS and RNA was 
isolated by Tri-reagent as described in section 2.9.2. Cells transfected with Ribocellin 
siRNA delivery reagent were excluded due to high toxicity and cell death. RNA 
concentration and purity was assessed by Nanodrop spectrophotometry as described in 
section 2.9.3. cDNA synthesis was performed using 2-3 μg of RNA as described in 
section 2.9.5. GAPDH primer-probe was used to analyze GAPDH expression and 18S 
primer probe was used as a house keeping gene. Because the latter is a non-exon 
spanning primer, a genomic DNA elimination step was performed before cDNA 
synthesis using a commercial kit (Promega) following the manufacturer’s instructions. 
No amplification was observed in wells containing RNA samples. Figure 5.5 (A) shows 
real time PCR data for HEK cell line using different reagents.  
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Figure 5.5: Optimization of GAPDH siRNA transfection in HEK cell line. 
HEK cells were transfected with 5 nM of silencer select siRNA using different reagents. 
Changes at mRNA level were determined by real time-PCR as shown in panel A using 
18S as a house keeping control. The change at protein level for GAPDH was assessed 
by western blotting as shown in panel B using tubulin as a loading control. 
Densitometric analysis was performed using AlphaImager software. The data are 
representative of three independent experiments. 
GAPDH 
α-Tubulin 
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5.3.4.6 Knockdown efficiency at protein level 
To examine the efficiency of the knockdown at the protein level after transfection, 
western blotting was performed as described in section 2.8. Cells were transfected for 
72 hours using different reagents on HEK and HMEC-1 cells, and different siRNA 
concentrations with lipofectamine reagent on HMEC-1 cells to assess the dose 
effectiveness. Briefly, cells were washed once with PBS and lysed by the addition of 
cold lysis buffer described in section 2.8.2 (without addition of phosphatase inhibitor) 
followed by cell scraping. The cells were incubated on ice for 10 minutes followed by 
sonication, centrifugation and determination of protein concentration as specified in 
section 2.8.3. Eight μg of proteins were separated on 12% SDS gel and transferred to 
PVDF membrane as described in section 2.8.4 and 2.8.6, respectively. After blocking 
for 1 hour with 5% milk, rabbit anti-human GAPDH antibody (Santa Cruz 
Biotechnology) was used at 1:1000 diluted in 5% milk. HRP-conjugated anti-rabbit 
secondary antibody was used at 1:4000 and the membrane was developed as described 
in section 2.8.7. As a loading control, the membrane was washed once with PBS and 
mouse antibody against tubulin was added (Sigma) followed by HRP-conjugated anti-
mouse secondary antibody. Figure 5.5 (B) and Figure 5.6 show western blots for HEK 
and HMEC-1 cells, respectively.                   
5.3.4.7 Transfection of CREB siRNA  
Optimization experiments of transfection showed that lipofectamine reagent produced 
efficient transfection of HMEC-1 cells with low toxicity; therefore, this was used for 
further experiments. T-CREB knockdown was performed using CREB siRNA silencer 
select and assessed by western blotting as shown in Figure 5.7. The CREB siRNA and 
negative control siRNA was supplied in a purified and dried form (Applied 
Biosystems). These were reconstituted using RNase free water at 5 μM stock 
concentration and diluted to 2 μM working solution. 50% confluent HMEC-1 cells were 
trypsinised and adjusted to 2X10
5
 cells suspended in 900 μl of transfection media. To 
form a transfection complex containing a final concentration of 5 nM siRNA, 50 μl of 
HMEC-1 media without any additive containing 2.5 μl of CREB or negative control 
siRNA (2μM) was mixed with 50μl of the same media containing 2μl of lipofectamine 
per well in a 12 well plate. Accordingly, higher concentrations were adjusted. The 
complex was allowed to form by incubation at room temperature for 25 minutes. The 
complex was added to 900 μl of cell suspension in 12 well plates with gentle mixing.  
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Figure 5.6: Optimization of GAPDH siRNA transfection on HMEC-1 cell line. 
The cells were transfected with siRNA for GAPDH and the change at protein level was 
assessed by western blotting. Panel A shows the transfection with 5 nM GAPDH siRNA 
using different transfection reagents. Panel B shows knockdown in response to different 
siRNA concentration using lipofecamine. Tubulin was used as a loading control. The 
data are representative of two independent experiments.  
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Figure 5.7: Total CREB knockdown in HMEC-1 cells using CREB-specific 
siRNA and lipofectamine reagent. 
Cells were transfected with different concentrations of CREB siRNA (5, 10, 20 nM) or 
negative control siRNA at concentration of 10 nM for 72 hours before western blot 
analysis. The membrane was probed with T-CREB, and tubulin was used as a loading 
control. The data are representative of two independent experiments.  
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 After 72 hours, the cells were lysed and assessed by western blotting as previously 
described in section 2.8. Mouse anti-human T-CREB and tubulin antibodies were used 
to validate the knockdown efficiency.  
5.3.5 Preparation of F(ab)2 fragment 
5.3.5.1 General principle 
The antibody consists of two antigen-binding fragments (Fab) and one class specific 
constant fragment (Fc) which are connected by a hinge region containing disulfide 
bridge to form a Y shape structure. The disulfide bonds in this region are accessible to 
different proteolytic enzymes which facilitate the formation of different antibody 
fragments as shown in Figure 5.8. To study the functional characteristics of each 
fragment separately, antibody fragmentation can be performed for this purpose. 
Antibody fragmentation can be achieved using reducing agents or proteases that 
selectively cleave the immunoglobulin molecule at a certain point into fragments in an 
agent-dependent manner. Commonly prepared antibody fragments include half-IgG, 
Fab, F(ab')2 and Fc fragments. Fragments can be produced by reduction of hinge-region 
disulfides or by digestion with proteolytic enzymes such as papain, pepsin or ficin. In 
this project, the ability of W6/32 antibody in inducing leukocyte adhesion independent 
of Fc receptors by preparing F(ab)2 fragments from W6/32 antibody was examined. 
Pepsin is a nonspecific endopeptidase enzyme that is widely used for F(ab)2 fragment 
preparation. Pepsin is active at acidic pH and irreversibly degraded at neutral or alkaline 
pH. Antibody digestion by this enzyme produces one F(ab')2 fragment with size 110 
kDa and various small peptides from the Fc portion. The resulting F(ab')2 fragment 
consists of two Fab units connected by disulfide bonds. The degraded Fc fragment can 
be separated from F(ab')2 fragment by dialysis, gel filtration or ion exchange 
chromatography as shown in Figure 5.9. 
5.3.5.2 F(ab)2 fragment preparation 
The preparation of F(ab)2 fragment was performed using a F(ab)2 preparation kit 
(Thermo scientific, USA) according to manufacturer's instruction. The kit consists of 
immobilized pepsin, a protein A spin column, phosphate buffer saline, IgG elution 
buffer, F(ab)2 digestion buffer, a desalt spin column and microcentrifuge tubes. The
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Figure 5.8: Antibody structure and enzymatic cleavage activity. 
(thermo scientific, http://www.piercenet.com/browse.cfm?fldID=4E03B016-5056-
8A76-4ECA-982DA6CAAC8A). 
 
 
Figure 5.9: Preparation of F(ab)2 fragments by pepsin treatment. 
 (thermo scientific, http://www.piercenet.com/browse.cfm?fldID=01010504). 
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 immobilized pepsin was equilibrated by washing once with 0.5 ml of digestion buffer 
in the provided spin column at 5000 g for 1 minute. To resuspend the sample in the 
digestion buffer, a desalt spin column was used. The latter was centrifuged once at 
1500g for 1 minute to remove the storage buffer. Subsequently, 300 μl of digestion 
buffer was added to the column and this was centrifuged at 1500 g for 1 minute. This 
step was repeated three times and the buffer was discarded after collection in a separate 
tube. After placement of the column in a new collection tube, 0.5 ml of 4 mg of W6/32 
antibody was applied to the centre of the column and this was centrifuged at 1500 g for 
2 minutes. The eluate contains the antibody suspended in the digestion buffer after the 
exchange step. The antibody was then added to the immobilized pepsin and incubated at 
37
ο
C on a shaker for 3 hours. After incubation, the spin column was centrifuged at 5000 
g for 1 minutes and the sample was collected into a microcentrifuge tube. To ensure the 
elution of all digested antibody, the spin column was washed once with PBS. To 
separate the undigested IgG, the antibody was then passed through protein A column.  
The protein A column was placed in a collection tube and centrifuged at 1000 g for 1 
minute to remove the storage buffer. To equilibrate the column, 400 μl of PBS was 
added followed by centrifugation at 1000 g for 1 minute. The digested antibody was 
applied to the column and mixed on the shaker for 10 minutes. The column was placed 
into a clean tube and centrifuged at 1000 g for 1 minute. The fraction collected 
contained F(ab)2 and Fc fragments. The column was washed twice with PBS to ensure 
the complete recovery of the fragments. To remove the Fc fragment, the digested 
antibody was passed through spin column with a cut-off of 50 kDa. The recovery of 
F(ab)2 fragments was confirmed by SDS-PAGE. Five μg of antibody was separated on 
10% SDS-PAGE under non reducing condition, without the addition of β-
mercaptoethanol followed by staining with comassie stain as described in section 2.8.4 
and 2.8.5, respectively. Figure 5.10 shows the comassie staining of the gel. Figure 5.11 
shows the binding of f(ab)2 fragments at 12 μg/ml to HMEC-1 cells. This was assessed 
by flow cytometry using anti-mouse IgG FITC conjugated antibody.  
5.3.5.3 Flow cytometry analysis of F(ab')2 fragment 
To assess the ability of F(ab')2 fragments to bind and activate endothelial cells, HMEC-
1 cells were stained and stimulated  with F(ab')2 fragments. Adherent cells were 
detached using cell dissociation buffer and 2X10
5
 cells were incubated with 12 μg/ml of  
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Figure 5.10：The preparation of F(ab)2 fragments from W6/32 antibody. 
W6/32 antibody was digested by pepsin treatment and the product was run on 10% 
SDS-PAGE under non-reducing condition. Lane 1 shows undigested antibody, Lane 2 
shows digested antibody before protein A purification and Lane 3 shows purified F(ab)2 
fragments. 
 
Figure 5.11：Binding of F(ab)2 fragments to HMEC-1 cells assessed by flow 
cytometry. 
HMEC-1 cells were stained with 12 μg/ml of F(ab)2 fragments followed by anti-mouse 
FITC conjugated antibodies. Cells stained with secondary antibody only were used to 
assess the background staining. 
Undigested IgG 
F (ab)2 fragment 110 
150 
kDa 
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 these fragments for 20 minutes at 4
ο
C. After washing with 2% FBS/PBS, cells were 
stained with anti-mouse FITC conjugated antibody. The cells were incubated with the 
secondary antibody for 20 minutes at 4
ο
C. After washing steps, cells were resuspended 
in 2% FBS/PBS before analysis by flow cytometry. For the activation experiments, 
adherent cells were incubated with 12 μg/ml of F(ab')2 fragments overnight before 
analyzing the expression of adhesion molecules. Cells were detached as previously 
described and 1X10
5
 cells were stained with PE-conjugated mouse anti-human ICAM-1 
and VCAM-1 antibody. Stained cells were washed twice with FBS/PBS and analyzed 
by flow cytometry. 
5.3.6 Chemotaxis assay  
5.3.6.1 General principle- the Boyden chamber 
This assay is used to evaluate the potential of chemotactic agents to induce leukocyte 
migration, modelling in vivo cell migration. The in vitro cell migration assay can be 
performed using a transwell chamber as described by Boyden in 1962 (Boyden, 1962). 
In this assay, a transwell chamber containing a polycarbonate multipore filter with 
different pore sizes is used. The size of the pore is dependent on the type of the cells to 
be investigated but generally it ranges from 3-8 μm for leukocyte migration. The cells to 
be examined are placed on the upper side of the chamber while the chemoattractant 
solution is placed in the lower side. During incubation, cells migrate in response to a 
concentration gradient from the lower chemokine concentration to the higher 
concentration. Migrant cells are then stained and counted. Figure 5.12 shows a diagram 
of a transwell chamber. 
5.3.6.2 Method for chemotaxis assay 
HMEC-1 cells grown in 6 wells plate were stimulated with 12 μg/ml of either W6/32 
antibody or isotype control for 72 hours.  The media was collected and used to perform 
chemotaxis assays. Conditioned media was passed through a 100 kDa cutoff 
concentrator tube to remove any remaining W6/32 antibody. Human THP-1 monocytic 
cells, expressing the corresponding receptors for the chemokines secreted by HMEC-1 
cells, were used in this assay. The ability of THP-1 cells to migrate in response to 
chemokine was examined by this method using different concentrations of recombinant 
human (rh) CCL5 (R&D systems) ranging from 1-200 ng/ml as shown in Figure 5.13. 
0.5 million THP-1 cells were resuspended in 200 μl of serum free medium containing  
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Figure 5.12: Transwell chemotaxis chamber. 
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Figure 5.13: Chemotaxis assay using rhCCL5 and human THP-1 monocytic 
cells. 
THP-1 cells were starved for 1 hour in 1% BSA media before placing them in 
chemotaxis chamber containing different concentrations of rhCCL5 ranging from 1-200 
ng/ml for 3 hours at 37
0
C. Filters were stained and migrant cells were counted. The data 
are representative of two independent experiments. 
 
Cell Suspension in the 
upper chamber 
Medium containing 
chemoattractante 
Filter membrane pore 
5 µm 
3 hours incubation 
Filter staining and counting 
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1% BSA for 1 hour. Simultaneously, a 24 wells plate was blocked with 1ml of 1% BSA 
for 1 hour at room temperature to prevent non-specific binding of the chemokine. 600 μl 
of conditioned media from both treated groups was placed in the wells and 200 μl of 
THP-1 cells were placed in the upper chamber with 5 μm pore size. The plate was 
incubated at 37
0
C for 3 hours. The chemotaxis inserts were removed and non-migrant 
cells were removed from the filter by cotton swab. The filter was fixed in absolute 
methanol at -20
0
C overnight. Filters were then washed with tap water followed by the 
addition of 1.5 ml of hematoxylin stain. After 10 minutes incubation at room 
temperature, the stain was removed and filters washed with tap water. The filters were 
then immersed sequentially in 50%, 75%, 90% and 100% ethanol for 10 minutes each. 
Filters were then mountened on the slides using DPX mountant (Sigma) and covered 
with cover slips. Migrant cells were counted by light microscopy. The cells in at least 6 
fields from each filter were counted. Migration of cells in the absence of chemokine was 
used as a negative control. 
5.3.7 In vitro flow based adhesion assays 
5.3.7.1 General principle-Cellix platform 
Cellix platform is a novel microfluidic system used to examine cell-cell interactions and 
the adhesion of leukocytes to recombinant proteins or monolayers of endothelial cells 
under physiological in vitro flow conditions. The system can be used to analyse cell 
morphology and track different steps of leukocyte migration including rolling and 
adhesion in a manner that is more physiological than the static chemotaxis assays. 
Different types of fluids can be used with the cellix plateform such as media and blood. 
Therefore, the system can be used to examine platelet adhesion, aggregation and 
thrombi formation by using whole blood samples. The efficiency of a particular drug 
can be also tested by this system in order to manage drug toxicity and development.  
The system consists of bright field and fluorescence microscopy with a motorised stage, 
microscope cage incubator, fluorescence and temperature controllers and, importantly, 
an adjustable syringe pump that is all controlled by Venaflux software, as shown in 
Figure 5.14. The syringe pump accurately maintains the flow rates at a desired fluid 
ranging from 5 picoliter/minute to 10 microliter/minute producing a wide range of shear 
stresses, reaching 450 dyne/cm
2
, depending on the syringe type. These characteristics 
facilitate the study of cell-cell interactions in an equivalent manner to that which occurs 
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in the blood vessels in vivo. The vena8 biochips are designed to mimic the blood 
vessels. Each chip consists of 8 channels which can be coated with different 
recombinant proteins for adhesion assays. Each channel is 20 mm length and 400 μm in 
width plus 100 μm in depth, as shown in Figure 5.15 (A). VenaEC biochips are 20 mm 
in length, 600 μm width and 200 μm depth. For this type of biochip, small square 
substrate is used to seed and culture endothelial cells after sterilization with UV light. 
Two microcapillary channels are then formed by placing a chip on the top of the 
substrate and are sealed via a customised frame as shown in Figure 5.15 (B).   
5.3.7.2 Flow based adhesion assay using recombinant human adhesion 
molecule 
Recombinant human VCAM-1/Fc supplied as a lyophilised powder (R&D system) was 
reconstituted in accordance with the manufacturer's instruction at 100 μg/ml stock 
solution. Ten μl of VCAM-1/Fc was injected into the desired channels of Vena8 chip 
and used at concentration 10 μg/ml diluted using carbonate buffer consisting of 
Na2CO3/NaHCO3 buffer at pH 9.6. The chip was kept at 4
0
C overnight in a humidified 
sealed box to prevent it from drying. The chip was then blocked with 1% BSA for 30 
minutes at room temperature. Chemokines were either immobilized on the chip at 500 
ng/ml or added directly at different concentrations to the cells before infusion onto the 
chip. The effect of immobilised rhCCL5 was examined in inducing THP-1 cells 
adhesion to VCAM-1/Fc. Furthermore, mixing of rhCCL5 and rhCXCL12 with cells in 
suspension was also used to examine the adhesion of PBMC to VCAM-1/Fc.  
THP-1 cells and PBMC were centrifuged and adjusted to 2X10
6
 cells/ ml in serum free 
medium containing 1% BSA for 1 hour before the assay. Negative controls included the 
adhesion of cells to BSA-coated channel and the adhesion of the unstimulated cells to 
VCAM-1/Fc coated channel in the absence of chemokine. The system was washed 
twice with filtered water followed by 70% ethanol. The system was then primed with 
RPMI medium without supplements and used as a flow buffer. The channels were 
washed once using the system pump by dispensing 40 μl solution at 40 dyne/cm2 to 
remove the unbound proteins. The assay was performed by infusing the cells into 
channels of chip at 10 dynes/cm
2
 for 10 seconds followed by 0.5 dynes/cm
2
 for 5 
minutes where the adhesion was assessed. Images were captured at the last minute and 
adhered cells were counted in at least 5 fields using DuoCell analysis software.   
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Figure 5.14: Cellix multifluidic plateform. 
 
                                                 
Figure 5.15: Cellix biochips. 
Panel A shows Vena8 biochip which consists of 8 channels that can be coated with 
recombinant proteins. Panel B shows VenaEC biochip in which endothelial cells are 
grown on the substrate until confluency followed by chip assembly. 
A) B) 
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5.3.7.3 Flow based adhesion assays using a monolayer of  endothelial cells 
Cellix substrates of VenaEC chips were kept in 6 wells plate and sterilised for one hour 
in UV light before use. Substrates were precoated with 50 μg/ml of fibronectin (Sigma) 
for 30 minutes at room temperature. HMEC-1 endothelial cells were then sub-cultured 
on VenaEC substrate and incubated until confluency at 37
0
C. The endothelial cells were 
then either treated overnight with 10 ng/ml of TNF-α, 12 μg/ml of W6/32 antibody or 
F(ab)2 fragments purified from W6/32 antibody. Where specified, rhCCL5 and 
rhCXCL12 chemokine at concentration 100 ng/ml or conditioned media from W6/32 or 
isotype control were immobilised on endothelial cells for 20 minutes. The system and 
the cells were prepared for the assay as described in the previous section. Monolayer 
endothelial cells were washed once by dispensing 40 μl of the media at 10 dynes/cm2. 
THP-1 and MOLT-16 cells were infused on the endothelial layer at 0.5 dyne/cm
2
 for 5 
minutes. Adhered cells seen in at least 5 fields were counted and plotted.      
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5.4 Results 
5.4.1 Effect of TNF-α stimulation on the expression of adhesion molecules 
on HMEC-1 cells  
Adhesion molecules are cell surface proteins that mediate the adhesion of circulating 
leukocytes enhancing their migration to inflammatory sites. Under normal condition 
endothelial cells express a limited number of these molecules, which are up-regulated 
upon exposure to inflammatory cytokines. To address the ability of HMEC-1 cells to 
express adhesion molecules, cells were stimulated with TNF-α and examined for the up-
regulation of VCAM-1, ICAM-1 and E-selectin by flow cytometry. Cells initially were 
stimulated with (20 ng/ml) of TNF-α for various time points. Figure 5.16 shows that 
under resting condition HMEC-1 cells showed negligible expression of VCAM-1 
molecules which was up-regulated 20 fold in response to stimulation with 20 ng/ml of 
TNF-α for 16 hours. VCAM-1 expression remained significantly high up to 72 hours 
after stimulation. The expression of these molecules was dependent on the concentration 
of TNF-α. Figure 5.17 shows that treatment of endothelial cells with TNF-α for 24 
hours at concentrations 0.1, 0.5, 1, 5, 10 and 20 ng/ml increased VCAM-1 expression 
by 1, 3, 6, 8, 10 and 15 fold, respectively. 
 In contrast, resting HMEC-1 cells expressed a detectable basal level of ICAM-1 antigen 
which was increased 40 fold in response to stimulation with 20 ng/ml of TNF-α for 16 
hours as shown in Figure 5.18. The expression of this adhesion molecule also showed 
dependency on the TNF-α concentration with a 10 to 50 fold increase in response to the 
treatment with TNF-α ranging from 0.1 to 20 ng/ml, respectively, as shown in Figure 
5.19. 
Figure 5.20 shows that resting HMEC-1 cells expressed E-selectin at a very low level 
but this was significantly up-regulated after stimulation with 20 ng/ml of TNF-α for 16 
and 24 hours compared to untreated group. The expression of this antigen was 
significantly increased after 48 and 72 hours of stimulation compared to 24 hours. All 
antibodies used were mouse anti-human IgG1 PE-conjugated, therefore, isotype control 
mouse IgG1 antibody was used in every experiment. 
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Figure 5.16: Expression of VCAM-1 molecules by endothelial cells following 
stimulation with TNF-α at different time points. 
HMEC-1 cells treated with 20 ng/ml of TNF-α at different time points were stained with 
PE-conjugated mouse anti-human VCAM-1 antibody and were analysed by flow 
cytometry. A, B, C, D, E and F represent unstained, isotype control, untreated, 24, 48 
and 72 hours treated groups, respectively. Median fluorescence intensity was plotted in 
bar chart, G. The data was analysed by two-way ANOVA followed by Bonferroni test. 
*** p<0.001. The data are representative of three independent experiments. 
 
F) TNF-α treated 72 h MFI 4,045 E) D) 
A) B) C) 
G) 
Unstained MFI 185 
TNF-α treated 24 h MFI 3,704 
Isotype  control MFI 142 Untreated MFI 197 
TNF-α treated 48 h MFI 4,741 
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Figure 5.17: Effect of different concentrations of TNF-α on VCAM-1 
expression by endothelial cells. 
HMEC-1 cells treated with different concentrations of TNF-α for 24 hours were stained 
with PE-conjugated mouse anti-human VCAM-1 antibody before flow cytometric 
analysis. A, B, C, D, E and F represent unstained, isotype control, untreated, 0.1 ng/ml, 
1 ng/ml and 10 ng/ml treated groups, respectively. Panel G is a bar chart of median 
fluorescence intensities. The data was analyzed by one-way ANOVA followed by 
Bonferroni test. ** p<0.01 and *** p< 0.001. The data are representative of three 
independent experiments. 
    
     
A) B) C) 
D) E) F) 
G) 
0.1 ng/ml MFI 145 1 ng/ml MFI 524 10 ng/ml MFI 942 
Unstained MFI 84 Isotype control MFI 90 Untreated MFI 107 
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Figure 5.18: Expression of ICAM-1 by endothelial cells following stimulation 
with TNF-α at different time points.  
HMEC-1 cells treated with 20 ng/ml of TNF-α at different time points were stained with 
PE-conjugated mouse anti-human ICAM-1 antibody and analyzed by flow cytometry. 
A, B, C, D, E and F represent unstained, isotype control, untreated, 24, 48 and 72 hours 
treated groups, respectively. Panel G shows a bar graph of the median fluorescence 
intensity of each group. The data were analyzed by two way ANOVA followed by 
Bonferroni test. *** p<0.001. The data are representative of three independent 
experiments. 
 
G) 
C) B) A) 
D) E) F) TNF-α treated 24 h MFI 91,496 TNF-α treated 48 h MFI 100,626 TNF-α treated 72 h MFI 103,792 
Unstained MFI 85 Isotype control MFI 142 Untreated MFI 1,285 
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Figure 5.19: Effect of different concentrations of TNF-α on ICAM-1 expression 
by endothelial cells. 
HMEC-1 cells treated with different concentrations of TNF-α for 24 hours were stained 
with PE-conjugated ICAM-1 antibody and analyzed by flow cytometry.  A, B, C, D, E 
and F represent unstained, isotype control, untreated, 0.1 ng/ml, 1 ng/ml and 10 ng/ml 
treated groups, respectively. The bar chart represents median fluorescence intensity, G. 
The data were analyzed by one way ANOVA followed by Bonferroni test at p<0.05. 
*** p<0.001. The data are representative of three independent experiments.
G) 
C) B) A) 
F) E) D) 0.1 ng/ml MFI 25,650 1 ng/ml MFI 56,085 10 ng/ml MFI 76,368 
Unstained MFI 84 Isotype control MFI 101 Untreated MFI 1,394 
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Figure 5.20: Expression of E-selectin on endothelial cells by TNF-α at 
different time points. 
HMEC-1 cells treated with 20 ng/ml of TNF-α at different time points were stained with 
PE conjugated antibody against E-selectin molecules and analyzed by flow cytometry. 
A, B, C, D, E, and F represent unstained, isotype control, untreated, 24, 48 and 72 hours 
treated group. Bar chart of the median fluorescence intensity is displayed on panel G. 
The data were analyzed by two way ANOVA followed by Bonferroni test. * p<0.05 and 
*** p<0.001. The data are representative of three independent experiments. 
G) 
C) B) A) 
F) E) D) TNF-α treated 24 h MFI 183 TNF-α treated 48 h MFI 212 TNF-α treated 72 h MFI 224 
Unstained MFI 87 Isotype control MFI 142 Untreated MFI 165 
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5.4.2 Effect of W6/32 antibody on the expression of adhesion molecules on 
endothelial cells 
To investigate the ability of HLA class I antibody to induce the expression of adhesion 
molecules, HMEC-1 endothelial cells were stimulated with a saturating concentration of 
W6/32 antibody or isotype control for various time points and examined for the 
expression of VCAM-1, ICAM-1 and E-selectin by flow cytometry. Stimulation with 
12µg/ml of W6/32 antibody induced a significant expression of VCAM-1 and ICAM-1 
on HMEC-1 cells in a time dependent manner as shown in Figure 5.21 and Figure 5.22, 
respectively. The expression of VCAM-1 peaked at 12 hours by 3 fold, while the 
expression of ICAM-1 peaked at 8-12 hours by 30 fold compared to isotype-treated 
group. Treatment with HLA class I antibody for 24-72 hours gradually decreased the 
expression of both antigens but remained statistically significant compared to untreated 
or isotype-treated groups. Figure 5.23 shows that the un-stimulated cells express E-
selectin at very low level and the stimulation of HMEC-1 cells with HLA class I 
antibody had a negligible effect on the expression of this antigen.   
It was previously reported that large vessel endothelial cells treated with sub-saturating 
concentrations of HLA class I antibody had a reduction in the expression of adhesion 
molecules in response to stimulation with inflammatory cytokines (Narayanan et al., 
2006). In this study, the effect of pre-exposure of the microvascular endothelial cells to 
different concentrations of HLA class I antibody on up-regulation of adhesion 
molecules induced by TNF-α stimulation was examined. HMEC-1 cells were treated 
with saturating and sub-saturating concentrations of W6/32 antibody or isotype control 
for 48 hours followed by stimulation with 10 ng/ml of TNF-α for 24 hours. The cells 
were then analysed for the expression of VCAM-1 and ICAM-1 by flow cytometry. 
Figure 5.24 and Figure 5.25 show that the pre-exposure to W6/32 antibody for 48 hours 
did not abrogate the ability of TNF-α to induce VCAM-1 or ICAM-1 expression, 
respectively. 
Endothelial-Leukocyte Interaction 
168 
 
       
2 4 8 12
 
24
 
48
 
72
 
0
200
400
600
800
Untreated
isotype treated
W6/32 treated
***
***
***
*** ***
***
Time of Treatment (hours)
M
e
d
ia
n
 f
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 
Figure 5.21: Expression of VCAM-1 on endothelial cells following stimulation 
with HLA class I antibody. 
HMEC-1 cells were left untreated or treated with saturating concentration 12μg/ml of 
W6/32 antibody or isotype control at various time points followed by flow cytometric 
analysis. A, B, C, D, E and F show the unstained, untreated, isotype treated group, 12, 
24 and 72 hours of W6/32 treated groups. Bar chart of median fluorescence intensity is 
represented in G. The data were analyzed by two-way ANOVA followed by Bonferroni 
test compared to isotype-treated group. *** p<0.001. The data are representative of 
three independent experiments. 
G) 
C) B) A) 
F) E) D) 
Unstained MFI 90 Untreated MFI 105 
Isotype treated MFI 100 
12 h MFI 726 24 h MFI 380 72 h MFI 237 
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Figure 5.22: Expression of ICAM-1 on endothelial cells following stimulation 
with HLA class I antibody. 
HMEC-1 cells were left untreated or treated with saturating concentration 12 μg/ml of 
W6/32 antibody or isotype control for various time points before analysed using flow 
cytometry. A, B, C, D, E and F represent unstained, untreated, isotype treated, 12, 24 
and 72 hours treated groups. Median fluorescence intensity is shown in bar chart, G. 
The data were analyzed by two-way ANOVA followed by Bonferroni test compared to 
isotype treated group. *** p<0.001. The data are representative of three independent 
experiments. 
 
F) E) 
A) 
D) 
B) C) 
G) 
W6/32 12 h MFI 27,299 W6/32 24 h MFI 22,906 
W6/32 72 h MFI 5,679 
Unstained MFI 90 Untreated MFI 1,399 Isotype treated MFI 1,480 
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Figure 5.23: Expression of E-selectin by endothelial cells following 
stimulation with HLA class I antibody. 
HMEC-1 cells were left untreated or treated with saturating concentration (12μg/ml) of 
W6/32 antibody or isotype control at various time points followed by staining with 
mouse anti-human E-selectin antibody. The cells were analysed by flow cytometry. A, 
B, C, D, E and F represent unstained, untreated, isotype treated, 12, 24 and 72 hours 
treated groups. Bar chart, G, represents median fluorescence intensity. Statistical 
analysis was performed using two-way ANOVA followed by Bonferroni test compared 
to isotype control. The data are representative of three independent experiments. 
D) E) F) 
C) B) A) 
G) 
Unstained MFI 98 Untreated MFI 145 Isotype treated MFI 148 
W6/32 treated 24 h MFI 152 W6/32 treated 48 h MFI 142 W6/32 treated 72 h MFI 150 
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Figure 5.24: Effect of the pre-exposure to HLA class I antibody on TNF-α-
induced VCAM-1 expression by endothelial cells. 
HMEC-1 cells were treated with different concentrations of W6/32 antibody for 48 
hours followed by treatment with TNF-α (10 ng/ml) for 24 hours. Cells were washed 
and stained with PE-conjugated mouse anti-human VCAM-1 antibody. Statistical 
analysis was performed by two-way ANOVA followed by Bonferroni test. The data are 
representative of two independent experiments. 
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Figure 5.25: Effect of the pre-exposure to HLA class I antibody on TNF-α-
induced ICAM-1 expression by endothelial cells. 
HMEC-1 cells were treated with different concentrations of W6/32 antibodies for 48 
hours followed by treatment with TNF-α (10 ng/ml) for 24 hours. Cells were washed 
and stained with PE-conjugated mouse anti-human ICAM-1 antibody. Statistical 
analysis was performed by two-way ANOVA followed by Bonferroni test. The data are 
representative of two independent experiments. 
 
 
 
 
 
 
 
 
Endothelial-Leukocyte Interaction 
173 
5.4.3 Effect of the PI3K/Akt pathway on the expression of adhesion 
molecules induced by W6/32 antibody 
To examine the effect of the PI3K/Akt pathway on the increase in the expression of 
endothelial cell surface adhesion molecules in response to HLA class I antibody, 
PI3K/Akt pathway inhibition was carried out. The examination of this pathway in 
particular stems from the involvement of the Akt in the activation of a wide range of 
other pathways involved in regulation of the expression of different proteins. The Akt 
pathway inhibitor LY294002 was used at concentration 50 μM to inhibit this pathway 
30 minutes before stimulation with a saturating concentration of W6/32 antibody for 8 
hours. The activity of this inhibitor was validated as described in section 4.4.4. Before 
analysis of treated cells for the expression of VCAM-1 and ICAM-1 antigens the cell 
viability was assessed using trypan blue staining. The inhibition of PI3K/Akt pathway 
significantly abrogated the expression of both VCAM-1 and ICAM-1 (P<0.01) as 
shown in Figure 5.26 and Figure 5.27, respectively. The contribution of the PKA 
pathway in regulation of the expression of these antigens was also assessed using H-89 
inhibitor. The inhibition of this pathway did not induce a significant reduction in the 
expression of either of the antigens (data not shown). 
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Figure 5.26: Effect of the PI3K/Akt pathway on VCAM-1 expression induced 
by HLA class I antibody. 
Adherent HMEC-1 cells were incubated with 50 μM of LY294002 inhibitor 30 minutes 
before stimulation with saturating concentration of W6/32 antibody (12 μg/ml) for 8 
hours. Cells were analysed by flow cytometry after staining with PE-conjugated mouse 
anti-human VCAM-1 antibody. A, B, C, D and E represent unstained, untreated, W6/32, 
W6/32+LY294002 treated cells and a bar chart of median fluorescence intensity. The 
data were analyzed by one-way-ANOVA followed by Bonferroni test. ** p<0.01 
compared to W6/32 treated group. The data are representative of three independent 
experiments. 
E) 
D) C) 
B) A) 
W6/32 MFI 269 W6/32+ LY294002 MFI 155 
Untreated MFI 153 Unstained MFI 82 
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Figure 5.27: Effect of the PI3K/Akt pathway on endothelial ICAM-1 
expression induced by HLA class I antibody. 
Adherent HMEC-1 cells were incubated with 50 μM of LY294002 inhibitor 30 minutes 
before stimulation with saturating concentration of W6/32 antibody (12 μg/ml) for 8 
hours. Cells were analyzed by flow cytometry after staining with PE-conjugated anti-
human ICAM-1 antibody. A, B, C, D and E represent unstained, untreated, W6/32, 
W6/32+LY294002 treated cells and median fluorescence intensity bar chart. The data 
were analyzed by one-way ANOVA followed by Bonferroni test. ** p<0.01 and *** 
p<0.001. The data are representative of three independent experiments. 
E) 
D) 
C) 
B) A) 
W6/32 MFI 25,344 
Unstained MFI 86 Untreated MFI 2,477 
W6/32+LY294002 MFI 16,739 
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5.4.4 Effect of W6/32 antibody on the expression of endothelial cytokines 
and chemokines  
Leukocyte recruitment and inflammatory responses observed during antibody-mediated 
rejection suggest a possible role for the expression of inflammatory cytokines and 
chemokines produced by endothelial cells. HMEC-1 endothelial cells were examined 
for their ability to up-regulate the expression of various chemokines and cytokines in 
response to stimulation with HLA class I antibody. The cells were stimulated with 12 
μg/ml of isotype control or a saturating concentration of W6/32 antibody for 24 and 72 
hours. Conditioned media was collected and applied to a human protein cytokine array. 
The array contains antibodies to specific chemokines and cytokines attached to a 
nitrocellulose membrane (appendix 10.5). Figure 5.28 shows that W6/32 treated cells 
significantly up-regulated various cytokines and chemokines compared to the isotype 
control-treated group after 72 hours. The treated group showed significant upregulation 
of CXCL8, IL-6, CXCL10, CXCL1 and CCL5. The positive spots on the membranes 
were used as an internal control. The HMEC-1 cells did not show any expression of 
IFN-γ, TNF-α, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-10, IL-13, IL-16, IL-17, IL-23, IL-27 
and IL-32α, which were included in the array, in either treated or control groups. 
However, treatment with W6/32 antibody significantly induced the secretion of C5a 
complement fragment by endothelial cells compared to isotype control (P<0.001). The 
presence of soluble ICAM-1 (sICAM) and colony stimulating factor-2 (CSF-2) were 
also significantly increased in HLA class I treated group when compared to isotype 
treated cells. Twenty four hours stimulation produced a similar profile as 72 hours 
stimulation, however, the spot intensity was lower at 24 hours (data not shown). 
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Figure 5.28: Expression of cytokines/chemokines by HMEC-1 endothelial 
cells following treatment with HLA class I antibody. 
Cells were treated with saturating concentration of W6/32 antibody or isotype control 
(12 μg/ml) for 72 hours. Supernatants were collected and examined for the protein 
expression of various cytokines and chemokines using human cytokine array. The 
density of the spots was determined by AlphaImager software. The data were analysed 
by two-way ANOVA followed by Bonferroni test. * p<0.01 and *** p<0.001. The data 
are representative of two independent experiments. 
Isotype treated 
W6/32 treated 
1 20 
A 
E 
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5.4.5 Dose and time response of W6/32 antibody on endothelial CXCL8 
expression. 
To allow quantitative analysis, the expression of endothelial chemokine was assessed at 
the molecular level. HMEC-1 cells were treated with saturating concentration of W6/32 
antibody or isotype control (12μg/ml) at different time points (3.5, 16 and 24 hours) and 
examined for mRNA CXCL8 expression by real time-PCR using the Taqman assay. 
Before performing PCR, isolated RNA was assessed for integrity as described in section 
2.9.4. Figure 5.29 shows that exposure of endothelial cells to W6/32 antibody induced a 
50 fold increase in the expression of CXCL8 within 3.5 hours compared to isotype 
treated group, and normalized to GAPDH expression (p<0.001). The gene expression of 
CXCL8 increased more than 60 fold at 16 hours, and then decreased by around 20 % 
after 24 hours of stimulation. The dose response of treatment was also examined by 
treating HMEC-1 cells with sub-saturating concentrations of W6/32 antibody. The 
expression of this chemokine showed a high dependency on antibody concentration as 
illustrated in Figure 5.30. No reactions were observed in negative wells containing 
master mix or RNA samples. 
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Figure 5.29: Time course of mRNA CXCL8 expression by HLA class I antibody. 
HMEC-1 cells were treated with isotype control or saturating concentration of W6/32 
antibody (12 μg/ml) at various time points before RNA isolation. cDNA was 
synthesised and amplified to assess the expression of CXCL8. GAPDH was used as a 
housekeeping gene. Data analysis was performed by REST 2009 software. *** p<0.001. 
The data are representative of three independent experiments. 
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Figure 5.30: Effect of the concentration of HLA class I antibody on endothelial 
CXCL8 expression. 
HMEC-1 cells were treated with different concentrations of W6/32 antibody ranging 
from 0.4 μg/ml to 12 μg/ml for 3.5 hours. After RNA extraction, cDNA was synthesised 
and amplified to assess the expression of CXCL8. GAPDH was used as housekeeping. 
*** p<0.001. The data were analyzed using REST 2009 software. The data are 
representative of two independent experiments. 
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5.4.6 Effect of PI3K/Akt and PKA/CREB pathways on CXCL8 expression 
induced by HLA class I antibody 
The signalling pathways which might have a role in the expression of CXCL8 in 
response to HLA class I antibody were investigated. The inhibition of PI3K/Akt and 
PKA pathways was performed using LY294002 and H-89 inhibitors, respectively. As 
shown in Figure 5.31 (A), treatment of HMEC-1 cells with 50 µM of LY294002 or 5 
µM of H-89 for 30 minutes followed by stimulation with W6/32 antibody (12 µg/ml) 
for 3.5 hours resulted in 52% and 35% reduction, respectively, in the expression of 
CXCL8 when compared to the control group. The role of PKA pathway was further 
explored by CREB knockdown with siRNA.  The knockdown efficiency was examined 
at protein level by western blotting 72 hours after transfection as shown previously in 
Figure 5.7. CREB siRNA transfected cells or a negative siRNA control for 72 hours 
were stimulated with 12 μg/ml of W6/32 antibody for 3.5 hours. As shown in Figure 
5.31 (B), silencing of CREB using 5 nM and 10 nM of CREB specific siRNA induced 
40% and 50% reduction, respectively, in the molecular expression of CXCL8 as 
determined by real time-PCR data. Transfection of endothelial cells with negative 
siRNA produced no significant effect on CXCL8 expression compared to stimulated 
untransfected cells (data not shown). 
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Figure 5.31: Effect of PI3K/Akt and PKA pathways on the expression of CXCL8 
in response to stimulation with HLA class I antibody. 
Panel A, HMEC-1 cells were treated with 50 µM of LY294002 or 5 µM of H-89 30 
minutes before stimulation with 12µg/ml of W6/32 antibody for 3.5 hours. RNA was 
isolated and assessed for the expression of CXCL8 by real time-PCR. Panel B, HMEC-
1 cells were transfected with 5 nM and 10 nM of either CREB siRNA or negative 
control siRNA for 72 hours. Transfected cells were stimulated with 12 μg/ml of W6/32 
antibody for 3.5 hours followed by RNA isolation. After cDNA synthesis, expression of 
CXCL8 was determined by qRT-PCR. The data was analyzed by REST 2009 software 
using GAPDH as a reference gene. *** p<0.001. The data are representative of three 
independent experiments. 
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5.4.7 Effect of W6/32 conditioned media on monocyte migration 
To examine the potential of HLA class I antibody-treated endothelial cells to induce 
leukocyte migration, a chemotaxis assay was performed using THP-1 human 
monocytes. THP-1 cells were chosen for this assay due to the known expression of 
CCR5 and CXCR2 chemokine receptors corresponding to the chemokines CCL5 and 
CXCL8, respectively, secreted by endothelial cells in response to HLA class I antibody. 
THP-1 cells migration was assessed in response to conditioned media from endothelial 
cells treated for 72 hours with either isotype control or saturating concentration of 
W6/32 antibody. Remaining antibody in the media was removed by passing through a 
100 kDa cutoff concentrator tube. THP-1 cells showed a significant cell migration in 
response to the conditioned media from HLA class I treated cells compared to isotype 
control (P<0.001) after 3 hours of incubation. The presence of migrant cells was 
assessed by staining the filters from both groups with hematoxilin staining. Figure 5.32 
shows the mean number of migrant cells per high power field. 
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Figure 5.32: Chemotaxis assay using THP-1 human monocyte cells. 
THP-1 cells were examined for their ability to migrate in response to supernatant of 
HMEC-1 cells treated with either 12 µg/ml of either isotype control or W6/32 antibody 
for 72 hours. Cells were incubated for 3 hours at 37
ο
C, fixed and stained. Migrant cells 
were counted by light microscope. The data represent the number of migrant cells per 
high power field. The data are representative of three experiments run on duplicate. The 
data were analysed by un-paired Student’s t-test. *** P < 0.001. 
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5.4.8 In vitro flow based adhesion assay using VCAM-1/Fc and THP-1 cells 
To optimise an in-vitro flow based adhesion assay using the Cellix platform, 
recombinant human (rh) VCAM-1/Fc was assessed for its ability to bind the ligand 
VLA-4 on THP-1 cells and PBMC in the presence or absence of chemokine. The 
optimisation involves evaluating immobilised and solubilised chemokines in inducing 
leukocyte adhesion under physiological flow condition. Vena8 chips were coated with 
VCAM-1/Fc (10 μg/ml) alone or in combination with chemokine rhCCL5 at 
concentration 500 ng/ml. THP-1 cells were infused at a flow of 0.5 dyne/cm
2
 for 5 
minutes. At the last minute of flow, images from different fields were captured and the 
number of adherent cells was counted. As shown in Figure 5.33, the presence of 
immobilized rhCCL5 with VCAM-1/Fc induced THP-1 cells adhesion compared to 
chips VCAM-1/Fc only. THP-1 cells also showed a significant binding to chip coated 
with VCAM-1/Fc alone compared to BSA-coated chip. But this binding is augmented in 
the presence of chemokine as observed that rhCCL5 significantly increased the 
adhesion of the cells by around 30%.  
By using monocyte-reduced PBMC preparations, the flow adhesion assay was 
performed using different concentrations of rhCCL5 (5-100 ng/ml) or rhCXCL12 
ranging from 5 to 60 ng/ml which was mixed with the cells just before starting the flow 
on VCAM-1/Fc coated chip. As shown in Figure 5.34 (A), soluble rhCCL5 at 
concentration higher than 10 ng/ml induced a significant adhesion of PBMC to VCAM-
1/Fc above the background level in concentration dependent manner. Maximum 
adhesion of these cells was observed at concentration of 50 ng/ml and using higher 
concentration reduced the capability of these cells to adhere. Soluble rhCXCL12 also 
induced the adhesion of PBMC in a concentration dependent manner as shown in Figure 
5.34 (B). Cells started to adhere at 5 ng/ml of rhCXCL12 and adhesion became 
statistically significant at 20 ng/ml. The adhesion reached a plateau at a concentration 
40 ng/ml with no extra enhancement of cell adherence at concentration 60 ng/ml. 
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Figure 5.33: In vitro flow based adhesion assay using recombinant VCAM-
1/Fc and THP-1 human monocytic cell line. 
The Vena8 cellix chip was coated with 10 μg/ml of VCAM-1/Fc before flow of THP-1 
cells was performed at 0.5 dyne/cm
2
 for 5 minutes. This assay was applied on chips 
coated with VCAM-1/Fc alone or in combination with 500 ng/ml of immobilized 
rhCCL5. (A) shows the cells adhered to BSA coated channel as a negative control, (B) 
shows the cells adhered to VCAM-1/Fc coated channel, (C) shows the cells adhered to 
channel coated with VCAM-1/Fc and rhCCL5 and (D) bar chart showing the mean of 
six fields from each group, means were calculated and plotted. Comaprison between 
groups was performed by one-way ANOVA followed by Bonferroni test at p<0.05. *** 
p<0.001. The data are representitive of three indepenent experiments. 
A) B) C) 
D) 
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Figure 5.34: In vitro flow based adhesion assay using recombinant VCAM-
1/Fc and PBMC preparation. 
Vena8 channels were coated with 10 μg/ml of VCAM-1 Fc before infusion of freshly 
isolated PBMC at 0.5 dyne/cm
2
 for 5 minutes. Flow assay was performed using 
unstimulated PBMC or after stimulation with different concentrations of rhCCL5 (A) or 
rhCXCL12 (B) immediately before starting the flow. Images were captured at the last 
minute and six fields were counted. Comparison between groups was performed by one 
way ANOVA followed by Bonferroni test at p<0.05.  *** p<0.001. The data are 
representitive of two indepenent experiments. 
B) 
A) 
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5.4.9  In-vitro flow based adhesion assay on TNF-α activated HMEC-1 using 
THP-1 cells and chemokines 
Adhesion of leucocytes to activated endothelial cells under flow condition was 
optimized using THP-1 monocytic cell line and MOLT-16 T-cell line. In these 
experiments, HMEC-1 endothelial cells were grown on specific chip until confluent 
followed by stimulation with TNF-α at concentration 10 ng/ml overnight to induce the 
expression of adhesion molecules and chemokines. After stimulation, cells were infused 
at 0.5 dyne/cm
2
 for 5 minutes in the absence or presence of immobilized chemokine at 
500 ng/ml. As shown in Figure 5.35, stimulation of endothelial cells with TNF-α 
induced significant adhesion of monocytes at the examined shear stress compared to 
untreated control. Immobilization of rhCCL5 on activated HMEC-1 cells augmented 
remarkably the adhesion of THP-1 cells by 50% compared to that in the absence of 
rhCCL5. Immobilization of rhCCL5 on untreated cells has a negligible effect on 
leukocyte adhesion (data not shown). 
Figure 5.36 shows an in vitro flow adhesion assay using rhCXCL12 and MOLT-16 cells 
on TNF-α stimulated endothelial cells. Activated HMEC-1 cells enhanced significantly 
the adhesion of T-cells compared to untreated endothelial cells, while the presence of 
rhCXCL12 augmented significantly cell adhesion by around 45% compared to that in 
the absence of chemokine. Immobilization of rhCXCL12 on untreated endothelial cells 
resulted in a non-significant cell adhesion (data not shown).  
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Figure 5.35: In vitro flow based adhesion assay on TNF-α stimulated HMEC-1 
cells using rhCCL5 and THP-1 cells. 
Endothelial cells grown on the endothelial chip (VenaEC) were stimulated with 10 
ng/ml of TNF-α overnight. Flow of THP-1 cells were infused at 0.5 dyne/cm2 for 5 
minutes on either (A) untreated or (B) TNF-α stimulated cells or (C) TNF-α stimulated 
cells where 500 ng/ml of rhCCL5 was immobilized. The mean values of at least six 
fields of each group were calculated and plotted as shown in (D). The data were 
analyzed by one way ANOVA followed by Benforroni test at p<0.05. *** p<0.001. The 
data are representitive of three independent experiments. 
A) B) C) 
D) 
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Figure 5.36: In vitro flow based adhesion assay on TNF-α stimulated HMEC-1 
cells using rhCXCL12 and MOLT-16 cells. 
Endothelial cells were grown on the endothelial chip (VenaEC) and stimulated with 10 
ng/ml of TNF-α overnight.  MOLT-16 cells were infused at 0.5 dyne/cm2 for 5 minutes 
on either (A) untreated or (B) TNF-α stimulated cells or (C) TNF-α stimulated cells 
where 500 ng/ml of rhCXCL12 was immobilized. The mean values of at least six fields 
of each group were calculated and plotted as shown in (D). The data were analyzed 
using one way ANOVA followed by bonferonni test at p<0.05. *** p<0.001. The data 
are representitive of three independent experiments. 
A) B) C) 
D) 
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5.4.10 In vitro flow based adhesion assay using whole molecule of W6/32 
antibody 
The presence of infiltrating leukocytes in antibody-mediated rejection highlights the 
necessity for the examination of the potential of HLA class I antibody in inducing 
leukocyte adhesion to endothelial cells under physiological conditions, the crucial step 
in leukocyte migration. To achieve this, HMEC-1 endothelial cells were grown until 
confluency on VenaEC chip coated with fibronectin as described in the section 5.3.7.3. 
The cells were treated with 12 µg/ml of either isotype control or W6/32 antibody 
overnight. THP-1 cells were then infused at 0.5 dyne/cm
2
 for 5 minutes and the adhered 
cells were counted at the last minute of the flow. As shown in Figure 5.37, cells pre-
treated with HLA class I antibody (B) induced significant monocyte adhesion compared 
to isotype control (A). The mean of cells adhered in 10 high power fields were 
calculated and plotted as shown in panel (C) of the same figure.   
To assess the ability of chemokines secreted by endothelial cells to induce leukocyte 
adhesion, conditioned media from W6/32 treated endothelial cells were used for flow 
based adhesion assay. HMEC-1 cells grown in VenaEC chip were treated with TNF-α at 
concentration 10 ng/ml overnight. After stimulation, conditioned media from both 
isotype and W6/32 treated cells were immobilised on stimulated endothelial cells. 
Conditioned media were passed through 100 kDa cutoff filtration tube to remove the 
remaining antibody from the conditioned media, eliminating interaction of the Fc 
fragments with the Fc receptors on THP-1 cells. The cells were infused on stimulated 
endothelial cells at 0.5 dyne/cm
2
 for 5 minutes and the adhered cells were then counted. 
As shown in Figure 5.38, human monocytes significantly adhered to endothelial cells 
where conditioned media from W6/32-treated cells (B) was used compared to isotype 
conditioned media (A), p<0.001. Since inflammatory cytokines treatment induce the 
secretion of chemokines and upregulation of adhesion molecules, THP-1 cells also 
significantly adhered to cells treated with TNF-α only. The mean of cells adhered at 
each group was plotted in panel (C). 
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Figure 5.37: In vitro flow based adhesion assay on HMEC-1 cells stimulated 
with HLA class I antibody. 
Endothelial cells grown on endothelial chip (VenaEC) were stimulated with 12 μg/ml of 
either W6/32 or isotype antibody overnight. Infusion of THP-1 cells was performed at 
0.5 dyne/cm
2
 for 5 minutes on either (A) isotype treated cells or (B) W6/32  stimulated 
cells. The mean values of 10 fields of each group were graphed, (C). Unpaired Student's 
t-test was performed at p<0.05. *** p<0.001. The data are representitive of three 
independent experiments. 
A) 
C) 
B) 
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Figure 5.38: In vitro flow based adhesion assay on TNF-α stimulated 
endothelial cells using conditioned media from W6/32 or isotype treated 
groups. 
HMEC-1 cells grown on endothelial chip (VenaEC) were stimulated with 10 ng/ml of 
TNF-α overnight.  Conditioned media from cells treated with either isotype or W6/32 
antibody for 72 hours were immobilised on the activated endothelial cells. THP-1 cells 
were infused at 0.5 dyne/cm
2
 for 5 minutes on TNF-α stimulated cells where 
conditioned media from either (A) isotype or (B) W6/32 treated cells was immobilised. 
The mean value of six fields of each group were plotted as shown in (D). Two way 
ANOVA followed by Bonferroni test was perfomed. * p < 0.05 and *** p<0.001. The 
data are representitive of three independent experiments. 
A) B) 
C) 
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5.4.11 Expression of VCAM-1 and ICAM-1 by endothelial cells following 
stimulation with F(ab)2 fragment of W6/32 antibody   
To eliminate the interaction through Fc receptors, F(ab)2 fragments from W6/32 
antibody were prepared and used for this assay. Cells were treated with these fragments 
at concentration 12 μg/ml overnight followed by examining the expression of VCAM-1 
and ICAM-1 antigens. The expression of these molecules was determined by flow 
cytometry using PE-conjugated mouse anti-human antigen specific antibodies. The 
exposure to these fragments significantly induced the expression of these antigens in 
comparison to untreated group. The expression of VCAM-1 was induced by around 4 
fold and the expression of ICAM-1 was induced by approximately 40 fold compared to 
untreated group. Figure 5.39 shows the flow cytometry histograms for VCAM-1 and 
ICAM-1 staining for both untreated and treated groups. The median fluorescence 
intensity for each group is represented in bar chart, F. 
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Figure 5.39: Expression of endothelial VCAM-1 and ICAM-1 after stimulation 
with F(ab)2 fragments of W6/32 antibody. 
HMEC-1 cells were incubated with these fragments overnight before staining with PE-
conjugated mouse anti-human VCAM-1 and ICAM-1 antibodies. Panel A shows 
unstained, panel B VCAM-1 staining of untreated cells, panel C VCAM-1 staining of 
treated cells, panel D ICAM-1 staining of untreated cells, panel E ICAM-1 staining of 
treated cells and panel F shows the median fluorescence intensity of the expression of 
both molecules. The analysis between untreated and treated groups was performed by 
unpaired Student's t-test. *** p<0.001. The data are representative of two independent 
experiments.  
D) 
C) B) A) 
E) 
F) 
Unstained MFI 84 Untreated VCAM-1 MFI 120 
F(ab)2 treated VCAM-1  
MFI 382 
F(ab)2 treated ICAM-1  
MFI 49,200 
Untreated ICAM-1 MFI 1,302 
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5.4.12  In vitro flow based adhesion assay using F(ab)2 fragment of W6/32 
antibody 
The potential of HLA class I antibody to induce monocyte adhesion was examined 
using F(ab)2 fragments produced from W6/32 antibody by pepsin treatment. HMEC-1 
endothelial cells were grown on fibronectine coated Vena EC chip and stimulated with 
12 μg/ml of F(ab)2 fragments overnight. THP-1 cells were infused over the monolayer 
endothelial cells at 0.5 dyne/cm
2
 for 5 minutes and the images were captured at the last 
minute. F(ab)2 fragment treated endothelial cells showed a significant monocyte 
adhesion compared to untreated endothelial cells (p<0.001). As shown in Figure 5.40, 
F(ab)2 fragment treated endothelial cells (B) induced 6 fold increase in the number of 
adhered cells compared to untreated group (A). 
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Figure 5.40: In Vitro flow based adhesion assay using F(ab)2 fragments of 
W6/32 antibody. 
Cells grown on cellix chip until confluent were treated with 12 μg/ml of F(ab)2 
fragments overnight. THP-1 monocyte cells were infused through (A) untreated and (B) 
treated endothelial cells at 0.5 dyne/cm
2 
for 5 minutes. Six fields from each group were 
counted and the means were plotted (C). Statistical analysis was performed using 
unpaired Student’s t-test. *** p<0.001. The data are representative of three independent 
experiments. 
A) B) 
C) 
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5.5 Discussion 
Leukocyte infiltration to the transplanted grafts is one of the main characteristics 
observed during antibody-mediated rejection. The histological evidence of cellular 
rejection is increased in patients who develop donor-specific HLA antibody (Caro-Oleas 
et al., 2012; Yousem and Zeevi, 2012). The link between antibody formation and cell-
mediated rejection is not fully understood. However, the transmigration of recipients’ 
leukocytes into grafts suggests the contribution of endothelial adhesion molecules and 
chemokines in this process. In this chapter, the possible interaction between endothelial 
cells and leukocytes in the presence of donor-specific HLA class I antibody was 
examined. In particular, the expression of adhesion molecules, VCAM-1, ICAM-1 and 
E-selectin, and chemokines was assessed. In addition, the potential of HLA class I 
antibody to induce monocyte adhesion and migration was determined.      
 In response to inflammatory cytokines, microvascular endothelial cells up-regulate the 
expression of cell-surface adhesion molecules (Xu et al., 1994). HMEC-1 endothelial 
cells were assessed for the expression of these molecules in response to stimulation with 
TNF-α at different time points and cytokine concentrations. In resting conditions, 
HMEC-1 cells express a negligible level of VCAM-1 and E-selectin but express a 
detectable level of ICAM-1. In response to TNF-α stimulation, HMEC-1 cells up-
regulate in a time and concentration-dependent manner the expression of VCAM-1 and 
ICAM-1 antigens and, to a lesser extent, the expression of E-selectin. Characterization 
of the cell line in early studies showed a similar profile in the expression of these 
molecules in resting and stimulated states (Xu et al., 1994). The ability to express cell 
surface adhesion molecules in response to inflammatory cytokines renders these cells a 
good model to study leukocyte adhesion. 
 In response to antibody stimulation, treatment of HMEC-1 cells with a saturating 
concentration of W6/32 antibody (12 µg/ml) induced a significant up-regulation of 
adhesion molecules VCAM-1 and ICAM-1 in a time dependent manner. The expression 
of both antigens decreased after 72 hours compared to 12 hours treatment but remained 
significantly elevated compared to an isotype control-treated group. Resting cells 
upregulated E-selectin at low level in response to TNF-α, but there was no modulation 
in the expression of this adhesion molecule following stimulation with W6/32 antibody 
compared to control. The up-regulation of VCAM-1 and ICAM-1 molecules has been 
previously reported for a model of large vessel endothelial cells stimulated with W6/32 
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antibody (Narayanan et al., 2006). The expression of these adhesion molecules has also 
been observed in in vivo model. Following single HLA mismatched heart 
transplantation in mice, the expression of endothelial adhesion molecules has been 
increased in the transplanted grafts measured at a molecular level (Fukami et al., 2012). 
The expression of these molecules suggests the involvement of HLA class I antibody in 
inducing allograft rejection rather than accommodation. In organ accommodation, it was 
previously reported that pre-exposure of endothelial cells to sub-saturating 
concentration of W6/32 antibody reduced the expression of adhesion molecules in 
response to TNF-α stimulation (Narayanan et al., 2006). In this project, the increase in 
the expression of adhesion molecules by TNF-α was also examined following the pre-
treatment with sub-saturating concentrations of W6/32 antibody. The treatment of 
HMEC-1 cells with saturating and sub-saturating concentrations of W6/32 antibody for 
48 hours followed by 10 ng/ml of TNF-α for 24 hours did not show a decrease in the 
expression VCAM-1 and ICAM-1 antigens. This might suggest that pre-treatment with 
sub-saturating concentrations of W6/32 antibody has no effect in providing protection, 
or longer incubation time to activate the protective pathways in endothelial cell line 
might be required.  
Adhesion molecules have a crucial role in exposing endothelial cells to circulating 
leukocytes and enhancing their adhesion. VCAM-1 mediates the adhesion of 
lymphocytes, monocytes and eosinophils, which express very-late antigen-4 (VLA-4, 
α4 β1 integrin) while ICAM-1 binds to LFA-1 molecules expressed on lymphocytes and 
neutrophils (Bevilacqua, 1993; Lay et al., 2007). This binding is one of the main steps 
in leukocyte adhesion to activated endothelium. In order to understand the mechanism 
responsible for the expression of these adhesion molecules, inhibitors for both PI3K/Akt 
and PKA pathways were used. The inhibition of PI3K/Akt pathway (LY294002) but not 
PKA pathway (H-89) induced a significant reduction in the expression of both VCAM-
1 and ICAM-1 compared to cells treated with W6/32 antibody alone. The role of 
PI3K/Akt pathway in the expression of adhesion molecules in response to inflammatory 
cytokine (TNF-α) was observed using human intestinal endothelial cells (Binion et al., 
2009). This expression was mediated by the activation of transcription factor, NF-kβ. 
Exposure of endothelial cells to a saturating concentration of W6/32 antibody for 24 and 
72 hours in this study induced the secretion of IL-6 and various chemokines into culture 
media. CXCL8, CXCL10, CXCL1 and CCL5 were significantly induced by endothelial 
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cells treated with W6/32 antibody compared to cells treated with isotype-control. The 
expression of CXCL8 was further assessed at the mRNA level. HMEC-1 cells treated 
with HLA class I antibody showed a significant expression of CXCL8 in a time and 
concentration dependent-manner compared to isotype-treated cells. The expression of 
inflammatory cytokines by microvascular endothelial cells showed a similarity to 
W6/32-stimulated large vessel endothelial cells. The expression of CXCL8, IL-6, TNF-
α and IL-1β was previously observed using human iliac artery endothelial cells treated 
with W6/32 antibody (Reyes-Vargas et al., 2009). Furthermore, a recent study showed 
that stimulation of human microvascular glomerular endothelial cells with sera 
containing HLA class I antibodies induced the expression of CCL5 chemokine 
(Mannam et al., 2013). In our study, endothelial cells stimulated with W6/32 antibody 
showed an increase in the expression of complement fragment C5a and soluble ICAM-1 
molecule. The expression of complement fragment C5a becomes in agreement with 
previous study showed the ability of glomerular and microvascular endothelial cells to 
produce complement components C4 in response to the stimulation with HLA class I 
antibody (Hamer et al., 2012). The expression of complement fragments might augment 
the cytotoxicity induced by HLA class I antibody. Fragments produced from 
complement activation such as C5a are anaphylatoxin which are able to activate both 
endothelial cells and circulating leukocytes, enhancing leukocyte recruitment to the 
inflamed sites  (Monsinjon et al., 2003). Moreover, stimulation of endothelial cells with 
a combination of W6/32 antibody and C5a induced a significant exocytosis of 
endothelial von Willebrand Factor compared to the treatment with antibody alone 
(Yamakuchi et al., 2007). In our project, soluble ICAM-1 was also observed following 
stimulation with W6/32 antibody compared to control. The serum level of this molecule 
has been shown to be associated with the increase in the rate of mortality following 
renal transplantation (Connolly et al., 2011).   
The mechanism responsible for the expression of CXCL8 in response to stimulation 
with HLA class I antibody was further examined by inhibiting the PI3K/Akt and PKA 
pathways using a pathway-specific inhibitor. Inhibition of the PI3K pathway 
(LY294002) led to a 52% reduction in the expression of CXCL8, while the inhibition of 
PKA pathway (H-89) resulted in a 35% reduction. Therefore, synergism between the 
two pathways in inducing CXCL8 expression is possible. Since the transcription factor 
CREB is a down-stream of PKA pathway, the contribution of this factor in the 
expression of CXCL8 was examined using siRNA. Transfection with CREB-siRNA 
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induced an 80% reduction in CREB expression compared to negative control siRNA as 
shown at the protein level by western blotting. Stimulation of CREB-siRNA transfected 
cells with W6/32 antibody produced a significant 50% reduction in the expression of 
CXCL8 compared to control. This result suggests that the transcriptional activity of 
CREB is essential for the expression of endothelial CXCL8 in response to HLA class I 
antibody. A previous study showed that the expression of CXCL8 in response to 
stimulation with cytokine was dependent on a synergistic effect between CREB and 
NF-kB transcription factors (Sun et al., 2008). Therefore, the participation of NF-kB 
downstream of PI3K/Akt pathway cannot be excluded. 
Leukocyte infiltration into the transplanted graft is observed in biopsies diagnosed with 
antibody-mediated rejection and it is used as a diagnostic marker of antibody-mediated 
rejection in the presence of circulating donor specific antibody (Higgins et al., 2010). In 
addition, depletion of macrophages or blocking monocyte-related chemokines before 
transplantation reduces the incidence of intimal thickening and improves allografts 
survival (Belperio et al., 2001; Kitchens et al., 2007). Therefore, the chemotactic 
potential of conditioned media from either W6/32 or isotype-treated endothelial cells 
was examined using static chemotaxis assays. THP-1 human monocytic cells 
significantly migrated in response to antibody-free media from endothelial cells treated 
with saturating concentration of W6/32 antibody for 72 hours compared to media from 
isotype control-treated cells. Characterization of THP-1 cells showed the expression of 
chemokine receptors CCR5 and CXCR2 that bind CCL5 and CXCL8 respectively, 
which might explain the cell response and migration. A recent study showed the ability 
of HLA class I antibody to induce monocyte adhesion using aortic endothelial cells and 
in in vivo model (Valenzuela et al., 2013a).  
The ability of HLA class I antibody to induce leukocyte adhesion was assessed using a 
flow-based adhesion assay. This assay models in vivo leukocyte adhesion and 
overcomes the limitations of static chemotaxis assays. Micro-biochips resembling blood 
microvessels were coated with human recombinant adhesion molecule VCAM-1/Fc. To 
optimize our system, immobilized and soluble chemokines were assessed for their 
efficiency in inducing significant leukocyte adhesion. THP-1 monocytic cells and 
MOLT-16 T-cells were examined for their ability to bind VCAM-1/Fc. MOLT-16 cells 
express chemokine receptor CXCR4 which binds CXCL12 chemokine as shown earlier 
by our group (data not shown). Both cell types express VLA-4 and LFA-1 integrins 
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which bind VCAM-1 and ICAM-1 molecules, respectively (McGilvray et al., 1997; 
Sandig et al., 1997).  
THP-1 monocytic cells significantly adhered to VCAM-1/Fc in the presence of 
immobilized rhCCL5. In a similar manner, MOLT-16 T-cells adhere significantly to the 
same adhesion molecule in the presence of immobilized rhCXCL12. Immobilization of 
chemokines into channels models the presentation of chemokine by endothelium where 
the chemokines are protected from the blood flow. In agreement with this study, 
immobilization of CXCL8 chemokine on VCAM-1 adhesion molecule induced 
significant adhesion of B-cells expressing VLA-4 (Campbell et al., 1996). THP-1 cells 
also significantly bound to VCAM-1/Fc in the absence of chemokines. This might be 
attributed to the presence of active low binding affinity of cell-surface integrins which 
can bind to the VCAM-1/Fc (Chan et al., 2000). However, this binding was 
significantly augmented in the presence of chemokine.  
In addition, peripheral blood mononuclear cells isolated from healthy volunteers were 
assessed for the adhesion to biochips coated with VCAM-1/Fc. To examine the role of 
chemokine concentration on leukocyte adhesion, soluble chemokines rhCCL5 or 
rhCXCL12 were used. Cells mixed with each chemokine showed significant adhesion 
to VCAM-1/Fc in a concentration-dependent manner. Although different studies have 
addressed the necessity of localized chemokine in inducing leukocyte arrest (Grabovsky 
et al., 2000), soluble chemokines can induce leukocyte adhesion in vitro (Gerszten et 
al., 1999; DiVietro et al., 2001). This might be attributed to the adsorption of 
chemokines under flow to the coated chips, causing localization of chemokines which is 
necessary for efficient integrin activation. However, localized chemokine might be more 
relevant to in vivo leukocyte adhesion where the chemokine is protected from dilution 
by the blood flow (Weber et al., 1999).  
Endothelial cells show a constitutive expression of some kinds of chemokines which are 
upregulated upon exposure to inflammatory cytokines. Apical chemokine along with 
endothelial adhesion molecules results in the increase of leukocyte adhesion. Therefore, 
TNF-α stimulated HMEC-1 cells were assessed for the adhesion of human monocytic 
cells infused at 0.5 dyne/cm
2
 for 5 minutes. Monocytic cells significantly adhered to the 
TNF-α-activated cells compared to untreated cells. However, the adhesion of these cells 
was augmented by the presence of immobilized chemokine rhCCL5. In a parallel 
manner, the adhesion of MOLT-16 cells to activated endothelial cells was enhanced in 
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the presence of immobilized rhCXCL12 compared to that in the absence of chemokine. 
This result shows that inflamed endothelial cells can induce the adhesion of leukocytes 
under flow condition which is augmented in the presence of immobilized chemokines. 
In agreement with this study, immobilization of chemokines on human umbilical vein 
endothelial cells induces lymphocyte adhesion under shear forces (Shamri et al., 2002; 
Lee et al., 2009). 
HLA class I antibody was examined for its potential to induce monocyte adhesion to 
microvascular endothelial cells. Treatment with whole molecule of W6/32 antibody 
induced a significant monocyte adhesion to endothelial cells compared to isotype 
control. This is attributed to the ability of mouse IgG2a antibody to bind human Fc-
receptors as observed in previous study (Valenzuela et al., 2013b). Therefore, F(ab)2 
fragments from W6/32 antibody were used to examine monocyte adhesion independent 
to Fc-receptors. HMEC-1 cells treated with these fragments overnight induced a 
significant binding of monocytes under flow compared to control group. This is 
attributed to the expression of adhesion molecules and chemokines by treated 
endothelial cells as shown earlier using flow cytometry and cytokine array, respectively. 
In addition, conditioned media from endothelial cells treated with HLA class I antibody 
also produced a significant increase in the adhesion of monocytes to stimulated 
endothelial cells compared to the conditioned media from the isotype-treated group. The 
presence of excess chemokines in antibody-treated conditioned-media might explain 
monocyte adhesion under flow conditions.  
In conclusion, endothelial cells treated with saturating concentration of HLA class I 
antibody showed an up-regulation of the expression of cell surface adhesion molecules, 
chemokines and cytokines. These mediators induced the interaction between donor 
endothelium and recipient leukocytes, enhancing their migration to the transplanted 
grafts. 
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6.  Chapter Six-Allospecific Antibodies and Endothelial Cell 
Activation   
6.1 Introduction 
Antibody-mediated rejection accounts for around 20-30% of all acute rejection episodes 
following kidney transplantation, reducing the one year allograft survival by 15-20% 
(Lucas et al., 2011). Donor specific HLA antibodies are one of the major causes of 
antibody-mediated rejection (Lachmann et al., 2009) and are a risk factor for the 
development of chronic rejection (Hill et al., 2011). The contribution of donor-specific 
HLA antibody to allograft rejection occurs also in other types of solid organ 
transplantation such as heart (Chih et al., 2012), lung (Hachem, 2012), pancreas 
(Torrealba et al., 2008) and liver transplantation (Abu-Elmagd et al., 2012). In addition 
to complement fixing antibody, complement-independent mechanism can also play a 
role in allograft rejection. In mice transplantation models, donor specific antibody to 
MHC class I molecules induces subsequent chronic transplant arteriopathy in a 
mechanism independent to complement activation (Hirohashi et al., 2010). The poor 
prognosis of antibody-mediated rejection is attributed to the lack of responsiveness to 
most anti-rejection treatments which mainly target cellular rejection pathways 
(Jirasiritham et al., 2010).  
De novo synthesized donor specific antibodies or preformed antibodies have both been 
shown to have a deleterious effect on allograft survival (Li et al., 2008; Hidalgo et al., 
2009). Transplantation across HLA class I or class II antibodies might occur due to 
prior use of low sensitivity detection techniques for HLA antibodies or after pre-
conditioning treatment in highly sensitized patients (Gloor et al., 2004). However, de 
novo HLA antibodies provide a more potent contribution to late allograft dysfunction 
(Gaston et al., 2010; Halloran et al., 2010). In the absence of pre-transplant antibody, 
the chance to develop donor specific HLA antibodies might reach 15% within the first 
4-7 years post-transplantation, as reported recently in kidney transplantation (Wiebe et 
al., 2012). In addition to antibody-mediated rejection, the presence of HLA antibodies 
also has an impact on the development of T-cell mediated rejection embedding a long 
term allograft survival (Caro-Oleas et al., 2012). Accordingly, 10 year allograft survival 
reduced from 96% in patients without donor specific antibody to 56% in patients with 
de novo donor specific HLA antibodies (Caro-Oleas et al., 2012).  
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Donor-specific HLA class I antibodies can be of any antibody isotype; IgG, IgA or IgM 
as determined earlier on the serum of kidney recipients after 1 month post-
transplantation (Groth et al., 1996). A recent study showed that the IgA antibody 
isotype is mostly formed against HLA class I antigens rather than HLA class II 
antigens, while the IgG isotype can form against both HLA class I or class II antigens 
(Arnold et al., 2013). HLA antibodies can be of any IgG subclasses or a mixture of 
different subclasses. Recently, IgG1 was identified as the most common HLA IgG 
subclasses followed by IgG2>IgG3>IgG4 in sensitized kidney patients. The mixture of 
antibodies may contain strong complement fixing antibodies; IgG1 and IgG3 or a 
mixture of strong and weak complement fixing antibodies; IgG1 or  IgG3I with gG2 or 
IgG4 (Honger et al., 2011).  
In this project, activation of microvascular endothelial cells was determined first using 
mouse monoclonal antibody (W6/32) against HLA class I antigens. The binding 
between HLA class I antigens and W6/32 antibody occurs through monomorphic 
conformational epitopes shared by all HLA class I antigens. Amino acid residues 
present on β2-microglobulin and α3 domain are crucial for W6/32 antibody binding 
(Ladasky et al., 1999). In contrast, allospecific antibodies are formed against 
polymorphic determinants of HLA class I antigens where the majority of polymorphism 
occurs in the α1 and α2 domains. Therefore, examining the role of these antibodies in 
inducing endothelial cell activation is fundamental. In this chapter, allospecific 
antibodies from multiparous females and sensitized kidney transplant patients who had 
specific HLA class I antibodies were used. Selection of the samples was carried out 
according to the specificity of HLA class I antigens expressed on HMEC-1 cells. As 
confirmation, monoclonal human HLA specific antibodies were also obtained to assess 
the activation of microvascular endothelial cells.  
6.2 Specific Aims 
In this chapter, allospecific HLA class I antibodies from both multiparous females and 
sensitized kidney patients who had a circulating HLA class I antibodies at the time of 
the rejection were used to assess changes in; 
 The phosphorylation of endothelial cell signaling proteins Akt, ERK and CREB; 
 The expression of cell surface adhesion molecules VCAM-1 and ICAM-1, and 
 The expression of mRNA CXCL8. 
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6.3 Specific materials and methods 
6.3.1 Sources of allospecific antibodies 
HLA allospecific antibodies were obtained from previously characterized serum 
samples collected from multiparous females who had developed HLA class I antibodies 
during pregnancy. Samples were previously used as reagents in serological typing in 
NHSBT (Ethical approval reference: 11/NE/0091). In addition, serum samples from 
sensitized kidney patients who had circulating HLA class I antibodies at the time of 
graft rejection were also used. Serum samples were selected according to the presence 
of HLA antibodies specific to HMEC-1 endothelial cell line; determined using Luminex 
single antigen bead IgG assay. Antibodies were purified from 400-700 μl of sera. 
Samples from non-sensitized volunteers were processed in the same way and used as a 
negative control. In addition, serum sample from patients with HLA class I antibodies 
against antigens not present on HMEC-1 were also used as a negative control.  
6.3.2 Antibody purification 
For IgG antibody purification, between 400-700 μl of serum was diluted with PBS to a 
total volume of 1 ml. The antibody was injected into equilibrated protein G column (GE 
healthcare) which has a capacity to bind all subclasses of human IgG at high affinity. 
The column was washed with PBS to remove the unbound material and the elution step 
was performed using 0.1 M glycine (pH 2). The concentration of antibodies was 
determined using the BCA protein assay as described previously in section 2.8.3. The 
purified antibodies were adjusted to 4.5 mg/ml with sterile PBS.     
6.3.3 Gel electrophoresis 
To assess the presence and integrity of the purified antibodies, they were separated on 
10% SDS gel under reducing condition to visualize the heavy and light chains. Eight μg 
of protein was loaded into each lane after heating with β-mercaptoethanol for 10 
minutes. The gel was run at 30 mA for 1 hour and 30 minutes followed by staining with 
coomassie blue stain for 20 minutes at room temperature and destained as described 
previously in section 2.8.5. Figure 6.1 and Figure 6.2 show the coomassie blue staining 
of the gels for antibodies purified from multiparous females and sensitized kidney 
samples, respectively. 
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Figure 6.1: Gel electrophoresis of purified IgG from multiparous female 
samples. 
Serum samples from multiparous females were passed through protein G column. 8 
µg/ml of purified antibodies were run under reduced condition on 10 % SDS-PAGE gel. 
Gel was stained with comassie blue stain to visualize the heavy and light chains at 55 
and 25 kDa, respectively. First band (C) is for negative control sample from non-
sensitized volunteer and 1, 2, 3, 4, 5 and 6 for serum 1, serum 2, serum 3, serum 4, 
serum 5 and serum 6, respectively.  
 
      
            
Figure 6.2: Gel electrophoresis of IgG antibodies purified from sensitized 
kidney patients. 
Total IgG antibodies were purified from sensitized patient samples using protein G 
column. 8 μg of the purified IgG were separated under reduced condition on 10 % SDS-
PAGE gel. Gel was stained with comassie blue to visualize the heavy and light chains. 
Band C is for the control sample containing HLA class I antibodies for antigens do not 
express on HMEC-1 cells and 1, 2, 3, 4, 5 and 6 for Patient 1, Patient 2, Patient 3, 
Patient 4, Patient 5 and Patient 6, respectively. 
kDa 
55 
25 
kDa 
55 
25 
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6.3.4 Indirect immunofluorescence 
The ability of allospecific antibodies purified from human sera or monoclonal HLA 
class I antibody to bind HMEC-1 cells was examined by flow cytometry as described in 
section 2.7.2. In brief, 2X10
5
 HMEC-1 cells were stained with different concentrations 
of antibodies and incubated for 20 minutes at 4
0
C. Following washing steps with 2% 
FBS/PBS, cells were incubated with anti-human IgG FITC conjugated antibody for 20 
minutes at 4
0
C followed by two washes with FBS/PBS solution. Cells were resuspended 
in 200 μl of FBS/PBS and analyzed by flow cytometry. Due to the limited amount of 
antibodies available, 0.18 mg/ml of purified IgG antibodies were used for all further 
experiments. Figure 6.3 shows the indirect immunofluorescence staining of the purified 
IgG from both multiparous and patient samples. Cells stained with secondary antibody 
only were used as a negative control.    
6.3.5 Antibody screening using Luminex cytometer 
6.3.5.1 General principle 
Luminex flow cytometry is a solid phase assay which can be used to determine the 
presence of specific HLA antibodies. It is a more sensitive and specific technique than 
complement-dependent cytotoxicity and ELISA assays. The main advantages of this 
assay are specificity and sensitivity for HLA antibodies, while the other assays show 
positive reactions to other types of antibodies such as autoantibody and non-HLA 
antibodies. Another advantage of using Luminex assay is the ability to detect both 
complement and non-complement fixing antibodies, whilst complement-dependent 
cytotoxicity assays detect complement fixing antibody only. Luminex-antibody 
screening is performed by incubating patient serum with HLA antigen-coated beads 
followed by staining with fluorescence-conjugated secondary antibody followed by 
analysis using the Luminex platform. The beads are groups of polystyrene microspheres 
that have HLA molecules on their surfaces and each bead having a unique fluorochrome 
intensity that is specific for a bead group. There are three types of assays differentiated 
according to the attached HLA molecules. The first type contains beads that are attached 
to a large number of HLA class I and class II antigens which are used as a screening for 
the presence or absence of HLA antibodies. In the second type of assays, each bead 
contains two sets of antigens from either HLA class I or class II prepared from platelets 
(class I) or cell lines (class I or class II) in a manner similar to that present in human 
nucleated cells. The third type of assay contains recombinant single HLA
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Figure 6.3: Indirect immunofluorescence staining of allospecific antibodies 
on HMEC-1 endothelial cells. 
The cells were stained with allospecific purified IgG antibodies at concentration 0.18 
mg/ml followed by anti-human IgG FITC conjugated antibody. Stained cells were run 
on a flow cytometer. Cells stained with secondary antibody only were used to show 
background staining. Panel A shows the staining of the purified antibodies from 
multiparous women samples and panel B shows the staining of purified antibodies from 
patients’ sera. The data are representative of two independent experiments. 
 
A) B) 
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molecules attached to beads in form of two separate sets for class I or class II. This 
assay is called a single antigen bead and is used for the determination of HLA 
antibodies in sera with high panel reactive antibodies. 
 In all assays, the patient serum is incubated with beads at room temperature for around 
30 minutes to allow antibody binding. Following washing steps, a secondary anti-
human IgG PE-conjugated antibody is added which bind to any attached HLA antibody. 
Washed beads are resuspended in PBS and run on the Luminex platform. When the 
cells pass through the detector, the fluorochrome in the beads is excited by one laser on 
the instrument while the other laser excites the PE attached to the secondary antibody. 
The signals from these molecules collectively determine the antibody specificity in 
serum sample. The presence of HLA class I antibodies specific to HMEC-1 cells in the 
purified IgG antibodies was confirmed by single bead antigen Luminex assay.  
6.3.5.1 Antibody screening using Luminex assay 
Screening for HLA class I antibodies was performed using single antigen bead kit (One 
Lambda). The kit contains all the reagents required for the assay. Plate filters were 
washed once with diluted buffer followed by mixing 20µl of buffer, 8 µl of purified 
antibodies and 2 µl of beads. The plate was incubated at 22
0
C for 30 minutes in dark on 
a rotating shaker. Following five washes, 40 µl of PE-conjugated antibody is added. The 
plate was incubated again at 22
0
C for 30 minutes in a dark on a rotating shaker. After 
five washes, 80 µl of sheath fluid was added to each well and then run through Luminex 
LX200 cytometer. The data were analyzed using HLA Fusion software with cut-off at 
500. Table 6.1 shows the purified samples with their specificities and median 
fluorescence intensity by both flow cytometry and Luminex assay. Figure 6.4 shows an 
example of the output sheet of the screening of purified IgG by single antigen bead 
Luminex assay.  
6.3.6 Stimulation of endothelial cells using allospecific antibodies  
For endothelial cell signalling, cells were stimulated with allospecific antibodies as 
described in section 4.3.2. In brief, adherent HMEC-1 cells were serum starved 
overnight in media containing 0.2% FBS. The cells were dissociated and resuspended in 
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Table 6.1: Allospecific human IgG purified from HLA sensitized individuals. 
Sample Antibodies Luminex MFI * Flow cytometry MFI 
Serum 1 
sensitized female 
A1, A68 13129-4883 
752 B35, B58 2459-709 
Cw4, Cw6 610-793 
Serum 2 
sensitized female 
A68 14632 
3358 B58 11343 
Cw4 1281 
Serum 3 
sensitized female 
A1, A68 3146-7410 
1342 B35, B58 11785-3161 
Cw6 1272 
Serum 4 
sensitized female 
B58 4369 
925 
Cw6 1694 
Serum 5 
sensitized female 
A68 791 
863 
Cw4, Cw6 8957-5732 
Serum 6 
sensitized female 
Cw4, Cw6 8952-14771 959 
Patient 1 
Kidney patients 
B35, B58 2971-1833 
4462 
Cw4, Cw6 11477-17766 
Patient 2 
Kidney patients 
A1, A68 7795-5083 
728 
Cw4, Cw6 1126-620 
Patient 3 
Kidney patients 
B35, B58 17741-12712 1256 
Patient 4 
Kidney patients 
A1, A68 11619-2589 
844 B35, B58 11399-7849 
Cw4, Cw6 672-728 
Patient 5 
Kidney patients 
A1, A68 7210-4845 2854 
Patient 6 
Kidney patients 
B35-, B58 910-970 
3410 
Cw4, Cw6 9208-15649 
Negative control A66 813 68 
Non-specific HLA class I 
antibody 
B7, B27 3569, 6728 80 
* MFI, Median Fluorescence Intensity. Each sample represents the absolute value after the subtraction the 
MFI of secondary antibody stained cells which are equal to 166 in the multiparous females’ sera and 201 
in patient samples. 
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Figure 6.4: Output of a single antigen bead assay for HLA class I antibody 
determination. 
Purified antibodies were screened by single bead antigen assay using labscreen kit. The 
samples were run through Luminex LX200 and analyzed using HLA Fusion software. 
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 0.2% FBS containing media and incubated at 37
0
C for 2 hours. Cells were then 
stimulated with 0.18 mg/ml of human IgG for 5 minutes. The stimulation was 
terminated by adding cold PBS and centrifuged at a cold centrifuge at 10,000 g for 3 
minutes. Cells were then lysed in a lysis buffer containing phosphatase inhibitor as 
described previously in section 2.8.2. Cell lysates were used for the determination of p-
ERK, p-Akt and p-CREB as described in section 4.3.2.  
To determine the expression of adhesion molecules by endothelial cells, adherent cells 
were stimulated overnight in a 12 well plate with purified antibodies at concentration 
0.18 mg/ml. Following incubation, adherent cells were detached using enzyme-free 
PBS-based cell dissociation buffer. 1X10
5
 cells were stained with mouse anti-human 
PE-conjugated antibody for VCAM-1 and ICAM-1 for 20 minutes at 4
0
C. Following 
washing, the expression of adhesion molecules was determined by flow cytometry. 
6.3.7 Assessment of the specificity of isolated IgG antibodies to endothelial 
HLA class I antigens. 
Polyclonal human sera were selected according to the presence of HLA specific 
antibodies confirmed by Luminex assay. As these samples are polyclonal, experiments 
were designed to confirm that the cell signalling was due to the HLA class I antibodies. 
Acid treatment of HMEC-1 cells as described in section 3.3.4 and knocking down of 
HLA class I antigens were used to confirm the specificity of the signalling.     
6.3.7.1 Acid treatment of HMEC-1 cells 
Endothelial cells were treated with citrate solution (pH 3) as described in section 3.3.4. 
After treatment, around 2X10
5
 cells were stained with allospecific antibodies at final 
concentration of 0.18 mg/ml for 20 minutes at 4
0
C. After two washes with 2% 
FBS/PBS, cells were stained with anti-human IgG FITC conjugated antibody for 
another 20 minutes at 4
0
C. After washing, cells were resuspended in 200 μl FBS/PBS 
and analyzed by flow cytometry. Cell viability was assessed by PI staining. Treatment 
did not induce more than 10% cell death.  
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6.3.7.2 Knockdown efficiency of HLA class I antigens (siRNA) using W6/32 
antibody 
To knockdown the expression of HLA class I antigens, three different pre-designed 
siRNA were used with following specificity: HLA-A locus heavy chain siRNA, HLA-B 
locus heavy chain siRNA and HLA-C locus heavy chain siRNA (Applied Biosystems). 
These were supplied as purified and dried forms which were reconstituted using RNase 
free water at stock solution 5 μM and working solution at 2 μM. The transfection 
process was performed as described in section 5.3.4.7. To knockdown all three HLA 
class I antigens, three different siRNA were mixed together at final concentration 5, 10 
or 20 nM for each siRNA. Where specified, B locus siRNA alone was used to assess the 
efficiency of HLA-B antigen knockdown. The transfection efficiency was determined 
by examining the expression HLA class I antigens at different time points and siRNA 
concentrations. Non-transfected cells, negative control siRNA and locus-specific siRNA 
HLA class I transfected cells were stained with 12 µg/ml mouse W6/32 antibody 
followed by FITC conjugated rabbit anti-mouse secondary antibody as described in 
section 3.3.7.5. The cells were detached and analyzed by flow cytometry.        
6.3.7.3 Knockdown efficiency using human monoclonal HLA class I antibody  
To assess the knockdown efficiency for each locus, monoclonal HLA specific 
antibodies were used. Human monoclonal antibody against specific HLA class I antigen 
expressed on HMEC-1 cells was kindly provided by Dr. Arned mulder, Leiden 
University Medisch Centrum, Department Immunohaematology and Blood Transfusion. 
Four different IgG1 antibodies (250 μg of each constituted in sterile PBS) at different 
concentrations were obtained with the following specificities; A2/B17, A2/A28, A1/A9 
and B51/B35 which bind B58, A68, A1 and B35 on HMEC-1 cells, respectively. These 
antibodies were obtained by heterohybridoma followed by antibody purification through 
protein A column (Mulder et al., 2010). The concentration of each antibody was 
adjusted to a working concentration of 1mg/ml. The binding of these antibodies to 
HMEC-1 endothelial cells were examined by flow cytometry as described in section 
6.3.4. Cells were stained with these antibodies followed by staining with FITC-
conjugated anti-human secondary antibody and flow cytometry analysis. Figure 6.5 
shows the staining of HMEC-1 cells with 40 µg/ml of human monoclonal HLA class I 
specific antibody. Due to limited amount of these antibodies, this concentration was 
chosen for all subsequent experiments. 
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Figure 6.5: Indirect immunofluorescence staining of HMEC-1 cells with 
human monoclonal HLA class I antibody. 
HMEC-1 cells were stained with 40 µg/ml of each antibody followed by FITC 
conjugated anti-human IgG secondary antibody. Cells stained with secondary antibody 
only were used to determine background staining. Cells were analyzed by flow 
cytometry and interpreted by WinMDI 2.9 software. 
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6.3.8 p-CREB Cell based ELISA  
Phosphorylation of CREB at serine residue 133 was performed using cell based ELISA 
kit (R&D system). The kit contains all reagents necessary for the determination of 
human p-CREB including; rabbit p-CREB, goat T-CREB, HRP-conjugated donkey 
anti-rabbit, alkaline phosphatase-conjugated donkey anti-goat antibodies, fixing 
solution, blocking buffer and substrates. The assay was performed on HMEC-1 cells 
transfected with HLA-B siRNA in response to HLA-B58 antibody stimulation. HMEC-
1 cells were grown in 96 well plates until confluency. Nontransfected and transfected 
HMEC-1 cells were serum starved in media containing 0.2% FBS for 2 hours. Cells 
were left un-stimulated or were stimulated for 5 minutes with 40 µg/ml of human 
monoclonal antibody or different concentrations of forskolin ranging from 1-50 µM as a 
positive control. Media was removed and 100 µl of fixing solution was added 
immediately. The following steps were performed following manufacturers’ instruction. 
The plate was read on fluorescence plate reader (Biotek, UK) at excitation 360 nm and 
emission 450 nm for T-CREB and at excitation 540 nm and emission 600 nm for p-
CREB. The ratio between the p-CREB and T-CREB was calculated and plotted. Figure 
6.6 shows p-CREB cell-based ELISA on HMEC-1 cells stimulated with forskolin.
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Figure 6.6: p-CREB cell based ELISA on HMEC-1 endothelial cells stimulated 
with forskolin. 
Adherent HMEC-1 cells were stimulated with different concentrations of forskolin for 5 
minutes followed by cell fixation. Cells were incubated with antibodies specific to p-
CREB and T-CREB followed by conjugated secondary antibodies. Fluorescence 
intensity was measured using fluorescence plate reader at excitation 360 and 540nm and 
emission 450 and 600nm for T-CREB and p-CREB, respectively. The data was 
analyzed by one-way ANOVA followed by Bonferroni test (* p<0.05, ** p<0.01 and 
*** p<0.001). The data are representative of two independent experiments. 
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6.4 Results  
6.4.1 Effect of allospecific antibodies on endothelial cell signalling 
6.4.1.1 Effect of allospecific antibodies from multiparous females on 
endothelial cell signalling 
 The effect of allospecific HLA class I antibodies purified from sensitized individuals 
on activation of endothelial signalling was determined. Six samples from multiparous 
females containing HLA class I antibodies specific to HMEC-1 cells were used. 
Samples were screened for the presence of HLA antibodies using single antigen bead 
Luminex assay both before and after purification. Purified IgG antibodies were adjusted 
to 4.5 mg/ml and used at concentration 0.18 mg/ml for endothelial cell activation. 
HMEC-1 cells were stimulated with these antibodies for 5 minutes and assessed for the 
phosphorylation of ERK, Akt and CREB proteins by western blotting. Stimulation of 
endothelial cells with allospecific antibodies for 5 minutes induced the phosphorylation 
of these proteins at specific residues. Figure 6.7 shows the phosphorylation of ERK1/2 
at tyrosine 202 and threonine 204 residues in response to these antibodies when 
compared to negative controls. Untreated cells, cells treated with purified IgG from 
HLA negative sample were used as negative controls. Figure 6.8 shows the Akt 
phosphorylation at serine residue (473) on stimulated HMEC-1 endothelial cells 
compared to negative control. The phosphorylation of the transcription factor CREB at 
serine residue 133 and ATF-1 in response to these antibodies is shown in Figure 6.9. 
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Figure 6.7: Effect of HLA class I allospecific antibodies purified from 
multiparous female samples on endothelial ERK phosphorylation. 
HMEC-1 cells were stimulated for 5 minutes with purified 0.18 mg/ml IgG antibodies 
from samples followed by cell lysis. Cell lysates were probed with p-ERK1/2 antibody. 
The membrane was stripped and probed for T-ERK using T-ERK antibody. The 
densitometric analysis was performed using Alphaimager software. The data are 
representative of two independent experiments. 
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Figure 6.8: Effect of HLA class I allospecific antibodies purified from 
multiparous female samples on endothelial Akt phosphorylation. 
HMEC-1 cells were stimulated for 5 minutes with 0.18 mg/ml of IgG antibodies 
purified from samples before probing with p-Akt antibody (serine residue 473). The 
membrane was stripped and probed for T-Akt using rabbit T-Akt antibody. The 
densitometric analysis was performed using Alphaimager software. The data are 
representative of two independent experiments. 
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Figure 6.9: Effect of HLA class I allospecific antibodies purified from 
multiparous female samples on endothelial CREB phosphorylation. 
HMEC-1 cells were stimulated with 0.18 mg/ml IgG antibodies purified from samples 
for 5 minutes before probing with rabbit p-CREB antibody (serine residue 133). The 
membrane was stripped and probed for T-CREB. The densitometric analysis was 
performed using Alphaimager software. The data are representative of two independent 
experiments. 
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6.4.1.2 Effect of allospecific antibodies from sensitized patients on 
endothelial cell signalling 
The activation of endothelial cell signalling in response to HLA class I allospecific 
antibodies from sensitized kidney patients was performed. Six patient samples were 
selected and total IgG antibodies was purified. These patients developed high level of 
HLA class I antibodies, detectable at the time of allograft rejection. The concentration 
of each preparation was adjusted to 4.5 mg/ml and used at concentration of 0.18 mg/ml. 
HMEC-1 endothelial cells were stimulated with these antibodies and examined for the 
phosphorylation of ERK, Akt and CREB. Treatment of endothelial cells with these 
antibodies induced a significant increase in the level of the phosphorylated forms of all 
proteins examined. Figure 6.10 shows the phosphorylation of ERK at tyrosine 202 and 
threonine 204 residues following 5 minutes of stimulation compared to the control 
groups; untreated cells, cells treated with IgG from non-sensitised volunteer and non-
specific HLA class I IgG antibodies. In addition, the phosphorylation of Akt at serine 
residue 473 is shown in Figure 6.11. Stimulation of endothelial cells with control IgG 
did not induce significant Akt phosphorylation. Figure 6.12 illustrates the 
phosphorylation of endothelial transcription factor CREB at serine residue 133 and 
ATF-1 in response to antibodies from kidney patients compared to controls. 
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Figure 6.10: Effect of allospecific HLA class I antibodies purified from 
sensitized kidney patients on endothelial ERK phosphorylation. 
HMEC-1 cells were stimulated with 0.18mg/ml of IgG antibodies purified from 
sensitized kidney patients for 5 minutes before probing with rabbit p-ERK antibody. 
The membrane was stripped and probed for T-ERK antibody. The densitometric 
analysis was performed using Alphaimager software. The data are representative of two 
independent experiments. 
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Figure 6.11: Effect of allospecific HLA class I antibodies from kidney patients 
on Akt phosphorylation. 
HMEC-1 cells were stimulated with 0.18 mg/ml of IgG antibodies purified from kidney 
patients for 5 minutes before probing with rabbit p-Akt antibody. The membrane was 
stripped and probed with rabbit T-Akt antibody. The densitometric analysis was 
performed using Alphaimager software. The data are representative of two independent 
experiments.
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Figure 6.12: Effect of allospecific HLA class I antibodies from sensitized 
kidney patients on CREB phosphorylation. 
HMEC-1 cells were stimulated with 0.18mg/ml of IgG antibodies purified from 
sensitized kidney patients for 5 minutes before probing with rabbit p-CREB antibody. 
The membrane was stripped and probed for T-CREB. The densitometric analysis was 
performed using Alphaimager software. The data are representative of two independent 
experiments. 
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6.4.2 Effect of allospecific antibodies on adhesion molecules expression 
6.4.2.1 Effect of antibodies from Multiparous females on adhesion 
molecules expression 
To explore the effect of allospecific HLA class I antibodies on inducing the adhesion 
properties of endothelial cells, the modulation of the expression of VCAM-1 and 
ICAM-1 antigens in response to these antibodies was examined. IgG antibodies from 
six different multiparous female samples was examined for the activation of these cell 
surface antigens on HMEC-1 cells. Endothelial cells were stimulated overnight with 
antibodies at a concentration of 0.18 mg/ml. After stimulation, cells were stained with 
PE-conjugated anti-human VCAM-1 and ICAM-1 antibodies and analysed by flow 
cytometry. Untreated cells and cells stimulated with IgG antibodies from non-sensitised 
volunteer were used as negative control groups. As shown in Figure 6.13, expression of 
VCAM-1 molecules on HMEC-1 cells was significantly induced after stimulation with 
allospecific antibodies compared to both control groups. The upregulation in the 
expression of VCAM-1 was variable between samples and ranged between 2 to 3 fold. 
Similarly, the expression of endothelial ICAM-1 was significantly induced in response 
to these antibodies as shown in Figure 6.14, (p<0.001). Treatment induced around 10 to 
30 fold increase in the expression of ICAM-1 compared to both control groups. 
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Figure 6.13: Effect of allospecific HLA class I antibodies purified from 
multiparous female samples on VCAM-1 expression. 
HMEC-1 cells were stimulated overnight with 0.18 mg/ml of IgG antibodies purified 
from multiparous samples before the analysis of the expression of VCAM-1 molecules 
by flow cytometry. Histograms A, B, C, D, E and F represent unstained, untreated, 
normal IgG, serum 1, serum 2 and serum 4 treated, respectively. Analysis was 
performed by one-way ANOVA followed by Bonferroni test. *** p<0.001. The data are 
representative of two independent experiments. 
G) 
A) 
F) E) D) 
C) B) Unstained MFI 80 Untreated MFI 101 Non-sensitized IgG MFI 110 
Serum1 treated MFI 202 Serum2 treated MFI 252 Serum4 treated MFI 242 
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Figure 6.14: Effect of allospecific HLA class I antibodies purified from 
multiparous female samples on ICAM-1 expression. 
HMEC-1 cells were stimulated overnight with IgG antibodies purified from samples 
before analysing the expression of ICAM-1 molecules using flow cytometry. 
Histograms A, B, C, D, E and F represent unstained, untreated, normal IgG, serum 1, 
serum 2 and serum 4 treated, respectively. Data analysis was performed using one-way 
ANOVA followed by Bonferroni test at p<0.05. *** p<0.001. The data are 
representative of two independent experiments.  
G) 
F) E) D) 
A) B) C) 
Serum1 treated  MFI 15,782 Serum2 treated MFI 18,054 Serum4 treated MFI 27,853 
Unstained MFI 81 Untreated MFI 1,488 Control IgG MFI 1,541 
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6.4.2.2 Effect of allospecific antibodies from sensitized patients on the 
expression of endothelial adhesion molecules  
Allospecific HLA class I antibodies purified from kidney patients who formed 
antibodies to HLA antigens to previous graft were also used to examine the expression 
of endothelial adhesion molecules. Expression of both VCAM-1 and ICAM-1 were 
determined using flow cytometry after stimulation with 0.18 mg/ml of antibodies. Both 
normal IgG antibodies as well as irrelevant HLA class I antibodies were used as control 
groups. Stimulation with antibodies from sensitised patients significantly induced the 
expression of both antigens compared to cells treated with irrelevant antibodies. As 
shown in Figure 6.15, these antibodies significantly induced the expression of VCAM-1 
molecules in comparison to control groups. The stimulation induced around a 2 fold 
increase in the cell surface expression of VCAM-1 when compared to IgG antibodies 
from non-sensitized volunteer. Figure 6.16 shows the upregulation in the expression of 
ICAM-1 antigens in response to allospecific HLA class I antibodies from kidney 
patients. The expression was increased by around 10 to 30 fold when compared with 
serum containing HLA class I antibodies which were not specific for the HLA class I 
antigens on HMEC-1 cells, p<0.001. 
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Figure 6.15: Effect of allospecific HLA class I antibodies purified from 
sensitized kidney patients on VCAM-1 expression. 
HMEC-1 cells were stimulated overnight with 0.18 mg/ml of IgG antibodies purified 
from sensitized kidney patients before analysing the expression of VCAM-1 molecules 
using flow cytometry. Histograms A, B, C, D, E and F represent: unstained, untreated, 
irrelevant IgG, patient 1, patient 3 and patient 6, respectively. The data analysis was 
performed using one-way ANOVA followed by Bonferroni test at p<0.05. * & *** 
P<0.05 and p<0.001, respectively. The data are representative of two independent 
experiments. 
F) E) 
A) 
D) 
B) C) 
G) 
Untreated MFI 185 Unstained MFI 176 Irrelevant HLA Ab MFI 158 
Patient1 treated MFI 378 
Patient3 treated  MFI 360 Patient 6 treated MFI 338 
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Figure 6.16: Effect of allospecific HLA class I antibodies purified from 
sensitized kidney patients on ICAM-1 expression. 
HMEC-1 cells were stimulated overnight with 0.18 mg/ml of IgG antibodies purified 
from sensitized kidney patients before analysing the expression of ICAM-1 molecules 
using flow cytometry. Histograms A, B, C, D, E and F represent unstained, untreated, 
irrelevant HLA class I antibodies, patient 1, patient 3 and patient 6, respectively. The 
data were analysed by one-way ANOVA followed by Bonferroni test. *** p<0.001. The 
data are representative of two independent experiments. 
F) E) 
C) A) B) 
D) 
G) 
Untreated MFI 1,822 Unstained MFI 112 Irrelevant HLA Ab MFI 2,442 
Patient1 treated MFI 37,791 Patient3 treated MFI 43,436 Patient6 treated MFI 27,570 
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6.4.3 Effect of allospecific HLA class I antibodies on CXCL8 expression 
Purified allospecific IgG antibodies were examined for their ability to induce the 
expression of chemotactic the chemokine, CXCL8, at the molecular level. Both groups 
of samples were used for this experiment. Purified antibodies from multiparous female 
samples and from sensitized patients were used at concentration 0.18 mg/ml. 
Endothelial cells (HMEC-1) were stimulated with these antibodies overnight before 
RNA was extracted. The expression of CXCL8 was then determined by q-PCR. As 
shown in Figure 6.17, stimulation with IgG from multiparous female significantly 
induced the expression of endothelial CXCL8. The increase ranged between 3 to 14 fold 
when compared to the negative controls. IgG from non-sensitised volunteer was used as 
a negative control and they did not show significant difference compared to untreated 
group. The fold change for each sample was calculated in comparison to the normal IgG 
sample using GAPDH as a housekeeping gene. Figure 6.18 shows the expression of 
CXCL8 at molecular level following stimulation with purified IgG allospecific 
antibodies from kidney patients. The expression was significantly induced by  3 to 300 
fold change when compared to non-specific HLA class I IgG allo-antibodies. 
Stimulation with HLA class I antibodies not specific for antigens on HMEC-1 cells 
showed a non significant change in the expression of mRNA CXCL8 when compared to 
the untreated group. GAPDH was used as a housekeeping gene. 
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Figure 6.17: Effect of allospecific HLA class I antibodies purified from 
multiparous female samples on CXCL8 expression. 
HMEC-1 cells were stimulated overnight with 0.18 mg/ml of IgG antibodies before 
analysing the expression of mRNA CXCL8 by q-PCR. The fold change was calculated 
in comparison to cells treated with IgG antibodies from non-sensitised sample using 
GAPDH as the normalizing gene. The data analysis was performed using REST 2009 
software. *** p<0.001. The data are representative of two independent experiments. 
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Figure 6.18: Effect of allospecific HLA class I antibodies from kidney patients 
on CXCL8 expression. 
HMEC-1 cells were stimulated overnight with 0.18 mg/ml of IgG antibodies purified 
from kidney patients before analysing the expression of CXCL8 by q-PCR. The fold 
change was calculated in comparison to HLA class I antibodies that not specific to 
HMEC-1 cells and normalized to GAPDH. The data analysis was performed using 
REST 2009 software. *** p<0.001. The data are representative of two independent 
experiments. 
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6.4.4 Examination of the specificity of the purified IgG antibodies by acid 
treatment  
Human sera were chosen according to the specificity of the HLA class I antibodies, 
determined by the Luminex assay. However, confirmatory experiments were performed 
to ensure that activation was due to HLA class I antibodies. Endothelial cells were 
treated with citrate buffer (pH 3) for 2 minutes followed by staining with purified 
allospecific IgG. Stained cells were analysed by flow cytometry. As shown in section 
3.4.4, this treatment induced 70-80% reduction in the expression of HLA class I 
molecules as observed by staining with W6/32 antibody. Purified IgG antibodies were 
tested for their ability to bind sodium citrate-treated cells. Staining of treated cells with 
purified IgG from multiparous female samples showed different degrees of binding. 
Sample 2 showed ~30-40% reduction in the binding to treated endothelial cells. Other 
samples showed a reduction in the binding to treated cells although this was not 
statistically significant. The median fluorescence intensity of all six multiparous female 
samples before and after acid treatment is shown as a bar chart in Figure 6.19. 
Histograms for two samples are displayed using secondary anti-human antibody as a 
background staining. Purified IgG from sensitized kidney patients were examined by 
the same method. As shown in Figure 6.20, purified IgG from sensitized patients 
showed ~40-60% reduction in antibodies binding to acid treated endothelial cells 
compared to untreated cells, although sample 4 did not show significant reduction in 
binding. Median fluorescence intensity for each sample on HMEC-1 endothelial cells 
before and after acid treatment was plotted in bar chart. Histograms from two patient 
samples are shown as an example. Cell viability was assessed by staining with PI. There 
was no significant difference in cell death between acid treated and untreated cells. 
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Figure 6.19: Examination of the binding of purified human IgG from 
multiparous female to acid treated endothelial cells. 
HMEC-1 cells treated with citrate buffer (pH 3) for 2 minutes were stained with purified 
human IgG isolated from multiparous female and compared to untreated endothelial 
cells. A, B, C, D, E and F show unstained, secondary antibody only, serum 2 with no 
acid treatment, serum 2 after acid treatment, serum 6 with no acid treatment and serum 
6 after acid treatment, respectively. G represents bar chart of median fluorescence 
intensity. The data analysis was performed using one-way ANOVA followed by 
Bonferroni test at p<0.05. *** p<0.001. The data are representative of three independent 
experiments. 
F) D) E) 
A) B) C) 
G) 
Unstained MFI 154 Secondary only MFI 185 Serum2 No acid MFI 3,734 
Serum2 with acid MFI 2,283 Serum6 No acid MFI 932 Serum6 with acid MFI 515 
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Figure 6.20: Examination of the binding of purified human IgG from 
sensitized patients to acid treated endothelial cells. 
HMEC-1 cells exposed to citrate buffer (pH 3) for 2 minutes were stained with purified 
human IgG isolated from sensitised kidney patients and compared with untreated 
endothelial cells. A, B, C, D, E and F shows unstained, secondary only, patient 1 with 
no acid treatment, patient 1 after acid treatment, patient 6 with no acid treatment and 
patient 6 after acid treatment, respectively. The data analysis was performed by one-way 
ANOVA followed by Bonferroni test at p<0.05. *** p<0.001. The data are 
representative of three independent experiments. 
E) D) 
A) C) B) 
G) 
F) 
Unstaind MFI 144 Secondary only MFI 174 Patient1 No acid MFI 3,034 
Patient1 with acid MFI 1,335 Patient6 No acid MFI 2,838 Patient6 with acid MFI 1,217 
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6.4.5 Knock down of HLA class I antigens on HMEC-1 cells  
Knocking down the expression of HLA class I antigens was performed to analyze the 
effects of locus specific HLA antibody in inducing endothelial cell activation. The 
transfection efficiency was initially assessed using monoclonal W6/32 antibody.The 
silencing process was performed using three sequences of siRNA specific for HLA-A, 
HLA-B and HLA-C heavy chains. HMEC-1 cells were transfected transiently with 5 
nM of each siRNA or negative control siRNA at different time points ranging from 24 
to 96 hours, followed by staining with W6/32 antibody. As shown in Figure 6.21, 
transfection with these siRNA significantly reduced the expression of cell surface HLA 
class I antigens compared to both non-transfected and negative siRNA transfected 
groups. The expression was reduced by 60 % after 24 hours and by 68, 63 and 50% 
after 48, 72 and 96 hours, respectively, with p<0.001. Transfection for 48 hours induced 
a greater reduction in the expression of cell surface HLA class I antigens, although 
complete knock down in the expression of these molecules could not be achieved. 
Therefore, assays using higher siRNA concentrations were performed to obtain efficient 
silencing. Both 10 nM and 20 nM siRNA were transfected into HMEC-1 cells for 48 
hours followed by staining with W6/32 antibody. Using higher siRNA concentrations 
resulted in only 5 and 7% extra reduction at 10 and 20 nM, respectively, compared to 5 
nM siRNA (data not shown). Therefore, 5 nM for 48 hours was used for following 
experiments. Staining of transfected cells with W6/32 anibody would not provide an 
information about which locus is successfuly knocked down. Because the knock down 
of HLA class I molecules produced similar results to acid treatment, the binding of 
purified IgG to transfected cells was excluded.  
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Figure 6.21: Knockdown of HLA class I antigens on endothelial cells using 
siRNA technique. 
HMEC-1 cells were transiently transfected with a mixture of siRNA specific for HLA-
A, B and HLA-C or negative siRNA at different time points at concentration of 5 nM. 
Cells were detached and stained with 12 µg/ml of W6/32 antibody followed by anti-
mouse FITC conjugated antibody and analyzed by flow cytometry. Panel A shows 
unstained, B secondary antibody only, C untreated, D example of negative siRNA, (E) 
HLA siRNA after 48 hours, (F) HLA siRNA after 72 hours and (G) median 
fluorescence intensity. The data was analyzed using Two-way ANOVA followed by 
Bonferroni test. *** p<0.001 compared to negative siRNA. The data are representative 
of three independent experiments.       
E) F) D) 
A) 
C) 
G) 
Unstained MFI 89 Secondary Ab only MFI 168 
F89 
B) Untreated MFI 18,862 
Negative siRNA MFI 19,262 
 
HLA/B/C siRNA 48 h  
MFI 6,062 
HLA/B/C siRNA 72 h  
MFI 6,565 
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6.4.6 Determination of knockdown efficiency using human monoclonal HLA 
class I antibody 
Human monoclonal antibodies specific for paticular HLA antigens were obtained from 
Dr. Arend mulder to evaluate the transfection efficiency of HLA class I antigens. 
HMEC-1 endothelial cells were transfected with a mixture of 5 nM of HLA siRNAs for 
class I antigens for 48 hours followed by staining with human monoclonal antibody 
separately at concentration 40 μg/ml. Figure 6.22 shows the staining with human HLA-
A1 and HLA-A68 antibodies on untreated, negative siRNA and HLA siRNA 
transfected cells. The transfection induced a negligable silencing of HLA-A1 molecules 
but induced ~50% reduction in the expression of HLA-A68 antigens. This reduction 
was statisticaly significant compared to negative siRNA stained with the same antibody 
at the same concentration (p<0.001). The transfection of negative control siRNA did not 
induce a significant change in the expression of specific HLA antigens when compared 
to the untreated group. Figure 6.23 shows staining of transfected HMEC-1 cells with 
HLA-B35 and HLA-B58 antibodies. The transfection significantly reduced (p<0.01) the 
expression of HLA-B35 and HLA-B58 antigens by around 90% and 80%, respectively, 
compared to negative siRNA control. The latter did not induce a significant change in 
the expression of these antigens when compared to untreated group. Because the 
antibody specific to HLA-C locus was not available; therefore, assessing the knocking 
down of HLA-C antigens could not be determined. Therefore, the binding of purified 
antibodies to transfected cells in attempt to determine the specificity was not 
investigated. 
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Figure 6.22: HLA class I transfected endothelial cells stained with human 
monoclonal antibody specific to HLA-A antigens. 
HMEC-1 cells were transfected with a mixture of siRNA specific to HLA-A, B and C 
for 48 hours at 5 nM each followed by staining with HLA class I antibody specific to 
HLA-A1 and HLA-A68 at concentration 40 μg/ml. Following staining with anti-human 
IgG FITC conjugated antibody, cells were run on flow cytometer. Panel A shows 
histograms for HLA-A1/A9 staining and panel B shows the median fluorescence 
intensity. Panel C shows histograms for HLA-A2/A68 staining and panel D shows the 
median fluorescence intensity. The data were analyzed by WinMDI software. *** 
p<0.001 by one way ANOVA followed by Bonferroni test. The data are representative 
of three independent experiments.  
A) B) 
C) D) 
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Figure 6.23: HLA class I transfected endothelial cells stained with human 
monoclonal antibody specific to HLA-B antigens. 
HMEC-1 cells were transfected with a mixture of siRNA specific for HLA-A, B and C 
for 48 hours at 5 nM each followed by staining with HLA antibody specific to HLA-
B58 and HLA-B35 at concentration 40 μg/ml. Following staining with anti-human IgG 
FITC conjugated antibody, cells were analyzed by flow cytometry. Panel A shows 
histograms for HLA-B35 staining and panel B shows the median fluorescence intensity. 
Panel C shows HLA-B58 staining and panel D shows the median fluorescence intensity. 
*** p<0.001 by one way ANOVA followed by Bonferroni test. The data are 
representative of three independent experiments. 
A) 
C) D) 
B) 
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6.4.7 Phosphorylation of CREB by monoclonal allospecific antibody 
Human monoclonal antibodies were used to determine whether antibody to specific 
HLA locus induced endothelial activation. P-CREB was assessed following stimulation 
with monoclonal HLA-B58 antibody which was chosen for this experiment due to the 
efficient knockdown of HLA-B locus. HMEC-1 cells were transfected with either 
negative siRNA or HLA-B siRNA at 5nM for 48 hours followed by stimulation with 40 
µg/ml of HLA-B58 antibody for 5 minutes. Cells were detached and analyzed by flow 
cytometry to examine knockdown efficiency. Transfection induced ~85% reduction in 
the expression of this antigen compared to control siRNA transfected cells (data not 
shown). Figure 6.24 shows that stimulation of non-transfected or negative siRNA cells 
with HLA-B58 antibody significantly induced the phosphorylation of CREB at serine 
residue 133. However, knocking down HLA-B locus significantly abrogated this 
phosphorylation to baseline level. Cells stimulated with 50 µM forskolin were used as a 
positive control. 
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Figure 6.24: p-CREB cell-based ELISA of HMEC-1 cells stimulated with HLA-
B58 antibody. 
Endothelial cells were transfected with either 5 nM of HLA-B locus siRNA or negative 
control siRNA followed by stimulation with 40 µg/ml of HLA-B58 antibody. Cells 
were fixed and the fluorescence intensity was measured using a fluorescence plate 
reader at excitation 360 and 540 nm and emission 450 and 600 nm for T-CREB and p-
CREB, respectively. The data were analyzed by one-way ANOVA compared to 
untreated followed by Bonferroni test at p<0.05. * p<0.05, ** p<0.01 and *** p<0.001. 
The data are representative of three independent experiments. 
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6.5 Discussion 
The development of donor specific HLA class I antibodies following transplantation 
causes the deterioration of allograft function. This is due to subsequent acute and 
chronic allograft rejection. In this chapter the effect of allospecific HLA class I 
antibodies in inducing the activation of donor endothelial cells was studied. This was 
compared to the effects produced by mouse monoclonal HLA class I antibody. 
Allospecific antibodies were chosen according to their specificity to HLA class I 
molecules expressed on HMEC-1 endothelial cells. Total IgG antibodies were purified 
from sera of two groups of samples; sera from multiparous female who develop HLA 
class I antibodies from multiple pregnancies, and sera from sensitized kidney patients 
with antibodies formed against HLA class I antigens. The ability of purified antibodies 
to induce the phosphorylation of endothelial cell signaling proteins and the expression 
of adhesion molecules and CXCL8 chemokine was examined. 
The presence and specificity of these antibodies was confirmed by single antigen bead 
Luminex assay both before and after antibody purification. Samples showed reactivity 
against different HLA class I antigens expressed on HMEC-1 cells. Purified IgG 
antibodies were also examined for their ability to bind HMEC-1 endothelial cells by 
flow cytometry and compared to the binding of negative controls. Allospecific 
antibodies showed a strong binding to endothelial cells when compared to the binding 
of IgG from HLA negative control or IgG from patient who had HLA class I antibodies 
not specific to antigens express on HMEC-1 cells. Antibodies at 0.18 mg/ml showed a 
significant binding to HMEC-1 endothelial cells and were used in all experiments.  
Exposure of endothelial cells to allospecific antibodies from both multiparous females 
and patient samples produced a significant phosphorylation of ERK, Akt and CREB 
compared to negative controls. This activation is the same as was shown with the 
phosphorylation produced by W6/32 antibody. The extent of phosphorylation produced 
was comparably similar with all samples. This might be attributed to the polyclonal 
nature of these samples with high antibody concentration. If maximum phosphorylation 
was induced by samples with lower HLA antibody content, using a higher concentration 
might not increase the phosphorylation further. The phosphorylation of intracellular 
proteins by treatment with allospecific antibodies was previously described using a 
model of large vessel endothelial cells (Narayanan et al., 2004). In addition, activation 
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of endothelial transcription factor NF-kB was reported in response to stimulation with 
sera from patients containing HLA class I specifc antibodies (Smith et al., 2000).  
In this project, the potential of allospecific HLA class I antibodies to induce the 
expression of cell surface adhesion molecules VCAM-1 and ICAM-1 was also 
examined. Endothelial cells were stimulated with 0.18 mg/ml of allospecific antibodies 
overnight before examining the expression of adhesion molecules by flow cytometry. 
Exposure to these antibodies induced a significant expression of both VCAM-1 and 
ICAM-1 compared to negative controls. Different samples induced different levels of 
adhesion molecule expression which might be attributed to different factors. Antibodies 
specific for particular HLA class I locus (A, B or C) might have different potential in 
inducing endothelial cell activation. In addition, different subclasses of IgG might be 
present in each sample with different potential to activate cell signaling. In a heart 
transplantation model, a passive transfer of IgG2b but not IgG1 antibodies against 
mismatch MHC class I antigens has been shown to induce acute rejection and 
endothelium activation characterized by the release of von-willebrand factor and P-
selectin and platelet aggregation (Wasowska et al., 2001). The expression of ICAM-1 
and VCAM-1 adhesion molecules by artery endothelial cells has been previously 
observed in an in vitro study using human polyclonal HLA class I antibodies 
(Narayanan et al., 2004). In addition, a recent study showed that stimulation of human 
microvascular glomerular endothelial cells with sera containing HLA class I antibodies 
induced the expression of both VCAM-1 and ICAM-1 molecules (Mannam et al., 
2013). The upregulation in the expression of endothelial adhesion molecules suggests 
an increase in the adhesion of recipient leukocytes to donor endothelium. 
The expression of endothelial CXCL8 chemokine in response to W6/32 antibody was 
confirmed using allospecific antibodies. Endothelial cells stimulated with antibodies 
from multiparous females and from sensitized patients showed a significant increase in 
the expression of this chemokine compared to negative controls, as examined using q-
PCR. This suggests that endothelial cells could produce chemotactic factors that can 
induce leukocyte recruitment. In a previous in vitro study, stimulation of human artery 
endothelial cells with HLA class I antibody showed a significant expression of IL-6, IL-
1β, CXCL8 and TNF-α (Reyes-Vargas et al., 2009). In a mice model of lung 
transplantation, passive transfer of donor specific MHC class I antibody induced the 
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expression of different cytokines and chemokines such as IL-10, IL-17, CCL9, CXCL1 
and CXCL12 (Fukami et al., 2009). 
Although serum samples were selected according to their HLA antibody specificity, 
additional experiment was performed to confirm that endothelial cell activation was due 
to HLA class I antibodies. The binding of purified antibodies from both sources to 
citrate-washed endothelial cells were assessed. HMEC-1 cells were treated with citrate 
buffer pH 3 for 2 minutes and assessed for their ability to bind purified allospecific IgG. 
Some samples showed a significant reduction in binding to treated cells compared to 
untreated cells. The acid treatment did not result in complete HLA class I antigen 
reduction; with 20-30% remaining on the cell surface. Therefore, not all samples 
showed a significant reduction in binding to acid-treated cells. 
In this study, the activation of endothelial cells in response to stimulation with locus 
specific HLA antibody was assessed. This was examined on normal non-transfected 
cells and on HLA-B knockdown cells. Silencing the expression of cell surface HLA 
class I antigens by HMEC-1 cells was achievable using the siRNA technique. The 
transient transfection was performed using a mixture of siRNA against HLA-A, B and 
C loci. This was performed to examine the binding of purified allospecifc IgG to HLA 
class I-knocked down cells. The knockdown efficiency was examined using flow 
cytometry after staining with W6/32 antibody. Although not complete, HMEC-1 
endothelial cells showed a significant but partial silencing for the expression of cell 
surface HLA class I antigens. Staining of transfected cells with W6/32 antibody showed 
around 60% reduction in the expression of HLA class I antigens after 48 hours of 
transfection. Since W6/32 antibody binds all classes of HLA class I antigens, human 
monospecific antibodies were obtained and used to examine the specific knockdown 
efficiency. Staining of HMEC-1 transfected cells with monospecific antibody against 
HLA-A1, HLA-A68, HLA-B35 and HLA-B58 showed a significant knockdown in 
HLA-B antigens but not all HLA-A antigens. Monospecific antibody targeting HLA-C 
antigens was not available. Because all of the polyconal samples have mixtures of 
antibodies against HLA-A, HLA-B and C antigens, binding of purified IgG to silenced 
cells was not investigated. Silencing of HLA class I antigens have been previously 
achieved in aortic endothelial cells using siRNA specific to HLA-A or B heavy chains 
or β2-microglobulin (Zhang et al., 2011b).    
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The HLA-B locus knockdown model was used to assess the phosphorylation of CREB 
at serine residue 133 using monospecific HLA-B58 antibody. Stimulation of endothelial 
cells with 40 µg/ml of HLA-B58 antibody induced a significant CREB phosphorylation 
compared to untreated cells examined by p-CREB cell based ELISA. Stimulation of 
HLA-B locus siRNA transfected cells with the same concentration of HLA-B58 
antibody showed a reduction in the extent of CREB phosphorylation compared to 
negative control. The knockdown induced 85% reduction in the cell surface expression 
of HLA-B58 as confirmed using flow cytometry staining. This reduction in the CREB 
phosphorylation suggests that the antibody against HLA-B antigen alone can induce 
endothelial activation. In a previous study, antibody specific to HLA-A2 antigen has 
been shown to induce the activation of aortic endothelial cells manifested by the 
phosphorylation of intracellular proteins and expression of adhesion molecules; 
suggesting the ability of antibody specific to HLA-A antigens to signal (Bian and Reed, 
1999; Narayanan et al., 2004). 
In conclusion, in this chapter we showed that the development of donor specific 
antibody against polymorphic determinants of HLA class I antigens induces 
microvascular endothelium activation. This is manifested by the upregulation of 
adhesion molecules and expression of chemokines in a manner inducing endothelium-
leukocyte interaction. In addition, HLA-B specific antibody is able to induce activation 
of endothelial cells as observed by phosphorylation of transcription factor CREB. 
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7. Chapter Seven-Discussion and Concluding Marks 
Circulating donor specific HLA antibody post-transplantation is one of the major factors 
that causes late antibody-mediated rejection. It is associated with subsequent acute and 
chronic rejection of kidney (Sellares et al., 2012), lung (Hachem, 2012), heart (Chih et 
al., 2012), pancreas (Torrealba et al., 2008) and liver allografts (Abu-Elmagd et al., 
2012). Microvascular endothelial inflammation and infiltration of mononuclear 
leukocytes through the capillaries are features associated with antibody-mediated 
rejection (Drachenberg and Papadimitriou, 2013). In addition to complement fixing 
antibody, non-complement fixing antibodies, IgG2 and IgG4, have been shown to have 
a crucial role in inducing allograft rejection (Heinemann et al., 2006). Non-complement 
fixing antibodies might be responsible for the phenotype of C4d-negative antibody 
mediated rejection. This project was designed to examine the mechanisms by which 
antibodies targeting donor HLA class I antigens can induce endothelium inflammation 
and allograft rejection in a complement independent mechanism. This was achieved by 
focusing on modulation of the expression of adhesion molecules and chemokines by 
endothelial cells. In addition, the consequence of this expression on endothelial-
leukocyte interaction was examined using a powerful flow-based adhesion assay that 
recapitulates the in vivo situation.     
Human microvascular endothelial cells (HMEC-1) were used in this study. These 
immortalized endothelial cells resemble primary endothelial cells in their cobblestone 
structure. They express the CD31 endothelial marker and high levels of HLA class I 
antigens. The HLA genotype of the cell line is A*01, A*68, B*35, B*58, C*04, C*06 
tested by PCR-SSP. The cell line is from a blood group ‘O’ donor, which eliminates the 
possibility of the interaction with ABO antibodies. Monoclonal mouse HLA class I 
antibody was purified from W6/32-hybridoma cell line using affinity chromatography 
and used in this project. The binding to HMEC-1 cells was confirmed by flow 
cytometry and 12 µg/ml was the saturating antibody concentration. Allospecific HLA 
class I antibodies from multiparous females and kidney transplant patients were used to 
assess their potential to induce endothelial activation. Samples were chosen according 
to their specificities assessed by Luminex single antigen bead assay. Activation of 
endothelial cells was determined using both mouse monoclonal antibody and 
allospecific antibodies.  
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Phosphorylation of intracellular proteins provides evidence of cell activation in 
response to an extracellular stimulus (Hunter, 2007). In this project, treatment of 
HMEC-1 cells with HLA class I antibody induced phosphorylation of a wide range of 
endothelial cell signaling proteins involved in cytoskeleton rearrangement, 
inflammatory responses and cell proliferation assessed by human phosphokinase array. 
The phosphorylation was further assessed by western blotting for Akt at serine residue 
473, ERK at tyrosine 202 and threonine 204 residues and transcription factor CREB at 
serine residue 133 at different time points and antibody concentrations. Endothelial cells 
showed different degrees of phosphorylation in response to saturating and sub-
saturating concentrations of the antibody. The phosphorylation of Akt was sensitive to 
antibody concentration; however, CREB phosphorylation still occured at the lower 
concentration of antibody used (0.35µg/ml). As far as we know, this is the first 
demonstration of the phosphorylation of CREB transcription factor by endothelial cells 
in response to HLA class I antibodies. The phosphorylation of cell signaling proteins 
such as ERK, Akt, FAK and others in response to stimulation with HLA class I 
antibodies has previously reported using large vessel endothelial cells (Jin et al., 2004; 
Jin et al., 2007; Jindra et al., 2008b). The phosphorylation of nuclear transcription 
factor CREB suggests a modulation in the endothelial transcriptional profile upon 
antibody ligation. Using pathway-specific inhibitors, CREB phosphorylation showed 
sensitivity to PKA pathway but not to the PI3K/Akt pathway. The phosphorylation of 
CREB by PKA is consistant with the increase in the level of cAMP previously observed 
on endothelial cells stimulated with HLA class I antibodies (Narayanan et al., 2006).  
Endothelial cells also respond to extracellular stimuli by activating the transcriptional 
machinery to synthesise new proteins. In this project, microvascular endothelial cell 
showed this type of activation in response to HLA class I antibodies. Treatment of 
endothelial cells with saturating concentration of HLA class I antibody induced 
expression of the cell surface adhesion molecules VCAM-1 and ICAM-1. The 
expression of these antigens peaked after 8-12 hours and declined after 72 hours. 
Activation of the endothelial signaling pathway was responsible for the expression of 
these antigens in response to antibody stimulation. PI3K/Akt pathway mediates the 
significant expression of VCAM-1 and ICAM-1 as examined by inhibiting this 
pathway. These results are in agreement with previous reports showed the expression of 
adhesion molecules on large vessel endothelial cells in vitro (Narayanan et al., 2006) 
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and in a MHC class I mismatched mouse transplantation model in vivo (Fukami et al., 
2012).       
Leukocyte migration is a process that is highly dependent on the presence of endothelial 
adhesion molecules along with chemokines at the site of inflammation. Therefore, the 
expression of endothelial adhesion molecules and chemokines in response to HLA class 
I antibody was assessed. HMEC-1 endothelial cells treated with saturating concentration 
of HLA class I antibody produced the inflammatory cytokine IL-6 and chemokines 
CCL5, CXCL8, and CXCL1 determined at the protein level. The upregulation of 
endothelial CXCL8 was time-dependent and sensitive to antibody concentration 
assessed at mRNA level. The expression of chemokines has been previously observed 
in vitro using aortic endothelial cells stimulated with W6/32 antibody (Reyes-Vargas et 
al., 2009) and in an in vivo MHC mismatched transplant model (Fukami et al., 2012). 
The expression of CXCL8 was dependent on both the PKA/CREB and PI3K/Akt 
pathways. The relative expression of CXCL8 mRNA was reduced by 52% and 35% in 
the presence of specific-inhibitor to PI3K and PKA pathways, respectively. In addition, 
CXCL8 mRNA was reduced by 50% in knockdown-CREB treated cells suggesting the 
involvement of CREB transcriptional activity in the expression of CXCL8. CREB-
dependent CXCL8 expression was previously observed in epithelial cells in response to 
cytokine stimulation (IL-β) (Sun et al., 2008). The increase in the expression of 
chemotactic proteins in response to donor specific antibody suggests modulation of the 
leukocyte-endothelial interaction.  
Extravasation of donor leukocytes to the transplanted grafts occurs not only in cellular 
rejection but also in antibody-mediated rejection. Histological examination shows that 
monocyte infiltration occurs in kidney patients with circulating donor specific 
antibodies (Fahim et al., 2007; Papadimitriou et al., 2010). Therefore, the potential of 
endothelial cells treated with HLA class I antibody in inducing monocyte adhesion and 
migration was examined. Conditioned media from endothelial cells treated with HLA 
class I antibodies induced significant migration of human monocytes examined using 
static chemotaxis assays. In addition, reflecting in vivo adhesion, human monocytes 
flowing at 0.5 dyne/cm
2
 significantly adhered to endothelial cells treated with F(ab)2 
fragments of W6/32-antibody. Furthermore, the secretion of chemokines by W6/32–
treated endothelial cells significantly augmented the adhesion of monocytes under 
inflammatory condition as observed using TNF-α-treated endothelial cells. The 
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adhesion was also independent to the interaction with Fc-receptors of THP-1 cells. 
Yamakuchi et al. observed monocyte adhesion to endothelial cells treated with whole 
molecule of W6/32 antibody (Yamakuchi et al., 2007). However, the contribution of 
Fc-receptors in the latter study could not be excluded. These results collectively 
consolidate the potential of HLA class I antibody in inducing leukocyte adhesion and 
migration. Furthermore, the presence of the antibody in the inflammatory environment 
augments the migration of recipient leukocytes. This is the first demonstration of 
monocyte adhesion under conditions remodeling in vivo blood flow.     
The results obtained from this project were confirmed using HLA class I IgG 
allospecific antibodies purified from multiparous females and transplanted kidney 
patients. After purification, the specificity of the samples was determined using a 
Luminex single antigen bead assay and measurement of binding to HMEC-1 cells using 
flow cytometry. Treatment of HMEC-1 cells with these antibodies induced endothelial 
cell activation evidenced by phosphorylation of endothelial cell signaling, expression of 
adhesion molecules, and CXCL8 compared to controls. Phosphorylation of ERK, Akt 
and CREB is induced in response to HLA class I allospecific antibodies compared to 
HLA class I antibodies not specific to HMEC-1 antigens. Furthermore, expression of 
the endothelial cell surface molecules VCAM-1 and ICAM-1 was significantly induced 
by allospecific HLA class I antibodies when compared to control groups. Our results 
agree with other in vitro and in vivo results (Fukami et al., 2012). In in vitro study, 
stimulation of human microvascular glomerular endothelial cells with sera containing 
HLA class I antibody induced the expression of these adhesion molecules (Mannam et 
al., 2013). In addition, the expression of CXCL8 mRNA was also significantly induced 
in response to these antibodies. Different samples produced distinct degree of 
expression which is probably dependent on the IgG subclass of the antibodies or their 
concentrations.       
The potential of locus specific HLA class I antibodies in inducing endothelial cell 
activation was examined. Human monoclonal HLA-B58 specific antibody was used to 
examine the phosphorylation of CREB at serine residue 133 using quantitative cell-
based ELISA. Stimulation with HLA-B58 antibody induced significant phosphorylation 
of CREB at specified residues. To confirm this result, the phosphorylation was 
examined on HLA-B siRNA transfected cells and compared to non-transfected cells. 
Silencing the expression of HLA class I antigens was performed using siRNA specific 
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to the heavy chain of each locus. Because the knockdown of HLA-B antigens was 
achieved at a high efficiency, HLA-B58 antibody was used for this assay. The extent of 
CREB phosphorylation in response to HLA-B58 antibody was reduced in trasnfected 
cells compared to the control group. Activation of endothelial cells in response to HLA-
A antibody has been previously reported (Narayanan et al., 2004). This result suggests 
that antibody against single HLA class I mismatch can induce endothelial cell 
activation.  
To sum up, graft microvascular endothelial cells are activated in response to the 
circulating donor specific HLA class I antibody. This involves the activation of various 
intracellular signaling pathways which contribute to the expression of endothelial 
adhesion molecules and chemokines. The upregulation in the expression of 
inflammatory mediators exposes donor endothelium to circulating leukocytes inducing 
their adhesion and migration. Additionally, recipient leukocytes can bind Fc fragment of 
the antibody inducing their recruitment to the transplanted graft. Antibody specifc to 
HLA-B antigen are able to induce endothelial cell activation in a manner comparable to 
monoclonal HLA class I antibody. Strategies that block endothelial-leukocyte 
interaction might provide a level of protection for the transplanted graft following 
transplantation and prolong allograft survival. Summary of this study is shown in figure 
7.1. 
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Figure 7.1: Mechanisms of HLA class I antibody in inducing microvascular 
endothelial-leukocyte interaction. 
Panel A shows that the cross linking of HLA class I antigens with intact HLA class I 
antibody induces activation of endothelial cell signaling and expression of adhesion 
molecules and chemokines. Panel B shows the binding of circulating leukocytes to the 
Fc-region of the HLA class I antibody. Panel C shows the activation of endothelial cells 
and leukocyte adhesion in response to stimulation with F(ab)2 fragments from W6/32 
antibody. Panel D shows endothelial CREB activation in response to stimulation with 
antibody specific to HLA-B antigen. 
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8. Future directions 
In this project, inflammation of human microvascular endothelial cells in response to 
mouse HLA class I antibody (W6/32, IgG2a) was examined. The project could be 
extended to examine the effect of different IgG subclasses and different isotypes. 
Different antibodies might have different mechanisms of inducing endothelial cell 
activation depending on their ability to bind Fc-receptors or activating complement 
system. In addition, examination of the potential of isotypes developed at the primary 
sensitisation, such as IgM, in inducing endothelium activation might address the role of 
antibody developed in non-sensitised patients in inducing allograft rejection. The 
pentameric IgM and dimeric IgA might not bind directly to the postcapillary 
endothelium but still might have a role in inducing large vessel endothelial cells or 
epithelial activation. However, HLA class I specific IgM and IgA antibodies are not 
easily available.  
In this study, we showed that the expression of chemokine CXCL8 is dependent on 
transcription factor CREB. However, activation of CREB and ATF-1 could be studied 
in depth. There are different genes such as proliferative and protective genes which are 
regulated by these transcription factors and might play a role in the pathogenesis of 
allograft rejection. Different techniques such as chromatin immunoprecipitation can be 
used to identify a set of target genes that are regulated by a particular transcription 
factor (Kirmizis and Farnham, 2004). Identifying genes that are regulated by these 
transcription factors would address whether targeting these factors will provide any 
protection to the grafts and prolong their survival.     
This project could be taken from bench to bed side if blocking the interaction between 
endothelium and leukocytes was examined. Due to time limitation, this could not be 
examined. However, different strategies can be used to block this interaction. 
Antibodies that targeted adhesion molecules such as P-selectin and ICAM-1 showed a 
beneficial effect in reducing monocyte adhesion following treatment with HLA class I 
antibody (Valenzuela et al., 2013a). However, different leukocytes bind different 
adhesion molecules and blocking each molecule might need extensive efforts. 
Therefore, blocking chemokine binding to endothelial cells might be more effective in 
preventing leukocyte extravasation. In our group, negatively charge molecules such as 
heparin have been shown to block chemokine binding to endothelium by inhibiting 
binding to heparan sulphate in a competitive manner (Harvey et al., 2007). These agents 
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might fulfil the requirement of inhibiting leukocytes adhesion and migrations in a 
broader way.   
Future studies can be performed to cover different aspects in the mechanism of HLA 
class I antibody inducing allograft rejection: 
1- Endothelial cells stimulated with HLA class I antibody express complement 
fragments as reported in this study (C5a) and by other groups (C4) (Hamer et al., 2012). 
Complement fragments are anaphylatoxin agents that induce leukocyte migration to the 
graft and augment the inflammatory response. Previously, treatment of endothelial cells 
with HLA class I antibody combined with C5a increased the exocytosis of von 
Willebrand Factor compared to cells treated with antibody alone (Yamakuchi et al., 
2007). Profiling the endothelial cells for the expression of complement-related proteins 
in response to HLA I class antibodies could be performed. This might highlight an 
indirect mechanism of injury mediated by these fragments particularly in non-
complement fixing antibody and may identify a useful therapeutic target.  
2- The effect of circulating HLA class I antibody on other cell types rather than 
endothelial cells can also be examined. Previous studies showed that HLA class I 
antibody can induce the production of growth factors by epithelial and smooth muscle 
cells inducing cell proliferation (Jaramillo et al., 2003; Reed, 2003). In addition, HLA 
class I antibody are able to activate platelets in a manner that induce their adhesion to 
monocytes through P-selectin activation (Takahashi et al., 2012). Different cells can be 
activated in response to HLA class I antibody, in addition, mediators secreted by 
specific cell type can induce activation of other cells such as endothelium. Examining 
the activation of different graft-related cells in response to HLA class I antibody might 
identify a set of proteins or cell types that are more potent in inducing cell injury. In 
addition, coculturing of different cell types together in the presence of HLA class I 
antibody might remodel cell-cell interactions in vivo. 
3- Chronic antibody-mediated rejection is characterised by irreversible arterial fibrosis 
(Harris et al., 1997). In lung transplantation, the expression of fibroblast growth factor 
and transformation growth factor-β are increased upon passive transfer of MHC class I 
antibody (Takenaka et al., 2012). The expression of these factors is responsible for the 
activation of fibrogenic pathway. One the other hand, transformation growth factor-β is 
responsible for endothelial-to-mesenchymal transition enhancing graft fibrosis 
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(Zeisberg et al., 2007). Therefore, examining the role of HLA class I antibody in 
inducing allograft fibrosis could be examined. Graft fibrosis can occur directly by HLA 
class I antibody or indirectly by mediator cells activated by the antibody. Investigating 
the possibility and the mechanism of this process might aid in understanding the 
mechanism of allograft injury and discovery of novel therapeutic targets.   
4- Finding diagnostic biomarkers for antibody-mediated rejection might identify 
organs at a risk of rejection before allograft failure. Emerging studies have shown that 
small non-coding RNA (microRNA) play a role in the pathogenesis of different diseases 
and can be used as a diagnostic marker. They act on a target mRNA at a post-
transcriptional stage effecting the translation process, therefore, the gene expression 
(Shan et al., 2011). Different types of microRNA were identified in biopsies with 
rejection compared to functional graft in kidney transplantation (Anglicheau et al., 
2009). In addition, a recent study in kidney transplantation showed that biopsies from 
patients diagnosed with antibody-mediated rejection had a distinct microRNA profile 
that was different from biopsies from those diagnosed with cellular rejection 
(Wilflingseder et al., 2013). microRNA can also be detected in the plasma in acute 
cellular rejection and tissue injury (Hu et al., 2013). Therefore, examining the 
modulation in microRNA in response to HLA class I antibody using different cell types 
might identify a set of microRNA that plays a role in the pathogenesis of the rejection. 
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10. Appendix 
10.1 HLA class II (DR,DQ) typing for HMEC-1 cells  
 
 
HLA class II genotyping of HMEC-1 endothelial cells using PCR-SSP method. The 
HLA class II genotype are DRB1*03, DRB1*12, DQ1*04, DQB1*05. 
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10.2 HLA class I and II typing for HKC-8 cell line 
   
 
 
Typing of HKC-8 cell line using PCR-SSP method. HKC-8 typing is A*24, A*29, 
B*37, B*44, C*06, C*16, DRB1*10, DRB1*15, DQB1*05, DQB1*06. The first two 
gels for HLA-A, B and C. Lanes from 1-25 represents HLA-A types, 26-76 for HLA-B 
and 77-93 for HLA-C. The third gel left hand side for DR and right side for DQ. 
Interpretation of data was performed using Biotest SSP typing Software.  
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10.3 HLA class I and II typing for HK-2 cell line 
    
 
 
Typing of HK-2 cell line by PCR-SSP method. HKC-8 typing is A*02, A*30, B*13, 
B*44, C*02, C*06, DRB1*01, DRB1*16, DQB1*05, DQB1*05. The first two gels for 
HLA-A, B and C. Lanes from 1-25 represents HLA-A types, 26-76 for HLA-B and 77-
93 for HLA-C. The third gel left hand side for DR and right side for DQ. Lanes from 1-
25 represents HLA-A types, 26-76 for HLA-B and 77-93 for HLA-C. Interpretation of 
data was performed using Biotest SSP typing Software. 
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Cell line HLA typing 
HKC-8 cell line A*24, A*29, B*37, B*44, C*06, C*16, DRB1*10, DRB1*15, 
DQB1*05, DQB1*06 
HK-2 cell line A*02, A*30, B*13, B*44, C*02, C*06, DRB1*01, DRB1*16, 
DQB1*05, DQB1*05 
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10.4 Human phospho-kinase array 
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10.5 Human cytokine array 
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